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Abstract
Background: There are two primary definitions of insight used in research. The first,
‘clinical insight’, concerns an accurate understanding of illness, the need for treatment for
that illness, and the consequences of the illness being untreated. Cognitive insight, a more
recent definition, places emphasis on capacity to reflect on one’s thinking and integrate
multiple viewpoints. Insight research is primarily focused on people living with
schizophrenia or other psychotic illnesses, however, has also expanded to other mental health
disorders. More recently, insight has been explored in people living with a substance use
disorder. Clinical insight has been the dominant definition used within the substance use
literature, but there are potential confounds between aspects of clinical insight (e.g., problem
awareness) and the self-report methods typically used in assessing substance use. For
accurate reporting of substance use and its consequences, people need to have good clinical
insight. To reduce the impact of such confounds, examining the function of cognitive insight
in substance use may be beneficial. A prominent measure of cognitive insight is the Beck
Cognitive Insight Scale, made up of two subscales. Self-Reflection concerns the ability to
reflect on past experiences and consider different explanations. Self-Certainty focuses on
one’s confidence in interpretation and meaning making. In essence, good cognitive insight is
made up of high Self-Reflection and low Self-Certainty. To date, cognitive insight has not
been extensively studied in people living with a substance use disorder. The aims of this
thesis are to examine the profile of cognitive insight in people with a substance use disorder
using the BCIS, and explore if there is a relationship between cognitive insight and treatment
outcomes for people accessing treatment for substance use disorder.
Methods: Study 1 was a systematic review, comprised of 20 empirical studies examining
clinical or cognitive insight in substance use disorder. Study 2 was a psychometric study that
aimed to validate the BCIS for people living with a substance use disorder. The sample
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(n=150) were people attending residential treatment for their substance use disorder. Study 3
was a longitudinal study that explored the relationship of cognitive insight to medication
adherence and methamphetamine cessation. The sample consisted of 152 people who were
screened for current methamphetamine dependence. Participants were administered the BCIS
at the start and end of an encompassing three-month medication trial.
Results: Study 1 found that there is little consistency with regard to how insight is being
measured in people with a substance use disorder. From 20 studies included in the review,
there were 13 different insight measures. Validation of the measures was also lacking, with
few studies providing evidence of construct validity. The most common conceptualization of
insight was clinical (i.e., awareness of the substance use problem and its consequences). It
was also found that there was a consistent relationship between clinical insight and worse
substance use (e.g., frequency, severity) and consequences of use. Factor-analysis conducted
in Study 2 confirmed a two-factor structure for the BCIS and after exclusion of two of the
original items, it was deemed suitable for use for people with substance use disorder. This
study also found similar relationships between BCIS scores and psychological distress as had
been found in prior research with samples with other mental health disorders. Study 3 found
the BCIS scales did not predict either medication adherence nor reduction in
methamphetamine use. Contrary to prediction, Self-Reflection decreased over the study
period. Self-Certainty increased in those who maintained or increased their substance use.
Discussion: Clinical insight has almost exclusively been studied within substance use
disorder. However, cognitive insight may have clinical utility, by reducing emphasis on
problem awareness. The results in this thesis indicate that the BCIS may not be the most
appropriate measure, particularly for people who are currently using substances. Implications
for conceptualization and measurement of insight, and application to clinical practice are
discussed.
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Chapter 1: Introduction
1.1 Insight
Insight is a multifaceted term, and its definition has varied across different studies and
measures (Amador & Seckinger, 1997; Riggs et al., 2012). Originally constituting a less
formal or defined idea in psychotherapy, insight began to gain traction within clinical work
with people living with schizophrenia (Cuesta & Peralta, 1994; Dam, 2006; Riggs et al.,
2012). Here it was noted that many people with a diagnosis of schizophrenia did not
recognize or accept their diagnosis or its symptoms. It was understood that helping a person
to improve their insight, that is to recognize their illness and its symptoms, was crucial in
achieving and maintaining positive treatment outcomes in schizophrenia. At its base, insight
is simply about forming reality based and accurate connections between thoughts, feelings,
events, and reactions. Despite the apparent simplicity of that explanation, clarifying
definitions and the importance of insight as a construct has been somewhat more
complicated.
One of the most common problems in insight literature is a lack of stability or
consistency in its definition and, by extension, measurement (Amador et al., 1993; Amador &
Seckinger, 1997; Marková & Berrios, 2001). Initially, insight was considered a dichotomous
construct; it was either present or not present (Amador & Seckinger, 1997). However, this
simplicity only serves to erase the complexity of a person’s insight. Clinically, it becomes
apparent that people may have varying levels and aspects of insight. They may be able to
acknowledge one symptom and its consequences, while being apparently unaware of the
other symptoms they are experiencing, or of their cause (Sevy et al., 2004). A person may be
able to recognize that they have ‘unusual experiences’, however, simultaneously deny the
need for treatment, or the consequences of these unusual experiences if they remain
untreated. Thus, there is a need to consider insight as a multidimensional construct and to
14

measure it appropriately.
Research in the area currently has two primary definitions of insight: Clinical insight
and Cognitive insight.
1.1.1 Clinical Insight
Clinical insight is the most common and longest standing conceptualization of insight.
As noted previously, it was broadly understood that people living with a psychotic disorder
often had some lack of awareness of their illness, and early formal conceptualizations of
insight focused only on this awareness of the illness as a dichotomous option (Amador &
Seckinger, 1997). Patients were rated as having only good or poor insight, based on their
verbal acknowledgement of their symptoms. However, this neglects the nuance of insight.
Clinicians will recognize that their patients can acknowledge one symptom, or cluster of
symptoms, while seemingly ignoring others, and without making steps towards accessing
treatment for their symptoms or illness (Amador et al., 1994). Similarly, patients may
recognize the need for medication only insofar as it alleviates the more disruptive symptoms
of their condition, rather than as a whole treatment (Reimer, 2010).
Based on this acknowledgement, clinical insight was initially formally defined as
awareness of one’s own illness, symptoms, and need for treatment (Riggs et al., 2012). Later,
awareness of consequences of untreated symptoms was added to this definition (e.g., Amador
et al., 1993; Birchwood et al., 1994; David et al., 1992). In its simplest form, for a person to
have intact clinical insight, they had to acknowledge that (a) they had an illness, (b) that the
symptoms they were experiencing (e.g., hallucinations, delusions) were a consequence of this
illness, (c) they needed treatment (e.g., medication and/or psychotherapy) for the illness, and
(d) the negative consequences they had experienced were due to having untreated symptoms.
Figure 1 contains an outline of the five aspects considered to make up clinical insight
(Amador & Seckinger, 1997). From this, the complexity and nuance of insight is apparent; in
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that, not only must a person be aware of illness/symptoms, but they must also be able to
acknowledge the impact. For example, a person must display both acceptance of their
diagnosis and awareness of what that diagnosis means for the concept of ‘awareness of
illness’ to be fully met.

a) Awareness of illness
Acceptance of illness label
Awareness of having a mental disorder
b) Symptoms as consequence of illness
Awareness of signs and symptoms
Attribution of signs and symptoms to mental disorder
Relabelling psychotic experiences accurately
c) Need for treatment
Perceived need for treatment
Attribution of benefits to treatment
d) Consequence of illness
Awareness of social consequences of mental disorder
Figure 1.
Concepts of Clinical Insight (adapted from Amador & Seckinger, 1997)

Clinical insight has been the dominant definition of insight through the literature, and
much of the current understanding of insight is based on this definition. However, arguments
have been made that clinical insight has potential for superficiality (Beck et al., 2004; Van
Camp et al., 2017). Specifically, because clinical insight assesses awareness of symptoms, it
has been suggested that people who are unwell could learn to essentially ‘pay lip service’ to
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their symptoms. This could involve reciting what they have previously been told by a medical
or health professional, rather than having a comprehensive understanding of their illness and
its effects (Beck et al., 2004). This means that superficially a person could appear to have
good clinical insight, but still not believe that their illness was having an effect on their life or
that they needed treatment for their illness. This could lead to a person moving through the
treatment system looking as though they agree and comply, but they may not actually be
participating in the treatment as prescribed, or fully understand the impact of their illness. For
example, a cross sectional survey of 85 people diagnosed with psychotic or mood disorders
found that implicit beliefs about medication, but not explicit beliefs, were positively related
to insight (Rüsch et al., 2009). The authors of this study suggest that social biases such as
positive impression management may influence the self-reporting of agreement with and
adherence to treatment, but it is the implicit beliefs that are a better indication of a person’s
willingness or intention to comply with treatment. This is supported by a meta-analysis that
found that the social sensitivity of a topic explained around a quarter of the variance in the
predictive ability of explicit belief measures, and only about 3% of the variance for implicit
belief measures (Greenwald et al., 2009). Based on these criticisms, there has recently been a
call for further development of the understanding and measurement of insight components
(Beck et al., 2004).
1.1.2 Cognitive Insight
Cognitive insight was formally introduced as a concept in the early 2000’s, to address
the above limitations of clinical insight (Beck et al., 2004). Cognitive insight refers to the
understanding of subjectivity of one’s thoughts and experiences, and the value of others’
views (Beck et al., 2004). Beck et al.’s definition of cognitive insight focuses on the ability to
reflect on different situations, with the idea that people living with low cognitive insight have
an “impaired capacity to evaluate their aberrant interpretations as susceptible to refutation
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[thus] they are compelled to believe that the experiences that others call symptoms of illness
are real, that their interpretations are facts, and that their thinking is rational” (Beck et al.,
2004, p. 321). Good cognitive insight recognizes the presence of multiple explanations for a
single experience and sits in the uncertainty of interpretation. For example, if an argument
were to occur between two people, a person with good cognitive insight would be more able
to reflect on the differing viewpoints and potentially form a different interpretation of that
situation, whereas a person with low cognitive insight would stick with their viewpoint and
hold onto the idea that they were right. Shifting the focus of insight onto the capacity for
metacognition, rather than an awareness of illness, may mean that cognitive insight is harder
to ‘fake’. This provides an opportunity to identify low insight in someone who has perhaps
been in and out of treatment and learnt the ‘right’ things to say, and therefore may allow the
implementation of appropriate treatment procedures.
Currently, there is only one formal measure of cognitive insight; the Beck Cognitive
Insight Scale (BCIS; Beck et al., 2004). The BCIS is a 15-item self-report scale, containing
two factors, Self-Certainty, and Self-Reflection. Self-Certainty captures a person’s selfassuredness, to the exclusion of being able to listen to other people’s interpretations or
explanations of events. Self-Reflection captures a person’s ability to reflect on past
experiences and re-evaluate these. In essence, ‘good’ cognitive insight is comprised of high
Self-Reflection and low Self-Certainty. The BCIS has been validated within both clinical
(Beck et al., 2004) and non-clinical populations (Martin et al., 2010). Unlike clinical insight
measures that focus on experience of symptoms, the items within the BCIS focus more on
metacognitive capacity rather than awareness of illness. Table 1 provides the items from the
BCIS separated into the two components, Self-Reflection and Self-Certainty. It has been
argued that clinical and cognitive insight are complementary rather than overlapping aspects
of the insight construct (Riggs et al., 2012).
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Table 1.
Items in the Beck Cognitive Insight Scale by cognitive insight component
Self-Reflection

Self-Certainty

(1) At times, I have misunderstood other

(2) My interpretations of my experiences are

people’s attitudes towards me.

definitely right.

(3) Other people can understand the cause

(7) If something feels right, it means that it

of my unusual experiences better than I can.

is right.
(9) I know better than anyone else what my

(4) I have jumped to conclusions too fast.
problems are.
(5) Some of my experiences that have
(10) When people disagree with me, they
seemed very real may have been due to my
are generally wrong.
imagination.
(6) Some of the ideas I was certain were

(11) I cannot trust other people’s opinion

true turned out to be false.

about my experiences.

(8) Even though I feel strongly that I am

(13) I can trust my own judgment at all

right, I could be wrong.

times.

(12) If somebody points out that my beliefs
are wrong, I am willing to consider it.
(14) There is often more than one possible
explanation for why people act the way they
do.
(15) My unusual experiences may be due to
my being extremely upset or stressed.
Note. Numbers in brackets refer to order of items in measure. Items from Beck et al. (2004)
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1.2 Insight and treatment outcomes in mental health
The majority of research regarding both definitions of insight has been conducted
with people living with psychotic disorders (Ghaemi & Pope, 1994; Koren et al., 2013; Lera
Calatayud et al., 2012; Weiler et al., 2000). As noted previously, poor clinical insight is
recognised as a common factor among people living with schizophrenia, with 50% to 80% of
people living with schizophrenia displaying low clinical insight into their illness (Crumlish et
al., 2005). Despite the decades of research, there is still uncertainty regarding the relationship
of clinical insight to treatment outcomes (Lincoln et al., 2007), and cognitive insight research
is in its early stages (Van Camp et al., 2017). Currently, there are a limited number of studies
examining the role of cognitive insight in the course of psychotic disorders (Engh et al.,
2010; Martin et al., 2010; O'Connor et al., 2013). Nevertheless, there are some important,
albeit preliminary, findings. Overall, people living with a psychotic disorder who have low
insight (both clinical and cognitive) have poorer outcomes; they are more likely to be
involuntarily hospitalized (Weiler et al., 2000), have a longer duration of symptoms
(O'Connor et al., 2013; Poyraz et al., 2016; Weiler et al., 2000), and are more likely to be
violent (Ekinci & Ekinci, 2013), potentially increasing their risk of crime. Clinical and
cognitive insight may also predict outcomes in first episode psychosis with studies showing
that people with lower clinical and cognitive insight at their first episode psychosis are more
likely to relapse and have subsequent psychotic episodes (O'Connor et al., 2013; Yen et al.,
2002). A link between low clinical insight and poor medication adherence is established
(Droulout et al., 2003; Lincoln et al., 2007; Rüsch & Corrigan, 2002). A large randomized
controlled medication trial comprising 1447 participants diagnosed with schizophrenia (not
first episode) from both inpatient and outpatient treatment settings found that people with
impaired clinical insight had higher rates of medication non-adherence at six months
compared to their intact insight counterparts (Kim et al., 2020).
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Insight has also been explored in other mental illnesses. Studies have been conducted
examining the clinical and cognitive insight of those living with bipolar disorder, depression,
obsessive compulsive disorder (OCD), and eating disorders (Ghaemi, 1997; Van Camp et al.,
2017; Weiler et al., 2000). The overarching conclusion from these studies is the importance
of understanding the unique profile of both clinical and cognitive insight in the specific
disorder being focused on. For example, in people diagnosed with bipolar disorder, clinical
insight has been shown to be dependent on the mood phase; people who are in a manic phase
tend to have worse clinical insight compared to those in a depressive or euthymic phase
(Colis et al., 2006; Ghaemi et al., 2000; Yen et al., 2007). Similar to the bipolar studies, for
people living with depression more severe symptoms tend to be related to better clinical and
cognitive insight (Colis et al., 2006; Crumlish et al., 2005; Ghaemi et al., 2000; Van Camp et
al., 2017). A meta-analysis examining the relationship of insight and depression in people
living with schizophrenia concluded that depression was weakly, though significantly, related
to global clinical insight (effect size r = 0.14), and Self-Reflection (effect size r = 0.13)
(Murri et al., 2015). When people are in a depressive state, they tend to be more reflective in
an unhelpful way, the rumination on their problems and current state becomes detrimental
rather than protective (Nolen-Hoeksema, 2000). Developing from these findings, there is
some suggestion that elements of insight related to self-reflection may link with rumination
(Carse & Langdon, 2013; Palmer et al., 2015). A study exploring the relationship between
insight and rumination found that, in a non-clinical sample, there was a significant
relationship between Self-Reflection (BCIS) and rumination, (r = .299) (Carse & Langdon,
2013). Thus, on insight measures that consider reflective abilities, people in depressive
moods will score higher for insight, while exhibiting worse mental health (Misdrahi et al.,
2014; Palmer et al., 2015; Van Camp et al., 2017).
Despite the disparity in profiles across mental health populations, there are some
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common trends with insight and treatment engagement and success. Relationships have been
shown with level of clinical or cognitive insight at the onset of treatment, and success of that
treatment (Ghaemi et al., 2000; Lincoln et al., 2007; Perivoliotis et al., 2010). For example,
studies have shown that poor clinical insight is correlated with lower medication and
treatment adherence in psychosis (Droulout et al., 2003; Lincoln et al., 2007), low cognitive
and clinical insight correlate with worse treatment outcomes in schizophrenia, mood
disorders, and OCD (Ghaemi, 1997; Ghaemi et al., 2000; Himle et al., 2006; Van Camp et al.,
2017), higher rates of hospitalization in schizophrenia (McEvoy et al., 1989; McEvoy et al.,
1993; Yen et al., 2002), and more severe symptomatology in schizophrenia (Mintz et al.,
2003; Van Camp et al., 2017). Consequently, both clinical and cognitive insight are
becoming recognized as important to consider when planning and conducting mental health
interventions (Himle et al., 2006; Mintz et al., 2003; Perivoliotis et al., 2010; Van Camp et
al., 2017; Yen et al., 2002). For example, in a group of 69 people attending outpatient
treatment for OCD, poor clinical insight at the start of treatment predicted poorer outcomes
post treatment (Himle et al., 2006). A study with people living with schizophrenia found that
adding motivational interviewing to routine outpatient treatment improved clinical insight
over the treatment period compared to the control group (Ertem & Duman, 2019). The
intervention group that included motivational interviewing also had increased medication
adherence compared to the control group, lasting up to six months post intervention (Ertem &
Duman, 2019).
Insight has been demonstrated to be important to consider within a mental health
population, with results broadly indicating that the better insight a person has, the better their
treatment outcomes will be. However, different symptom profiles across the disorders means
there is a need for careful consideration of what constitutes insight, and how best to measure
it. It is not enough to assume that the profile of insight seen in one disorder will translate
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wholly across to another.
1.3 Insight in Substance Use
Insight within people who use substances is poorly understood, and under researched.
This is exacerbated by research that has been conducted with mental health populations often
excluding people who used substances from their sample (Koren et al., 2013), not reporting
substance use (Martin et al., 2010), or having only a small representation of people who use
substances (Ghaemi et al., 2000). However, given the links found between insight and
treatment adherence, treatment success, and ongoing recovery in mental health populations,
not to mention the high levels of comorbidity of mental illness and SUD (Kingston et al.,
2017), it is worthwhile exploring insight in substance use disorders. Numerous studies have
shown the difficulty in treating people living with substance use disorders, with problems
associated with treatment engagement (Digiusto & Treloar, 2007; Tsogia et al., 2001),
retention (Ball et al., 2006; Chen et al., 2015; Lappan et al., 2020), and ongoing recovery
(Manning, Garfield, et al., 2017) commonly arising. Notably, studies have highlighted a lack
of recognition of the problem, and beliefs that their substance use is ‘not that bad’, as
significant barriers to treatment for people living with a substance use disorder (Islam et al.,
2013; Pennay & Lee, 2009; Quinn et al., 2013; Sarkar et al., 2020). It is probable that a
proportion of people with substance dependence have low insight, which would have a
negative effect on their ability to engage in treatment. The potential severity of this issue is
reflected in a study that administered a measure of cognitive insight (Insight Orientation
Scale [IOS]; Gori et al., 2015), and found people with a diagnosed SUD had significantly
lower insight than those living with schizophrenia, a depressive disorder, or a personality
disorder. There is a small, but growing, literature regarding insight in substance use disorders
(e.g., Benedict, 2015; Kim, Park, et al., 2007; Maremmani et al., 2012; Slepecky et al., 2018).
There is little evidence currently of collaboration between groups within this literature,
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highlighting the need for a review which forms the first study of this thesis.
When thinking of a lack of awareness within SUD, denial is a more common term.
Thus, it is important to distinguish between the terms ‘denial’ and ‘lack of insight’. These
terms are often used interchangeably by clinicians working in the alcohol and other drug
treatment field to describe a person’s apparent lack of recognition of their substance use and
its consequences. Denial is conceptualized as a purposeful minimization of the consequences
of substance use (Stein & Rogers, 2008). Denial is commonly considered as a psychological
protection, or defense mechanism with people who are considered to be ‘in denial’ thought to
be protecting themselves from the severity of their situation (Dare & Derigne, 2010; VerdejoGarcía et al., 2013; Williams et al., 2015). For example, if a person is confronted with the
harms their substance use has caused (e.g. hurt caused to family members), denial may come
into play to protect against the confrontation (e.g. the hurt party is overreacting, it was not
that bad) (Dare & Derigne, 2010). While denial may be considered a ‘choice’ to some extent,
research is indicating that aspects of insight may be an inherent ability, and some people’s
ability to be insightful may be more developed than others (Lai, 2011). This is particularly
evident in neuroimaging studies that show significant differences in brain structures in people
with good versus poor insight (Cooke et al., 2005; Goldstein et al., 2009; Morgan et al.,
2010). That is not to say that insight is static, or unchangeable. There is presently a lack of
longitudinal neuroimaging studies available to fully explore changes in brain structure of
function, however in psychosocial treatment studies there is some evidence of changes on
measures of clinical insight when engaging in appropriate treatment (Jung et al., 2011; Weiler
et al., 2000; Wiffen et al., 2010; Willems et al., 1973b). Potential for changes in cognitive
insight is less established.
1.3.1 Relationship of insight to substance use
At present, the role of insight in substance use is not clearly established. Measurement
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difficulties (discussed in next section) make it difficult to synthesize research across different
studies. However, there are some early results showing consistent patterns. Associations have
been found between higher clinical insight and higher alcohol use (Blume et al., 2000; Islam
et al., 2013; Yen et al., 2008), higher number of past hospitalizations (Lyu et al., 2017),
experience of withdrawal symptoms (Lyu et al., 2017), and experience of legal and other
consequences of use (Blume et al., 2000; Lyu et al., 2017). Blume et al. (2000) found that
experience of negative consequences from substance use significantly predicted better
clinical insight. Taken together, studies that have used a measure of clinical insight (focus on
problem awareness and need for treatment) have typically found a relationship where better
insight is associated with worse substance use patterns. These relationships suggest that the
more negative the consequences of substance use for an individual the more evident their
problem is to them.
Research using a cognitive insight measure is more limited in availability. However, a
study that employed the Capacity for Dynamic Processing Scale, a measure that assesses
capacity for self-reflection more so than problem recognition (i.e., a cognitive insight
conceptualization), found that longer duration of opiate use was associated with lower insight
scores in people attending outpatient detoxification (Giyaur et al., 2005). Although this is
only one study with a small sample (n=63) it suggests different relationships may exist
between substance use variables and cognitive insight compared to clinical insight. Thus,
further exploring the relationship of cognitive insight to substance use variables seems
warranted in order to improve the broader understanding of the relationship between insight
and substance use characteristics and outcomes.
1.3.2 Insight and substance use treatment outcomes
There is currently a lack of longitudinal studies that evaluate how insight is related to
substance use treatment outcomes. However, existing studies suggest that insight may be
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important to consider for aspects such as treatment engagement. A Belgian study explored
fixed and dynamic variables of 157 participants across five residential substance use
treatment facilities (Goethals et al., 2012). The aim was to identify and explore what factors
help or hinder engagement in a residential setting. To quantify this, the study employed the
Dimensions of Change Instrument, which contains the subscales ‘Problem Recognition’
(related to clinical insight) and ‘Introspection and Self-Management’ (related to cognitive
insight). The study found that Problem Recognition showed small though significant
relationships to worse psychological distress (r = .35), as measured by the Brief Symptom
Inventory (BSI; Derogatis & Melisaratos, 1983), and higher Motivation for Treatment (r =
.22), as measured by Circumstances Motivation Readiness and Suitability Scales (CMRS; De
Leon & Jainchill, 1986). There was no significant correlation found for Introspection and
Self-Management across the variables of motivation or readiness for treatment, though it was
positively related to perceived suitability of treatment (measured by CMRS; r = .29). In a
similar vein, a Korean based study examined readiness to change in men currently engaged in
inpatient treatment for alcohol (Kim, Kim, et al., 2007). It found that as clinical insight
increased, the likelihood of the person being in the contemplation stage went up 1.2 times
higher, and the likelihood of being in the action stage increased 1.3 times higher (both
statistically significant increases). A study conducted in an outpatient opiate detoxification
unit found that better cognitive insight was related to a higher number of treatment sessions
attended (Giyaur et al., 2005).
Few studies have looked at insight and long-term treatment effects. Of those studies
that followed up participants, participants who had higher clinical insight at discharge from
inpatient hospital treatment were more likely to be abstinent at 12- and 24-month follow up
(Kim, Park, et al., 2007; Willems et al., 1973b). In the Willems et al. (1973b) study, a
measure of clinical insight was taken at admission and discharge, but only the discharge
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insight was significantly related to ongoing abstinence. This suggests that if the aim of the
substance use treatment is to maintain abstinence, enhancing insight prior to discharge from
treatment may be a helpful part of this process. More studies are needed to clarify the
relationship between insight and treatment outcomes and to determine whether insight
contributes to more positive treatment outcomes.
Examining clinical and cognitive insight in substance use may not just be useful for
understanding the in-treatment processes but could also potentially guide understanding
around risk of relapse post treatment. Currently, few longitudinal studies have been
completed. On top of the limited literature, the studies that do exist have almost exclusively
recruited people already in treatment for their substance use (often inpatient or other
residential settings), and therefore participants are typically already abstinent (e.g., Goethals
et al., 2012; Slaski & Zylicz, 2006). This precludes the opportunity to explore insight through
the process of actively reducing and ceasing use, which may provide richer information about
the dynamics of clinical and cognitive insight in people living with a substance use disorder.
A third area that may prove beneficial to explore is the role of insight in medication
adherence in SUD, particularly given research that has found clinical insight being positively
related to medication adherence in mental health (primarily psychosis) populations. Available
pharmacotherapies for substance use disorders are increasing (Butelman & Kreek, 2017;
Klein, 2016), and for medications to work adherence is necessary. To date, research
examining medication adherence in substance dependence has not been conducted, though
the importance of examining adherence in this population has been highlighted (Weiss,
2004). A challenge for such research is reliable and valid measurement of insight.
1.4 Quantifying insight in substance use
Studies into insight that have been undertaken with a substance using population have
used varying measures and quantifications of insight. The extant literature has highlighted
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three overlapping considerations when measuring insight in people living with substance use
disorder. First, what is the accuracy of self-report measures and how does variation in
accuracy influence results (Kim, Park, et al., 2007)? Second, is the measure actually
capturing insight (Maremmani et al., 2012)? Third, does the profile of cognitive or clinical
insight differ depending on primary substance of choice (Salloum et al., 1998)?
There is one well validated measure of clinical insight for people living with alcohol
use disorder. The Hanil Alcohol Insight Scale is a 20-item self-report measure (HAIS; Kim et
al., 1998; Kim, Park, et al., 2007). Participants respond either ‘agree’, ‘not sure’, or ‘disagree’
to statements related to beliefs about drinking (e.g., ‘I can’t do without drinking’). Scores are
summed and divided into one of three categories (poor, fair, and good insight). This measure
has been used across several studies for people who are in treatment for their alcohol use
disorder (Im et al., 2007; Jung et al., 2011; Kim et al., 1998; Kim, Park, et al., 2007; Kim,
Kim, et al., 2007; Lyu et al., 2017; Yen, Dai, et al., 2009; Yen, Hsiao, et al., 2009). The
findings of these studies generally link better clinical insight with worse substance use
history, that is, higher severity of alcohol use (Yen, Dai, et al., 2009; Yen et al., 2008), more
experience of alcohol related consequences (Lyu et al., 2017), longer duration of alcohol use
(Lyu et al., 2017), and more experience of hospitalizations for alcohol use (Kim, Park, et al.,
2007; Lyu et al., 2017). However, there are potential limitations associated with using this
measure. As clinical insight is focused on problem awareness, and the substance use
measures employed in these studies were self-report (as is typical in addiction research), one
can see how those with better clinical insight, that is better awareness of their drinking, might
report more accurately than their low insight counterparts. Researchers are requiring
participants to be able to accurately report their use, such as number of standard drinks or
experience of substance related consequences and this also reflects good clinical insight. This
may mean that studies in substance use that use clinical insight are not so much finding
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relationships between better insight and worse substance use severity, but rather asking the
same question in different ways (that is, how aware are you of your substance use?).
Assessing cognitive insight may be part of the solution to mitigate this problem by avoiding a
‘doubling up’ of knowledge of one’s substance use patterns.
Other measures have been less rigorously designed than the HAIS (Kim et al., 1998)
and there is regularly little evidence of validity in measures used. Measurement of insight in
substance use research has varied from semi-structured interviews with a focus on problem
awareness and treatment (Maremmani et al., 2012), to deriving insight from other concepts,
such as choice awareness (i.e., accurate identification of the choices one made in a set task)
(Moeller et al., 2010). This range of measurement raises the question of how certain
researchers can be that what they are capturing is actually insight. For example, a study with
1066 people who use heroin (Maremmani et al., 2012) utilized a semi-structured interview
consisting of four open-ended questions rated by two psychiatrists. Insight was
dichotomously scored as either present or not present. The authors do not provide inter-rater
reliability scores, or psychometric properties of the measure due to changing staff raters and
refinement of the measure during the study period, and state themselves that their “tool may
not really measure insight but might show the awareness of negative life situations”
(Maremmani et al., 2012 p. 8).
A study with 65 people who use cocaine (Moeller et al., 2010) utilized a probabilistic
choice task in their assessment of insight. Participants were asked to choose cards one by one
from one of four electronically presented decks containing pleasant, unpleasant, and neutral
pictures, as well as pictures of cocaine and cocaine use. Each deck contained a majority of
one category (i.e., one deck contained a majority of pleasant images). At the conclusion of
the task, participants were asked which pictures they believed they chose to look at most
often. The final rating was dichotomous (impaired/unimpaired) with participants rated as
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having unimpaired insight if they correctly reported the category of images that they had
looked at the most. The study found that participants who had recently used cocaine were
more likely to choose cocaine-based images, and less likely to acknowledge this choice. The
authors attribute this to low insight but it may also be the case that there was some social
desirability at play (Davis et al., 2010). It is reasonable to assume that people who are
dependent on substances would not always be willing to admit to researchers or treating
professionals that they find drugs pleasurable. Despite this measure being used a number of
times (Benedict, 2015; Moeller et al., 2010; Moeller et al., 2009) there is no available
evidence of its validity as a measure of insight.
Another limitation of the current literature base of insight in SUD is the lack of
diversity in substances assessed. The majority of the research has been conducted with people
living with alcohol or cocaine use disorders. Alternatively, studies have included people with
a range of substance use disorders with little or no differentiation between substances. With
research showing that treatment outcomes can vary depending on primary substance of use
(Brorson et al., 2013; Deane et al., 2012; Velazquez-Millings, 2017), and the differing
psychosocial (e.g., associations with violence, or poor physical health outcomes) and
neurological effects of drugs, it is important to understand how insight functions across each
substance class. Mental health insight literature indicates that insight is more impaired when
there are active delusions or hallucinations (Engh et al., 2010; Mintz et al., 2003).
Methamphetamine use is associated with experience of psychosis, with research indicating
that, compared to people who don’t use methamphetamine, people who use
methamphetamine are two to three times more likely to experience clinically significant
symptoms of psychosis (McKetin et al., 2010; McKetin et al., 2006). Given the overlap of
delusions and hallucination between those with methamphetamine use and psychotic
disorders such as schizophrenia (Darke et al., 2008; McKetin, Leung, et al., 2019; Salo et al.,
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2011; Thomas et al., 2016; Zweben et al., 2004), and the extensive prior research on insight
in psychosis, it may be particularly fruitful exploring insight amongst those with
methamphetamine use.
1.5 Methamphetamine
Methamphetamine dependence is a rising global health problem (United Nations
Office on Drugs and Crime, 2020) resulting in increased individual and societal harms
(Australian Institute of Health and Welfare, 2020; Degenhardt et al., 2017; Farrell et al.,
2019; Liu et al., 2017; Marshall & Werb, 2010; McKetin et al., 2014). Methamphetamine use
within Australia is on the rise; since 2010, Australians reporting use of methamphetamine in
the previous 12 months has more than doubled to 300,000 in 2019 (Australian Institute of
Health and Welfare, 2020; Commonwealth of Australia, 2015), and it is noted that this is
likely an under-representation. Recent studies have indicated that of people already using
methamphetamine, more are choosing to use crystalline methamphetamine (commonly
known as ‘ice’) over other types of less potent methamphetamine (Australian Institute of
Health and Welfare, 2014, 2020). Among people who use methamphetamines, the number of
people who primarily use crystalline methamphetamine has increased from 22% in 2010
(Commonwealth of Australia, 2015), to 50% in 2019 (Australian Institute of Health and
Welfare, 2020). Additionally, people are using crystalline methamphetamine more
frequently, with daily or weekly use rising from 12% in 2010 to 25% in 2013
(Commonwealth of Australia, 2015), through to 29% in 2019 (Australian Institute of Health
and Welfare, 2020). Crystalline methamphetamine use brings with it a broad spectrum of
public health issues, such as poorer health outcomes (Rawson, 2013), increased risk of crime
(Sommers et al., 2006), higher rates of unemployment (McKetin et al., 2005), and poorer
mental health (Rawson, 2013).
1.5.1 Physical health impacts of methamphetamine use

31

Methamphetamine use is associated with poorer physical health. Ongoing use has
been associated with higher rates of heart problems, dental problems, and renal problems
compared to the general population (Darke et al., 2008). People who use methamphetamine
have lower life expectancies and higher rates of mortality from preventable diseases (Herbeck
et al., 2015). There is a relationship between dependence and poor health outcomes; greater
dependence on methamphetamine is more likely to result in worse health (Vincent et al.,
1998). Health risks from methamphetamine are particularly pertinent for people who inject
the drug (Domier et al., 2000). Especially in situations in which people are sharing needles,
or not using clean equipment, injecting may result in higher rates of transmittable diseases
such as Hepatitis (Greenwell & Brecht, 2003) and HIV (Domier et al., 2000). In a
retrospective review of deaths related to methamphetamine use, the average age of the
decedents was 33 years (Kaye et al., 2008). This average stands in contrast to the global
average lifespan of around 82 years (World Health Organisation, 2016).
1.5.2 Mental health impacts of methamphetamine use
Along with poorer physical health outcomes, people who use methamphetamine
generally have worse mental health outcomes (Darke et al., 2008; McKetin, Leung, et al.,
2019). Methamphetamine use has been associated with a number of mental health problems,
such as depression, anxiety, and psychosis (Darke et al., 2008). People who use
methamphetamine are more likely to report lifetime symptoms of depression (McKetin et al.,
2005) and anxiety (Hall et al., 1996; Salo et al., 2011). The connection between
methamphetamine use and psychosis is widely recognised (Glasner-Edwards & Mooney,
2014; Grant et al., 2012; Medhus et al., 2015; Rognli & Bramness, 2015). Around half of all
people who regularly use methamphetamine have experienced some symptoms of delusions
or hallucinations since using methamphetamine (Hall et al., 1996; McKetin et al., 2006).
Given that the national rate of experiencing psychotic symptoms is 1.2% (Degenhardt & Hall,
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2001), the high rate of these symptoms in those using methamphetamines is particularly
notable.
1.5.3 Public health impacts of methamphetamine use
Perhaps one of the most well publicised consequences of methamphetamine use is its
association with violent behaviours. A longitudinal study of an Australian population found
that the probability of a person exhibiting violent behaviours increased from 10% while
abstinent to 60% while intoxicated with methamphetamine (McKetin et al., 2014). This not
only has implications for the public who are at risk of harm, but also for the person, as they
face legal consequences, which have a flow on impact on employment, housing, and general
wellbeing.
There is also a large burden on hospital and health care systems. A recent study
indicated that while actively using methamphetamine, people’s attendance to emergency
department increases, and their attendance at general health care services (such as a general
practitioner, or other non-emergency health care) decreases (McKetin et al., 2017). This lack
of engagement with non-acute health care services has the potential to exacerbate any health
problem a person has, thereby having an impact on longevity and quality of life (Domier et
al., 2000; Greenwell & Brecht, 2003; Herbeck et al., 2015; Vincent et al., 1998).
1.5.4 Treatment options for methamphetamine use
As methamphetamine use is increasingly becoming a global problem (Chomchai &
Chomchai, 2015; United Nations Office on Drugs and Crime, 2020), there is a growing need
to focus on the differing driving forces behind treatment outcomes in people who use
methamphetamine. Research has explored various aspects of methamphetamine use and its
effect on the above-mentioned public health issues (Darke et al., 2008; Degenhardt et al.,
2017; Glasner-Edwards & Mooney, 2014), however, there is much left to be understood
about people who use methamphetamine, and the underlying drivers of health outcomes from
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methamphetamine use. It is widely acknowledged that the effects of methamphetamine bring
unique challenges and barriers to therapeutic interventions (Pennay & Lee, 2009). In a
qualitative survey examining perceived barriers to methamphetamine treatment amongst 24
drug and alcohol treatment providers (Pennay & Lee, 2009), challenging behaviours such as
impulsivity, inconsistency, and aggression were highlighted as interfering with successful
adherence and engagement with therapy. Interestingly, in this survey (Pennay & Lee, 2009)
and another conducted with people who use methamphetamine (n = 126; Kenny et al., 2011),
both treatment providers and treatment consumers indicated that there was a perceived lack
of need for treatment. Amongst the people who use methamphetamine (who had all been
screened for methamphetamine dependence), 35% reported that they did not see a need to
seek treatment due to their drug use being neither severe nor problematic, or simply not
considering formal treatment necessary (Kenny et al., 2011). Most people who use
methamphetamine continue to use the drug despite experiencing significant negative effects
(Quinn et al., 2013). Some may even deny that methamphetamine use has had a negative
influence on their life, despite being able to list a range of negative side effects experienced
(Bungay et al., 2006; Quinn et al., 2013). Indeed, in one qualitative study, participants did not
acknowledge any negative effects of drug use until brought up by the interviewer (Bungay et
al., 2006).
There is some research exploring denial in people who use methamphetamine that
draws inferences as to the role of insight in connection with denial (Dean et al., 2015). The
study tested participants’ cognitive ability and assessed their level of denial of their drug use
using a motivation to change measure. MRI scans were also performed with some
participants. The results indicated that participants in denial about their substance use were
also lacking connectivity between areas in the brain associated with self-awareness,
connectivity that participants not in denial exhibited. The authors suggested that denial in
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substance use may have a relationship to self-awareness deficits. This exploration of
neurocircuitry has been a primary focus of research in the area of substance use and the broad
concept of insight (including self-awareness and denial) (Goldstein et al., 2009).
Understanding the effect of substances on the brain is obviously important, but there is a lack
of information regarding the impact of these changes on the person’s functioning, and how
insight may be improved over time. While mental health outcomes present as the most
obvious outcome measure that may be influenced by insight, it may be that other negative
side effects of methamphetamine use are moderated by level of insight of the user (e.g.,
hostility, psychosis, treatment access and outcomes). There is a broad range of literature
exploring the various negative effects of methamphetamine use (Darke et al., 2008; Henry et
al., 2010; Kaye et al., 2008; McKetin et al., 2005; Petit et al., 2012), however, the role of
insight is rarely explored. Given the high prevalence of methamphetamine use (Australian
Institute of Health and Welfare, 2017), examining the factors potentially related to continued
methamphetamine use, and how they may influence the consequences of methamphetamine
use is timely and important.
1.6 Aims of Thesis
The overall goal of this thesis was to examine insight in people with a substance use
disorder, with a focus on methamphetamine dependence. This encompasses identifying the
appropriate definition and measurement of the construct, developing a clearer profile of
insight in a substance use disorder population (e.g., relationship between insight and
substance use frequency, experience of consequences), and the relationship of insight to
treatment outcomes for people with SUD. Specifically, there are three primary aims for this
thesis.
The first aim is to conduct a systematic review to gather and synthesise the literature
on insight in people who use substances (Study 1). The purpose is to provide an overview of
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the state of the current literature, what is known and the future directions for research in this
area.
The second aim is to validate the Beck Cognitive Insight Scale (Beck et al., 2004) for
use with a substance dependent population (Study 2). To date, there is no consistency in
studies with substance dependent populations regarding what insight is and how best to
measure it. Many studies do not provide evidence of the validity of their insight measures, or
of its appropriateness for use within SUD. Doing so will promote opportunities for further
research in this area, with any further findings more able to be translated and compared
across different classes of substances.
The third aim is to explore the relationship between cognitive insight and outcomes in
people who are dependent on methamphetamine and who were enrolled in a medication trial
(Study 3). Of specific interest was the relationship between cognitive insight at enrollment
and subsequent (i) medication adherence, and (ii) reduction in methamphetamine use. This
was the first longitudinal study of the impact of insight on treatment outcomes with this
population. It is also novel in that participants in this study were actively using
methamphetamine at time of recruitment.
1.7 Outline of Thesis
This thesis consists of three published studies comprising a systematic review, a
validation study, and a longitudinal study. Each study is presented in its own chapter.
Chapter 2 contains a published manuscript that resulted from a systematic review
examining the current research on insight in substance use disorders.
Chapter 3 contains a published manuscript from a cross-sectional study conducted to
validate the Beck Cognitive Insight Scale for people living with a substance use disorder.
Chapter 4 contains a published manuscript detailing the relationship of cognitive
insight for 152 people enrolled in a National Health and Medical Research Council
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(NHMRC) funded methamphetamine pharmacotherapy trial. This trial was a 12-week
randomized controlled trial testing a medication (N-Acetylcysteine) to support people
currently using methamphetamine to reduce or completely stop their substance use.
Chapter 5 contains a general discussion, including a summary of findings and their
implications, limitations of the studies, and considerations and recommendations for future
research regarding insight in substance use disorder.
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Chapter 2: A Systematic Review of the Literature on Insight in Substance Use
Disorder

This chapter has been published in Addictive Behaviors. The chapter is identical to the
published manuscript except for figure numbers (Figure 2) and table numbers (Table 2 and
Table 3) which have been altered to ensure uniformity in formatting across the thesis, and the
updating of references for measures listed in Table 3.

Raftery, D., Kelly, P. J., Deane, F. P., Baker, A. L., Ingram, I., Goh, M. C. W., Lubman, D. I.,
Carter, G., Turner, A., Dean, O. M., Sinclair, B., & McKetin, R. (2020). Insight in substance
use disorder: A systematic review of the literature. Addictive Behaviors, 106549.
https://doi.org/10.1016/j.addbeh.2020.106549
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2.1 Introduction
Classical conceptualizations of insight refer to a person’s awareness and
understanding of their own self and experiences (Amador & Seckinger, 1997; Beck et al.,
2004). The concept of insight was initially identified as being important within psychosis
(Beck et al., 2004; Cuesta & Peralta, 1994; Ekinci & Ekinci, 2013; Martin et al., 2010), as
people with a diagnosis of schizophrenia often did not acknowledge or recognise their illness.
This original ‘lack of illness recognition’ has since developed into a multi-dimensional
construct that has been explored within other mental health diagnoses (e.g., bipolar disorder
(Engh et al., 2007; Yen et al., 2007), depression (Colis et al., 2006), and obsessivecompulsive disorder (Himle et al., 2006)). Across these diagnoses, poor insight was found to
be related to poor treatment outcomes (Amador & Seckinger, 1997), including poor treatment
adherence, more severe symptomatology, and higher rates of hospitalization (Ghaemi &
Pope, 1994; Himle et al., 2006; Van Camp et al., 2017). Within the last two decades, an
alternate definition of insight has developed, with a focus on metacognitive processes;
‘Cognitive’ insight (Beck et al., 2004) is defined as the ability to reflect on one’s own
thoughts and experiences, and consider the view of others regarding these thoughts and
experiences. The definitions of ‘clinical’ and ‘cognitive’ are considered complementary
(Riggs et al., 2012) and there is value in exploring all aspects of insight.
More recently, researchers have begun to examine the broad idea of insight amongst
people presenting with substance use disorders (SUDs). Heavy, prolonged substance use can
impair cognitive functioning and decision making (Goldstein et al., 2009; Goldstein &
Volkow, 2002). This may reduce a person’s capacity for insight (Lysaker et al., 1998; Rinn et
al., 2002) into the role that substance use plays in contributing to negative health outcomes
(Goldstein et al., 2009) and this may in turn reduce their treatment seeking behaviour
(Digiusto & Treloar, 2007; Nwakeze et al., 2002). Understanding insight in people with
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SUDs may help to explain and overcome the difficulties people with SUDs have in accessing
treatment (Digiusto & Treloar, 2007), staying in treatment (Ball et al., 2006), and attaining
their treatment goals (Kenny et al., 2011; Pennay & Lee, 2009).
There is little consensus about the definition of insight as a construct relating to SUD
and few insight scales specifically designed for use in SUDs currently exist (e.g., Kim et al.,
1998). Multiple measurement scales (Beck et al., 2004; Birchwood et al., 1994; David, 1990;
Gori et al., 2015) that were developed to measure insight in psychosis, including self-report
and interviewer-rated checklists, have been used to measure insight in people with SUDs,
however their appropriateness has not been thoroughly examined. There is currently no
consensus on the most appropriate way to measure insight in SUDs. Given the impact that
understanding insight has had on the treatment and prognosis of mental illnesses (Dam,
2006), a more comprehensive understanding of insight in SUDs may promote similar
advancements within the addiction field.
The current systematic review sought to answer the following questions:
1)

How has insight in adults been defined and conceptualised within the

substance use literature?
2)

How has insight been measured in people with SUDs?

3)

Within adults with SUD:

a.

Does insight have a relationship to substance use variables, such as frequency

and amount of use, or access to treatment?
b.

Does insight play a role in treatment outcomes, such as length of abstinence,

quality of life variables, and other psychosocial variables?
4)

Does insight change over time in people with a SUD following intervention

for SUD?
2.2 Method
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2.2.1 Search strategy and selection of studies
The review protocol was registered with PROSPERO CRD42018075551.
Following consultation with a librarian, a database search was conducted in January
2018, and updated in February 2020. The following databases were searched: Medline,
PsychINFO, SCOPUS, CINAHL, and Web of Science. Keywords related to insight, and
substance use terms (see Appendix 1 for an example search). No publication date limits were
set in order to capture all existing literature. Language was restricted to English only. Types
of documents included were research articles, doctoral theses, and books. Figure 2 shows the
PRISMA flow chart of the number of articles identified across the databases. All searches
were imported into Endnote X8 and duplicate articles were removed. The reference lists of
eligible articles were hand searched to identify any further relevant articles.
2.2.2 Inclusion criteria
For an article to be included it was required to meet the following criteria:
a)

Human participants aged 18 years of age or over.

b)

Participants were sourced from a SUD population. This included people who

self-reported a SUD diagnosis, research that screened for SUD with a quantifiable measure of
substance use severity (e.g., AUDIT, or diagnostic interview), or people in treatment for a
SUD.
c)

A clear and quantifiable measure of insight (including self-awareness) was

d)

The relationship between level of insight and substance use factors (e.g.,

used.

frequency of use) was reported.
2.2.3 Study selection
Articles were initially screened by DR based on the title and abstract, and any
ineligible articles removed. At this level of screening, inclusion was quite liberal; articles
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were screened for the first two criteria (human studies of SUD populations) with an
indication of insight as a measured variable. Two authors (DR and II) then screened the full
text of the articles for eligibility (96% agreement, Cohen’s Kappa of .88), with disagreements
(n = 4) resolved by ratings of a third rater (MG) and final decisions made through consensus.
2.2.4 Data extraction
Following screening, data were extracted into an Excel (MS Office) form.
Information extracted included study design, study setting, number of participants, mean age,
gender, substance type, measures of substance use employed, comorbid mental health, and
the type of insight measure used.
2.2.5 Risk of bias assessment
Risk of bias assessments were undertaken using the National Institute of Health Tool
for Observational and Cohort Studies (2019) scale, and the Cochrane Collaboration’s Tool
for Assessing Risk of Bias in Randomized Studies (Higgins et al., 2011). Studies were
assigned a quality label depending on their rating across the quality criteria. The number of
items scored as ‘high’ quality was divided by the total number of items rated (as not all items
were relevant to all studies due to design). Studies were assigned a rating of ‘poor’ if less
than 60% of the quality criteria were met, ‘fair’ if between 60% and 80%, and ‘good’ if
above 80% of the criteria were met.
2.3 Results
The search resulted in 10,067 articles. Removing duplicates brought the total
number of articles to 8,496. After title and abstract screening, 96 articles were identified for
full-text screening, 20 of which met the inclusion criteria. See Figure 2 for the PRISMA flow
chart.
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Figure 2. PRISMA flow chart

2.3.1 Study Characteristics
Table 2 summarizes the characteristics of the included studies. The eligible studies
included 12 cross-sectional designs (one study (Blume et al., 2000) conducted a three month
follow-up, however baseline insight was not compared to follow up results so for the purpose
of this review it is counted as a cross-sectional design), one randomized controlled trial, two
quasi-experimental studies, and five longitudinal observational studies. Studies came from
the United States of America (5), South Korea (5), the United Kingdom (2), Spain (2),
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Taiwan (2), Australia, Belgium, and Poland (1 each). Another study was conducted across
Poland, Czech Republic, and Slovakia. All studies had a majority male sample (pooled
percentage = 76.1%, range 54% to 100%), with six studies having an entirely male
population. The majority of papers (n = 15) utilized a sample currently obtaining treatment
for alcohol or drug problems (either inpatient, outpatient, or group programs). Four papers
utilized community samples not in treatment. One paper recruited from a sample undergoing
inpatient treatment for schizophrenia who screened positive for alcohol use disorders (AUD)
on the AUDIT (Babor et al., 2001).
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Table 2. Details of included studies
Author (Year)

Study Design

N

Mean age (SD)

% male

Substances Used

Using at
Baseline

Study
Quality

Benedict (2015)

cohort study

90

NTS1 45.73
TS 46.07
NU 23.03

80% NTS1
96.7% TS
16.7% NU

100% cocaine

Y

Poor

Blume et al. (2000)

cohort study

50

22.3

54% (n=27)

100% alcohol

Y

Poor

Burns et al. (2011)

cross sectional

417

40.3 (10.63)

60%

NR

Y

Poor

Castine et al. (2018)

cross sectional

65

32.91 (7.03)

87.7%

98% cocaine
89% alcohol

N

Poor

Giyaur et al. (2005)

cross sectional

63

30.2 (8.3)

63.50%

100% heroin

N

Fair

N

Fair

Goethals et al. (2012)

pre-post

157

27 (5.05)

84%

22% amphetamine
19% cocaine
39% heroin
10% marijuana
11% other

Im et al. (2007)

quasi experimental

44

NR (63.6% <45)

100%

100% alcohol

N

Poor

Jung et al. (2011)

RCT

41

48 (7.6)

75.30%

100% alcohol

N

Low2

100%

100% alcohol

N

Good

Kim, Park, et al. (2007)

cross sectional

123

Poor3 44.16 (8.80)
fair 45.14 (9.73)
good 38.21 (6.05)

Kim, Kim et al. (2007)

cross sectional

131

47.6

100%

100% alcohol

N

Fair

Lyu et al. (2017)

cross sectional

174

NR (range 20-70yrs)

100%

100% alcohol

N

Fair

45

Moeller et al. (2012)

Raftery et al. (2018)

cross sectional

cross sectional

91

340

Impaired3 44.3 (8.1)
intact 43.3 (7.2)
control 41.4 (6.9)

37.5 (9.85)

89.01%

100% cocaine

Y

Poor

68.59%

45% amphetamine
36% alcohol
12% heroin
9% cannabis
8% other

N

Fair

NR

Fair

Salloum et al. (1998)

cross sectional

75

35.9 (7.2)

59%

52% alcohol
35% cocaine
28% other

Slaski et al. (2006)

cohort study

57

40 (prison)
45 (community)

100%

100% alcohol

NR

Fair

Slepecky et al. (2018)

cohort study

380

44.6 (10.5)

74%

100% alcohol

N

Fair

N

Poor

4

Verdejo-García et al.
(2006)

cross sectional

38

29.9 (6.56)

92%

alcohol
amphetamines
cannabis
heroin
MDMA

Willems et al. (1973)

quasi experimental

69

44.84 (short stay)
44.97 (long stay)

100%

100% alcohol

NR

Fair

Yen, Dai et al. (2009)

cross sectional

165

NR

100%

100% alcohol

NR

Poor

Yen, Hsiao et al. (2008)

cross sectional

332

41 (9.7)

61.10%

100% alcohol

Y

Fair

Note. NR = Not reported. 1 NTS = Non treatment seeking, TS= Treatment seeking, NU=Non using. 2Rating based on Cochrane Risk of
Bias Tool. 3Categories refer to insight groups. 4No percentages reported.
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2.3.2 Study Quality and Risk of Bias
Study quality is included in Table 2. For the RCT included in this review (Jung et al.,
2011), risk of bias was rated as low. However, the study did not have a rigorous
randomization schedule, as they conducted a one-to-one randomization by admission date.
Blinding was supported by having a physician unaware of treatment condition conducting the
final follow up assessment.
Amongst the remaining studies, ratings of quality were primarily ‘poor’ (eight
studies) or ‘fair’ (10 studies). Only one study (Kim, Park, et al., 2007) achieved a ‘good’
rating. A number of studies did not consider the impact of confounding variables or attempt
to control for this in their analyses. Only one paper (Shad et al., 2015) provided a power
analysis statement.
2.3.3 Measurement of Insight
Table 3 contains all of the insight measures used in the included studies. From 20
papers, there were 13 different measures identified. There was a lot of variability between
these measures in terms of how they conceptualized and measured insight, and the validity of
the measures related to the measurement of the insight construct. Of the 13 measures used,
eight (Benedict, 2015; Burns et al., 2011; Castine et al., 2018; Im et al., 2007; Jung et al.,
2011; Kim, Park, et al., 2007; Kim, Kim, et al., 2007; Lyu et al., 2017; Moeller et al., 2010;
Raftery et al., 2019; Slaski & Zylicz, 2006; Verdejo-García & Pérez-García, 2008; Willems
et al., 1973b; Yen, Hsiao, et al., 2009; Yen et al., 2008) were designed to capture insight,
though only one was specifically for substance use (alcohol only) (HAIS; discussed below).
Four measures contained an insight item or subscale within a broader measure (Giyaur et al.,
2005; Goethals et al., 2012; Salloum et al., 1998; Slepecky et al., 2018), and one measure was
a non-insight measure from which insight was derived (discussed below) (Blume et al.,
2000).
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Table 3. Study design and insight measure description
Clinical Components
Insight
measure used

Behavioural
Insight Measure

Administration

Problem
Need for Consequences Self
Internal
awareness treatment
of problem
in the experiences
world

Computerised

Choice of one of three decks stacked
with positive, neutral, or negative
images, then asked which images they
chose most. Insight derived from
comparing self-report to actual choice
(intact vs impaired)

Self-report

14-item measure assessing interest and
capacity for self-reflection, includes
Insight subscale. High scores = high
psychological mindedness

Clinician rated

Insight derived from subtracting precontemplation score from contemplation
score

x

x

Self-report

11-item semi-structured self-report
questionnaire, interviewer rated on a 3point scale. Categorical based on total
score – Good, Fair, and Poor

x

x

1,2

(Moeller et al., 2010)

Balanced Index
of Psychological
Mindedness1

Measure Description

(Nyklícek & Denollet,

Cognitive
Components

x

x

x

2009)

Readiness to
Change3
(Rollnick et al., 1992)

Insight and
Treatment
Attitudes
Questionnaire4
(McEvoy et al., 1981)

x
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Capacity for
Dynamic
Process Scale5

Clinician rated

Assesses nine areas related to
engagement in psychodynamic therapy.
Rated on a 5-point scale, summed to a
total score with higher scores indicating
better capacity.

DCI Subscales 'introspection
and selfmanagement'
and 'problem
recognition6

Self-report

Two subscales of a larger measure,
assessing capacity for self-reflection,
and awareness of substance problem.
Each item is rated on a 5-point
agreement scale.

x

x

x

Twenty questions over five subscales.
Half are scored negatively (-2 to 0) and
half are scored positively (0 to 2). Range
is -20 to 20. Categorical; poor (-20 to 3),
fair (4 to 15) and good insight (16+).

x

x

x

Self-report

Problem Awareness and Readiness for
Treatment subscales, 14-items.

x

x

Clinician rated

Measures four ‘modes’ of selfawareness: individual, defensive,
external, reflective.

Clinician rated

Rated from 1 (best) to 5 (worst).
Reassessed at discharge, A (Recovered),
B (Improved), C (Unchanged), and D
(Unknown)

(Thackery et al., 1993)

x

x

x

x

x

x

(Orlando et al., 2006)

Hanil Alcohol
Self-report
Insight
Scale7,8,9,10,11,12,13
(Kim et al., 1998)

Alcohol Use
Inventory14
(Wanberg et al., 1977)

IDER15

(Zaborowski & Slaski,
2003)

Single item
assessing
insight16
(Willems et al., 1973a)

x

x
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Beck Cognitive
Insight Scale17

Self-report

Fifteen items across two subscales (SelfCertainty and Self-Reflection).
Composite score from subtracting SC
from SR. Higher scores indicative of
better insight.

Self and
informant

Forty-six items to assess behaviours
associated with frontal lobe dysfunction.
Insight (self-awareness) rated by
discrepancy in scores between self and
informant ratings.

x

x

Self-report

Measures attitudes towards substance
use. Measure contains three subscales,
Recognition, Ambivalence, and Taking
Steps. Recognition scores used as
insight.

x

x

(Beck et al., 2004)

Frontal Systems
Behaviour
Scale18,19
(Grace & Malloy, 2001)

Stages of
Change
Readiness and
Treatment
Eagerness
Scale20

x

x

x

(Miller & Tonigan,
1996)

Note. 1 Benedict, 2015, 2Moeller et al., 2010, 3Blume et al., 2000, 4Burns et al., 2011, 5Giyaur et al., 2005, 6Goethals et al., 2012, 7Im et al.,
2007, 8Jung et al., 2011, 9Kim, Park, et al., 2007, 10Kim, Kim, et al., 2007, 11Lyu et al., 2017, 12Yen, Hsiao, et al., 2009, 13Yen et al., 2008,
14

Salloum et al., 1998, 15Slaski et al., 2006, 16Willems et al., 1973, 17Raftery et al., 2018, 18Castine et al., 2018, 19Verdejo-Garcia et al., 2006,

20

Slepecky et al., 2018.
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The categorization of insight also varied across the studies. Out of the measures
identified, one used a dichotomous insight (present or not present) rating (Benedict, 2015;
Moeller et al., 2010), three used a categorical system (Im et al., 2007; Jung et al., 2011; Kim,
Park, et al., 2007; Kim, Kim, et al., 2007; Lyu et al., 2017; Willems et al., 1973b; Yen, Hsiao,
et al., 2009; Yen et al., 2008), and nine were rated on a continuous scale of insight (Benedict,
2015; Blume et al., 2000; Burns et al., 2011; Castine et al., 2018; Giyaur et al., 2005;
Goethals et al., 2012; Lysaker et al., 2017; Raftery et al., 2019; Salloum et al., 1998; Slaski &
Zylicz, 2006; Slepecky et al., 2018; Verdejo-García & Pérez-García, 2008). Blume et al.
(2000) employed the Readiness to Change measure (Rollnick et al., 1992), deriving an
insight score by subtracting the pre-contemplation score from the contemplation score.
Slepecky et al. (2018) also used a Readiness to Change measure, the Stages of Change
Readiness and Treatment Eagerness Scales (SOCRATES; Miller & Tonigan, 1996). This
measure contains a subscale of ‘Recognition’ which was conceptualised as insight in their
study. Two studies (Benedict, 2015; Moeller et al., 2010) derived insight from a behavioural
choice task (Moeller et al., 2009) that assessed insight as the concordance between
participants’ reported choice and actual choice, although neither study report on the validity
of this measure of insight. Two studies (Castine et al., 2018; Verdejo-García & Pérez-García,
2008) utilised the Frontal Systems Behaviour Scale (Grace & Malloy, 2001), a measure in
which the participant and a nominated informant rate the participant’s apathy, disinhibition
and executive dysfunction. Insight was derived through discrepancy between the participant
and informant ratings, with larger discrepancies indicating poorer participant insight.
The most common measure used was the Hanil Alcohol Insight Scale (HAIS, seven
studies; Im et al., 2007; Jung et al., 2011; Kim, Park, et al., 2007; Kim, Kim, et al., 2007; Lyu
et al., 2017; Yen, Dai, et al., 2009; Yen et al., 2008). This measure is a 20-item self-report
measure to which the participant responds with either Agree, Disagree, or Not Sure. Scores
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are summed to provide a total value reflecting varying levels of insight. Typically,
respondents are then placed into one of three categories based on their total score (poor: -20
to 3; fair: 4 to 15; good; 16 to 20). The measure focuses on perceptions of drinking harms
(e.g., ‘My drinking did no harm to any member of the family’) and the need for treatment
(e.g., ‘It was fortunate to have a chance to be hospitalized’). The HAIS was the only measure
of the included studies rigorously designed for a substance using population, although it is
specific to alcohol use.
2.3.4 Insight in People with Alcohol Use Disorders
Five studies (Im et al., 2007; Jung et al., 2011; Kim, Park, et al., 2007; Yen, Hsiao, et
al., 2009; Yen et al., 2008) using the HAIS reported on the categories (poor, fair, or good
insight). The pooled sample size of these studies was 585. Within this pooled sample, 56.6%
had poor insight, 36.4% had fair insight, and only 7% had good insight. The study with the
largest sample size (Yen et al., 2008, n = 332) was the only study to not utilize an intreatment sample. They recruited from a community sample of indigenous Taiwanese people,
and found that no participants had ‘good’ insight. Removing this study from the pooled
sample changes the relative distribution, with 35.6% poor insight, 48.2% fair, and 16% good.
2.3.5 Relationship between Insight and Substance Use
Better clinical insight was correlated with greater alcohol use in people with an AUD
(Blume et al., 2000; Yen et al., 2008), more hospitalizations (Lyu et al., 2017), experiencing
withdrawal symptoms (Lyu et al., 2017), and experiencing legal and other consequences of
substance use (Blume et al., 2000; Lyu et al., 2017; Yen et al., 2008). In contrast, a
retrospective study with a focus on problem awareness found that more severe drug use was
related to worse self-awareness (Verdejo-García & Pérez-García, 2008) and another found
longer duration of opiate use was associated with worse cognitive insight (Giyaur et al.,
2005). Better clinical insight was also related to a greater desire to change substance use
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(Blume et al., 2000; Castine et al., 2018; Kim, Kim, et al., 2007; Slepecky et al., 2018),
although Benedict (2015) failed to find any relationship between cognitive insight and
treatment seeking (the sample for this study was relatively small, n=30 per group).
Two studies (Benedict, 2015; Moeller et al., 2010) found that people who had used
cocaine had poorer insight (measured as awareness of choice) compared to ‘healthy’ controls
who did not use cocaine. Moeller et al. (2010) found that poor insight was related to greater
spending on cocaine in the past month for people who had not used cocaine recently (within
the previous 72 hours) but did not find a difference for those who had recently used.
Four studies (Raftery et al., 2019; Salloum et al., 1998; Yen, Hsiao, et al., 2009; Yen
et al., 2008) explored the relationship between insight and mental health in SUD populations.
One study conducted with a community population found that people with high clinical
insight were more likely to have poor mental health status (Yen et al., 2008) as measured by
the Chinese Health Questionnaire-12, a result similar to that found in residential
rehabilitation where psychological distress correlated with higher cognitive insight scores
(Raftery et al., 2019). Two studies were conducted with a dual diagnosis population (Salloum
et al., 1998; Yen, Hsiao, et al., 2009). In a comorbid schizophrenia and AUD outpatient
population, higher clinical insight into alcohol use was correlated with higher clinical insight
into schizophrenia (Yen, Hsiao, et al., 2009).
2.3.6 Impact of insight on treatment outcomes
Problem recognition was significantly related to motivation for treatment (Goethals et
al., 2012). Better clinical insight was correlated with attending more treatment sessions (r =
.64) (Giyaur et al., 2005). Clinical insight at discharge from residential treatment was found
to have a significant relationship to future abstinence in two studies (Kim, Park, et al., 2007;
Willems et al., 1973b). In the Kim et al. (2007) study, the odds ratios for achieving
abstinence by 12 months was 0.07 and 0.17 respectively among participants with poor or fair
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insight, compared to participants with good insight, on the HAIS. Similarly, Willems et al.
(1973b) found that participants with higher insight at discharge from hospital were
significantly more likely to have remained abstinent after two years. One study (VerdejoGarcía & Pérez-García, 2008) did not find a relationship between clinical insight and
abstinence.
2.3.7 Changes in insight over time
Three studies investigated an intervention targeting insight in people who used
alcohol. These studies concluded that insight was modifiable over time with targeted therapy
work. Jung and colleagues (2011) compared a clinical insight intervention to treatment as
usual amongst 41 residents of an alcohol treatment centre. The intervention group completed
five additional brief (15 minute) therapy sessions focusing on insight enhancement. The
distribution of the clinical insight scores (poor, fair, good) in the intervention group changed
significantly after treatment, with more people being scored as ‘good’ or ‘fair’ rather than
‘poor’, while the control group did not show significant change over time. In a similar study,
Im et al. (2007) found that adding a daily 20-minute session that focused on “mental attitudes
and manners” to the existing inpatient schedule significantly improved the clinical insight
level of participants in the treatment group compared to those who received treatment as
usual. In a Polish study that compared a group program for substance dependence (Slaski &
Zylicz, 2006) in a prison population (three months duration) and in a community population
(one year duration), the study found that Self-Reflection improved in both samples, but was
only significantly improved in the prison population. The prison population also showed a
significant decrease in defensive awareness, defined as the exclusion of new information that
harms the concept of the self (Zaborowski & Slaski, 2003).
Outside of targeted insight interventions, a retrospective study (Castine et al., 2018)
indicated that the absence of substance use improves clinical insight though it is important to
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note this study sampled currently abstinent people in treatment, and asked participants to
think back to a time when they were using. Two studies measured clinical insight before and
after inpatient substance use treatment (Slepecky et al., 2018; Willems et al., 1973b). Patients
who completed 6-week treatment showed greater change in insight (recognition of problem)
than those had completed 12-week treatment (Slepecky et al., 2018). Willems and colleagues
(1973b) found that ongoing abstinence at the 12- and 24- month follow-up time points was
related to good clinical insight at discharge from hospital, but not clinical insight at admission
to hospital, suggesting there was a change in clinical insight from admission to discharge.
The paper only reported the mean insight scores at intake and discharge, thus the significance
of the insight change during treatment cannot be determined.
2.4 Discussion
There is a lack of consensus on how to best conceptualize or measure insight within
substance-using populations. Out of 20 papers, there were 13 different measures employed.
The measurement varies considerably, dependent on what researchers considered important.
The broader research literature has mostly focused on clinical insight characterised by
problem awareness and need for treatment. This focus has also carried into SUD research,
reflected in 15 of the 20 studies using a measure that mostly reflected clinical insight.
However, it is important to consider the growing recognition of a more cognitive-based
conceptualization of insight, through capacity for self-reflection and critical thought
regarding one’s opinions and experiences. Five of the 20 studies used a measure with this
more cognitive conceptualization. The lack of clarity regarding definitions of insight has led
to considerable measurement variability, making it difficult to synthesise results.
Additionally, some studies (Benedict, 2015; Moeller et al., 2010) included measures of
‘insight’ without showing evidence of construct validity. These papers were included given
the studies explicit statements regarding use of an insight measure, and to provide a more
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comprehensive view of measurement in this relatively small study pool.
There is some acknowledgement in the literature of the difficulty of measuring insight
in substance-using populations (Kim, Park, et al., 2007). The conundrum being that, as most
substance use measures are self-report, researchers require participants to have some level of
insight to their use if we are to gain accurate pictures of use. This tends to result in circular
findings where participants with better clinical insight (problem awareness) had more severe
substance use, and suffered more consequences due to their use (e.g., relationship or work
problems (Kim, Park, et al., 2007)). However, problem awareness in addictions is complex
for a multitude of reasons, such as variability in what is considered to be ‘problematic’ use
(Islam et al., 2013; Tsogia et al., 2001). That is, people who use substances often do not view
their use as problematic even though research indicates it is damaging their health (Pettigrew
et al., 2017). Compounding this is the difficulties of gaining accurate reporting (Whitford et
al., 2009). Large proportions of the population underreport their drinking in part because they
don’t know what a “standard drink” is (Sprague & Vinson, 2017). It is often only when there
are other consequences such as loss of job, relationship problems, legal problems, or financial
problems that people start to think they may have a problem that needs treatment. This could
explain results from studies where participants with better insight also reported higher use,
and more consequences of use such as relationship or work problems (Kim, Kim, et al.,
2007). An important finding from this review was identification of a relationship between
readiness to change and clinical insight (Kim, Kim, et al., 2007; Slepecky et al., 2018).
People with higher clinical insight were more ready to change than their low insight
counterparts. This points to the importance of considering and addressing insight at the onset
of treatment.
The majority of the studies included in this review recruited from a population already
in treatment, and when a measure of clinical insight is being used (which targets acceptance
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of need for treatment) it stands to reason that people in treatment will tend to have higher
insight than those not in treatment. This is evidenced through the pooled HAIS categories;
Removing the non-treatment engaged sample (n=332) from the pooled sample changed the
distribution of insight from majority in ‘poor’ to majority in ‘fair’. Therefore, measuring
clinical insight in a treatment sample has the potential to skew findings as there is presumably
already some recognition of problem awareness and need for treatment. Seeking out nontreatment seeking populations for insight research will provide further information on insight
in a substance using population.
Four studies found increasing insight is associated with more positive treatment
outcomes. Additionally, the studies that specifically targeted insight as a part of their
interventions showed that insight (at the least, clinical insight) can improve significantly over
time. Interestingly, none of the studies that specifically targeted insight for intervention (Im et
al., 2007; Jung et al., 2011; Slaski & Zylicz, 2006) report on clinical outcomes. There was no
follow up period in any of these three studies and Jung et al. (2011) and Im et al. (2007)
recruited from a sample already in treatment (so use was presumably absent). Slaski et al.
(2006) did use a community population (alongside an incarcerated cohort), however no
substance use variables were collected at follow up beyond re-administration of the insight
measure. This is certainly a gap in the literature. The interventions in the included studies did
not focus so much on the substance use problem itself, but rather looked at a more reflective
and mindful way of being in the world, which fits in more with a cognitive insight
conceptualization. It would perhaps be worthwhile to measure cognitive insight with these
interventions, and explore the function of cognitive insight in these populations further.
The search and inclusion criteria were deliberately broad in order to capture as much
of the relevant research as possible, and yet there was a lack of longitudinal studies found and
only one randomized controlled trial looking at insight and its effects on substance use. There
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was a lack of follow up across the studies that intervened to improve insight that limits the
conclusions that can be drawn about whether the effects are lasting. The studies that had a
targeted insight intervention did not follow up with regards to substance use variables, and
longitudinal studies that followed up substance use variables did not specifically target
insight. The results of Willems et al. (1973b) showed clinical insight at discharge (but not at
admission), was significantly related to ongoing abstinence indicating that insight may be an
important factor to consider when making decisions about treatment completion or transition
to community care. Additionally, this finding further lends to insight being a malleable
construct and one that may be beneficial to consider when designing interventions for SUD.
However, as insight was not directly targeted in this study the mechanism for change is
unclear. This lack of clearly articulated mechanisms of change in insight was also seen in
other studies. For example, does insight start to improve even prior to treatment and then
continue to improve throughout? What are the key strategies that might promote insight at
different stages of treatment (e.g., self-monitoring substance use, information about harms,
reflective problem solving)? These questions remain unanswered.
2.4.1 Limitations and future directions
The current review has several limitations. As mentioned above, many of the samples
were sourced from people already in treatment, which may influence rates of insight and
other outcomes. Though one study indicated there was no difference in insight between
treatment and non-treatment seekers, this is only one study of 20, and it used a behavioural
measure that has not been thoroughly validated. There has been little research done with
people with substance dependence who are not currently in or seeking treatment.
Additionally, a meta-analysis was not conducted due to the heterogeneity of the included
studies, and lack of power that would be evidenced in conducting a meta-analysis (Jackson &
Turner, 2017).
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This research area is still relatively young and ripe for exploration. There is still
groundwork to attend to, particularly with regard to how insight is conceptualized and
measured within SUD samples. It would be beneficial for more longitudinal studies to be
conducted, including observational cohort studies. The majority of studies presented in the
current review were cross-sectional in design, limiting exploration and conclusions of causal
relationships. Utilizing samples not actively in treatment will also allow for greater clarity
regarding the utility of clinical and cognitive insight in broader SUD samples. Within this,
exploring the role of more cognitive measures will be important. It may be that more
experience of drug consequences helps to build insight, however the confounding nature of
needing good insight to accurately respond to self-report use measures shouldn’t be ignored.
Understanding the function of cognitive insight in this population, alongside clinical insight,
will provide a more comprehensive understanding of how best to measure insight, and
importantly, what to do with those measurements, in terms of interventions. Insight has a role
to play in the treatment of substance use, however the current state of the literature means
that our knowledge on how to best address insight in this population is limited. Future
research should aim to conduct more randomized controlled trials, carefully consider the
measure and conceptualization of insight, and, where possible, utilize objective measures of
substance use.
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Chapter 3: Measuring cognitive insight in people with problematic substance use:
An exploration of the factor validity of the Beck Cognitive Insight Scale

This chapter has been published in Drug and Alcohol Review. The chapter is identical to the
published manuscript except table numbers (Table 4, Table 5, Table 6, and Table 7) which
have been altered to ensure uniformity in formatting across the thesis.
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3.1 Introduction
Insight is a crucial part of recovery among people living with mental illness (Connolly
Gibbons et al., 2007; Ghaemi et al., 2000; Van Camp et al., 2017). There are two primary
conceptualizations of insight: clinical and cognitive insight. Clinical insight is centered on a
person’s awareness of illness, recognition of symptoms as part of the illness, and
acknowledgement of need for treatment (David, 1990). Cognitive insight refers to a person’s
capacity to reflect on their own thought processes, and understanding of their experiences
(Beck et al., 2004). Clinical insight has been criticised as being easily inflated through people
learning to provide the ‘right’ responses over time (Beck et al., 2004). Comparatively,
cognitive insight may be harder to falsely inflate (Beck et al., 2004), given the generally
introspective nature of the questions (Van Camp et al., 2017).
The Beck Cognitive Insight Scale (BCIS; Beck et al., 2004) is a widely used, 15-item
measure of cognitive insight. It is comprised of two subscales: Self-Reflection and SelfCertainty. Self-Reflection captures a person’s ability to reflect on their own thoughts and
behaviours, whereas Self-Certainty refers to a person’s inability to accept other’s views or
consider alternate explanations. The BCIS has been found to have convergent validity with a
number of clinical insight measures (Beck et al., 2004; Pedrelli et al., 2004; Uchida et al.,
2009), and has acceptable three week test-retest reliability of the two subscales and the
composite score (Uchida et al., 2009). While initially created for use with people with
psychosis, the BCIS has been found to have the same factor structure in a healthy population
(Martin et al., 2010), indicating the measure’s capacity to be used outside of a population
with psychosis.
Further research has shown the BCIS to have different profiles across populations. In
people with depression, there appears to be a relationship with more severe symptoms
correlating with higher Self-Reflection scores (Van Camp et al., 2017; Warman & Martin,
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2006). In people with bipolar disorder, cognitive insight varies depending on mood phase,
with cognitive insight being lower after a manic state, compared to after a depressive state
(Colis et al., 2006). The BCIS has further been utilized with people with neurodegenerative
disorders (Mack et al., 2013), bronchial asthma (Innamorati et al., 2015), and in healthy
populations (Martin et al., 2010; Orfei et al., 2011). The results of these studies indicate that
cognitive insight may be useful in populations other than those with a psychotic disorder,
such as identifying low insight as a barrier to noticing and acting on symptoms (Innamorati et
al., 2015). Given the varied results across different populations, these studies also highlight
the importance of understanding the profile of the measure in each population.
To date, the BCIS has not been employed among a substance dependent (SUD)
population. Utilizing a measure of cognitive insight, rather than clinical insight, may mitigate
current problems with measuring insight in substance use, such as the confounding factor of
denial (Kim, Kim, et al., 2007). Studies using a measure of clinical insight with a SUD
population highlight that low clinical insight is often associated with false negative reporting
of use (Kim, Park, et al., 2007; Kim, Kim, et al., 2007). The BCIS has previously been
critiqued (Van Camp et al., 2017) due to the calculation of the composite score, and the
current lack of norms regarding what constitutes ‘good’ insight. However, currently there are
no other validated measures of cognitive insight.
The utility of the BCIS within people who use substances may also extend to being
able to predict treatment outcomes. In particular, the Self-Certainty subscale is likely to be
relevant in this population; In a study of Filipinos who use methamphetamine (Tuliao &
Liwag, 2011), participants who relapsed were generally overconfident of their abilities to
avoid substances, which lead to exposure to risky situations. Additionally, the authors noted
that “…overconfidence about one’s recovery led to a belief of [just this once], which
eventually led to… a full-blown relapse.” (Tuliao & Liwag, 2011, p. 173). Thus, there
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appears to be a balance between having some confidence without being overconfident about
one’s capacity to manage high risk situations. Exploring a person’s level of self-certainty
may make the difference between a realistic evaluation of self-efficacy, and one that is overinflated and leads to relapse.
The aims of the current study were to:
(i) Confirm the factor structure of the BCIS in a SUD population through
confirmatory factor analysis (CFA).
(ii) Determine whether psychological distress or presence of psychotic disorder
influences BCIS scores in a SUD population. Research has shown the discriminant ability of
the BCIS in identifying between those with and without a psychotic disorder (Beck et al.,
2004; Martin et al., 2010), and on measures of psychological distress (Warman & Martin,
2006). It is hypothesised that the same discriminant ability will be evident in a SUD
population.
(iii) Explore the relationship of psychosocial factors (e.g., substance of choice,
education level, and age) with the BCIS within a SUD population. Existing literature has
shown that interpretation of the BCIS can vary depending on the group in focus (Van Camp
et al., 2017).
3.2 Method
3.2.1 Participants
Participants were residents of nine specialist alcohol and other substance use
treatment facilities run by The Salvation Army (three services across New South Wales and
Queensland) and We Help Ourselves (six services across New South Wales and Queensland).
Treatment programs occur in a modified therapeutic community, are abstinence based, and
run for up to 10 months. These services have been described previously (Dingle, Kelly, et al.,
2015; Kelly et al., 2015). All current residents were approached to participate in the study.
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There were no exclusion criteria. Of the 346 surveys handed out, 340 were completed
(98.2%). The sample was made up of 68.6% men, with an average age of 37.51 years (SD =
9.85). Full demographics are in Table 4. Due to ethics procedures, comparison between
participants and non-participants is not possible. However, comparison to the Australian
AOD National Minimum Dataset (Australian Institute of Health and Welfare, 2018a, 2018b)
indicates our sample is representative of people accessing drug and alcohol treatment in terms
of age (median=33 years), gender (67.7% men) and principal substance of concern (within
residential treatment: alcohol 38.5%, amphetamines 37.6%).

Table 4.
Demographics and clinical characteristics of participants attending residential treatment for
substance dependence (N=312)
N
Age
Gender
Male
Female
Unknown
Aboriginal or Torres Strait Islander

312

Mean (SD)

Percent

37.51 (9.85)

214
97
1

68.59
31.09
0.32

Aboriginal
Torres Strait Islander
Both
Other
Not ATSI
Education

29
1
6
4
255

9.83
0.34
2.03
1.36
86.10

Less than high school
Completed high school
TAFE/Trade
University
Years of problem substance use

112
62
103
35

35.90
19.90
33.01
11.22

Length in treatment (weeks)

18.05 (9.78)
10.81 (12.09)
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Previously sought treatment
Abstinence period (weeks)

64.42

201
13.41 (12.00)

3.2.2 Measures
3.2.1 Demographics collected included age, gender, marital status, education, and
employment history. Participants were asked if they had ever been treated for a mental health
problem, any diagnosis, and current mental health medication.
3.2.2. Insight was measured by the BCIS (Beck et al., 2004). All 15 items were
included in the study and rated on a four-point scale (see Table 5). The BCIS is scored by
subtracting the Self-Certainty (6 items) total from the Self-Reflection (9 items) total, giving
an overall insight score (range: -18 to 27).
3.2.3 Substance use was collected by asking participants to nominate which
substances they had used in the previous 12 months, and to identify their primary substance
of concern. Participants were asked how often they used their primary substance prior to
entering treatment. Participants were further asked how long they had been abstinent from all
substances (excluding tobacco), and how long they had been in the treatment service.
3.2.4 Psychological Distress was evaluated by the Kessler Psychological Distress
Scale (K-6; Kessler et al., 2002). This is a 6-item measure of psychological distress over the
past month. Scores range from 0 to 24, with 0-7 indicating low distress, 8-12 moderate
distress, and 13-24 high distress (Kessler et al., 2003). The scale has been shown to have
excellent reliability (Kessler et al., 2002), and achieved α=.90 in the current study.
3.2.3 Procedure
The research team visited each residential facility during May to August 2017.
Participants were provided with a verbal explanation of the study, and a written participant
information sheet. Participation was voluntary and anonymous. Participants were informed
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that completing and returning the surveys would indicate their consent to participate.
Participants completed the surveys on their own; however, the research team were available
as required. This study received ethics approval from the University of Wollongong Human
Research Ethics committee (approval number 2017/115).
3.2.4 Analysis
Participants with three or more missing data points on the BCIS were
excluded from analysis (n= 22). Of the sample, 18 participants had one (n=14) or two (n=4)
missing data points. The BCIS has previously been analysed with missing responses (Engh et
al., 2007). Given the self-report nature of the survey, data was screened for effort in
responding. Participants who provided the same response across all items on the BCIS were
excluded from analysis, as the nature of the items mean that providing the same response for
all items is unlikely to represent a true responder (e.g., Item 7 and 8, see Table 5). Of 340
respondents, 14 did not answer the BCIS, two did not answer enough items, and 12 provided
the same answer across the entire measure. Therefore, the following analyses were conducted
for 312 respondents.
The most non-responses on any one item of the BCIS was four (Item 3). Little’s
MCAR test indicated the missing data was missing completely at random (Χ2(206, n=312) =
192.79, p = .74). Less than 5% of the data was missing, indicating that imputation method
would have little impact on the results (Shrive et al., 2006; Tabachnick & Fidell, 2013). As
the CFA required a complete dataset, and imputation would have little impact, it was decided
to impute by single imputation based on series mean.
The CFA was conducted on the BCIS using AMOS Version 21. The CFA was
compared to the factor analyses conducted in Beck et al. (2004) and Martin et al. (2010). As
per recommendations (Jackson et al., 2009), model fit was estimated using chi square, the
root mean square error of approximation (RMSEA; Steiger, 1990), comparative fit index
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(CFI; Bentler, 1990), and the non-normed fit index (NNFI; Tucker & Lewis, 1973).
Reliability analyses assessing internal consistency were conducted using Cronbach’s alpha
for each subscale, and the whole scale.
T-tests were performed to determine if there was a significant difference in insight
scores between those with and without psychological distress and between those who selfreported a lifetime diagnosis of a psychotic disorder and those who did not. It was initially
planned to examine differences between all nominated substances, however alcohol (n = 110)
and methamphetamine (n=138) were overwhelmingly nominated as the primary substance of
choice (e.g., the next most common substance was heroin, n = 33). Therefore, a t-test was
performed to determine any differences in BCIS scores between methamphetamine and
alcohol. Correlations examined the associations between insight and age, gender, length in
program, abstinence length, education level, drug use frequency, and K-6 total. The
significance level was set at p = .01 to reduce risk of Type 1 error, and effect sizes were
calculated for t-tests.
3.3. Results
3.3.1 Substance Use
Most people reported using their substance of choice at least once per day (84.7%)
prior to entry to the residential facility, with the majority of the sample reporting multiple
daily use (55.8%). Almost half of the sample identified methamphetamine (45.2%) as their
primary substance of choice, followed by alcohol (35.9%), heroin (12.2%), cannabis (9%),
prescription medication (3.5%), cocaine (2.6%), and other substances (1.6%). Within this
sample, 10.9% identified more than one primary substance. In the 12 months prior to the
survey, 78.2% had used alcohol and 65.4% had used methamphetamine.
3.3.2 Mental Health
Of the respondents, two thirds had previously received treatment for a mental health
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problem. The most common self-reported diagnosis was depression (37.2%), followed by
anxiety (23.7%), post-traumatic stress disorder (8%), bipolar disorder (7.7%), a psychotic
disorder (7.4%), with other disorders (e.g., attention deficit/hyperactivity disorder, or a
personality disorder) making up 8.3% of the sample.
The mean score on the K-6 was 8.58 (SD=5.21) with almost half of the sample
(48.7%) in the low distress category, 28.9% moderate distress, and 22.2% high distress. This
is comparable to national survey data (Australian Bureau of Statistics, 2007) for people with
a lifetime substance use disorder with 12 month symptoms (K-10: 48%, 26%, and 25%
respectively).
3.3.3 Factor Analysis of BCIS
A two-factor model was created to run the CFA. Factor loadings are shown in Table
5. The items were loaded onto either Self-Reflection or Self-Certainty as per Beck’s (2004)
original model. Several modification indices were indicated regarding covariances between
the error terms for items 8, 12, 14, and 15. The error terms for items 1 and 4 also covaried.
All of these items belonged to the Self-Reflective factor. These modifications were included
in the next model, and the model was tested again. Examining the fit indices showed that
some indices reached cut off thresholds, while others did not (see Table 6). Based on the
covariances between residuals in this model, it was decided to test the presence of a third
factor in the model. Items 8, 12, 14 and 15 were loaded onto a third factor. The resulting
model produced fit indices similar to the original model, and a chi-square test indicated that
the three-factor model was not a significantly better fit (Χ 2(2, n=312) = 4.19, p > 0.05). It was
noted that items 12 and 14 had low loadings (Table 5) and so were removed from the twofactor model. Removing these items resulted in a significantly improved model fit (Χ 2(22,
n=312)

= 76.43, p < 0.02). Therefore, the best model fit was a two factor model excluding items

12 and 14.
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Table 5. Factor Analysis of the Beck Cognitive Insight Scale

1. At times, I have misunderstood other people’s attitudes towards me.

Beck et al (2004)
Factor 1
Factor 2
0.58
0.07

Current Study
Factor 1
Factor 2
0.39

2. My interpretations of my experiences are definitely right.

0.12

0.49

0.38

3. Other people can understand the cause of my unusual experiences better than I can.

0.43

0.11

0.36

4. I have jumped to conclusions too fast.

0.63

0.19

0.58

5. Some of my experiences that have seemed very real may have been due to my imagination.

0.59

0.19

0.82

6. Some of the ideas I was certain were true turned out to be false.

0.66

0.04

0.78

7. If something feels right, it means that it is right.

-0.06

0.64

8. Even though I feel strongly that I am right, I could be wrong.

0.57

-0.24

9. I know better than anyone else what my problems are.

0.11

0.61

0.59

10. When people disagree with me, they are generally wrong.

0.08

0.67

0.60

11. I cannot trust other people’s opinion about my experiences.

0.15

0.63

0.56

12. If somebody points out that my beliefs are wrong, I am willing to consider it.

0.41

-0.10

13. I can trust my own judgment at all times.

-0.12

0.25

14. There is often more than one possible explanation for why people act the way they do.

0.33

-0.19

0.06

15. My unusual experiences may be due to my being extremely upset or stressed.

0.50

0.18

0.38

0.60
0.24

0.06
0.55

Note. Item scale: (0) ‘I do not agree at all’, (1) ‘Agree Slightly’, (2) ‘Agree a lot’, (3) ‘Agree completely’
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Table 6.Goodness of Fit indices for the three BCIS models.
χ2

df

p

CMIN/DF

RMSEA (90% CI)

CFI

NNFI

a) Two factor

244.14

84

< 0.001

2.91

0.078 (0.067 - 0.090)

0.84

0.81

b) Three factor

248.33

86

<0.001

2.89

0.078 (0.067 - 0.089)

0.81

0.84

c) Two factor without items 12, 14

167.71

62

<0.001

2.71

0.074 (0.061 - 0.088)

0.84

0.88

>0.05

<3

<0.06

>0.80

>0.90

Good-fit model

Note. n = 312. RMSEA = root mean square error of approximation; CFI = comparative fit index; NNFI = non-normed fit index.
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3.3.4 Internal Consistency
Reliability analyses were run for both the full scale and without items 12 and 14.
Including all items, reliability for the Self-Reflection subscale, α = .72, Self-Certainty α = .72
and the whole scale achieved α = .75. Excluding items 12 and 14 produced similar results,
with Self-Reflection achieving α =.73, Self-Certainty α = .72 and the whole scale α = .75.
This is comparable to the alphas achieved by Beck et al. (2004) and Martin et al. (2010). The
average Self-Reflection score was 13.20 (SD = 4.42, range 0 to 27; item average = 1.42, SD
= 0.47) and Self-Certainty was 7.10 (SD = 3.28, range 0 to 18; item average = 1.19, SD =
0.55). The average composite score was 6.10 (SD = 4.90, range -7 to 21). Excluding items 12
and 14 brought the average Self-Reflection score down to 9.73 (SD = 3.77, range 0 to 21;
item average = 1.33, SD = 0.52) and the mean composite score became 2.63 (SD = 4.42,
range -10 to 16). Self-Certainty remained unchanged. Table 7 compares the current BCIS
scores to Beck et al. (2004), Engh et al. (2007) and Martin et al. (2010) samples. It is
important to note the large difference in sample sizes. The current sample were significantly
less Self-Reflective than a bipolar (t402 = -2.82, p = .005, d = 0.32) and a healthy sample (t403=
-2.32, p = .02, d = 0.27), with less overall insight compared to a healthy sample (t403= -2.24,
p = .03, d = 0.26). There was no significant difference between the current sample and a
schizophrenia sample.
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Table 7. Comparison of BCIS scores across substance dependent, psychiatric and non-clinical samples
Current Study (n=312)

Beck et al. (n=32)

Engh et al. (n=92)

Martin et al. (n=93)

(substance dependence)

(schizophrenia)

(bipolar disorder)

(healthy population)

Self-Reflection

13.20 (4.42)

12.97 (5.00)

14.7 (4.7)**

14.41 (4.36)*

Self-Certainty

7.10 (3.28)

7.94 (3.78)

7.4 (3.0)

7.02 (3.36)

Composite

6.10 (4.90)

5.03 (5.76)

NR

7.39 (4.79)*

Note. Totals for the current study were calculated for all 15 items, to allow comparison. T-test conducted comparing current study to Beck,
Engh, Martin. * p< .05, ** p<.01.
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3.3.5 Discriminant Ability of the BCIS
The following analyses were conducted excluding items 12 and 14.
Participants were categorised as ‘distressed’ or ‘not distressed’ based on the cut off
score of 13 on the K-6 (Kessler et al., 2002). There was a significant difference on the SelfReflection subscale with distressed participants scoring higher (M = 11.03, SD = 3.43) than
non-distressed participants (M = 9.35, SD = 3.79), t(309) = 3.31, p = 0.001, d = 0.46. There
was also a significant difference on the BCIS composite between these two groups with the
distressed group (M = 3.91, SD = 3.59) scoring higher than the non-distressed group (M =
2.26, SD = 4.58), t(309) = 2.77, p = 0.006, d = 0.40. There was no significant difference
between the groups on the Self-Certainty scale.
There was a significant difference in scores on the Self-Certainty index with those
with a self-reported psychotic disorder (n = 23, M = 8.91, SD = 3.20) scoring significantly
higher than those without (n = 155, M = 7.01, SD = 3.11), t(176)=2.73, p = 0.007, d = 0.60. No
significant differences were found for either the Self-Reflection subscale or the composite
index.
3.3.6 Relationship between BCIS and Psychosocial Variables
There was a small, though significant, relationship between K-6 total and SelfReflection (r = .33, p < 0.001), and between K-6 total and BCIS total (r = .26, p < 0.001).
There were no other significant correlations.
T-tests indicated there were no significant differences between participants who
primarily use alcohol compared to those who use methamphetamine on either subscale, or the
composite score.
3.4. Discussion
The current study set out to explore the use of the BCIS within a sample of substance
dependent individuals. Overall, the CFA supported the two-factor structure of the BCIS
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within a SUD population, although the exclusion of items 12 and 14 may best capture
cognitive insight in this population.
The suggested exclusion of item 12 (‘If somebody points out that my beliefs are
wrong, I am willing to consider it’) and item 14 (‘There is often more than one possible
explanation for why people act the way they do’) is not entirely unexpected. Both Beck et al.
(2004) and Martin et al. (2010) achieved relatively low loadings for these items (Beck et al.:
.44, .33; Martin et al.: .23, .38 respectively) . A third study (Pedrelli et al., 2004) of an older
population with a psychotic disorder achieved .08 loading for item 14, however removing it
reportedly did not improve model fit and reasons why this item was poorly aligned were not
discussed. In another study (Kao & Liu, 2010), items 12 and 14 aligned more strongly with
Self-Certainty. It may be the case that there is something within these items that does not
strongly reflect the concept of Self-Reflection, and this is more pronounced in a SUD
population, particularly in treatment. On face value, the content of items 12 and 14 relate to
relationships with others, and ability to consider other people’s viewpoints. Changes to social
networks, and social identity, is recognised as a pivotal part of recovery from addiction
(Bathish et al., 2017; Dingle, Stark, et al., 2015). Items 12 and 14, which could be argued to
be related to value placed on relationships, may elicit differing responses for people in
substance use treatment. Further research is needed to determine if these items are similarly
interpreted in people who are using substances but not seeking treatment.
Concordant with previous research (Van Camp et al., 2017; Warman & Martin,
2006), participants in the current study who scored higher on the K-6 also scored higher on
the Self-Reflection subscale. The current results also supported the discriminant ability of the
BCIS for psychosis (Beck et al., 2004; Martin et al., 2010), as people with a self-reported
psychotic disorder scored significantly higher on the Self-Certainty subscale than those
without. These results should be interpreted cautiously due to the diagnosis being self-
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reported, however, it is a positive indicator of the validity of using the BCIS within a SUD
population. It is perhaps a positive note that there were no significant differences in insight
across different substances, as this may allow for broader generalizability within a SUD
population. Further research should be conducted regarding generalizability given the small
numbers of participants who nominated substances other than alcohol or methamphetamine
in the current study. A further point of support for the BCIS was that most people were able
to answer the full questionnaire, showing no difficulties with the “unusual experience”
questions.
There were a few limitations to the present study that may have affected the results.
First, survey data were self-reported and anonymous so there is no sure way to ascertain level
of engagement with the survey. Although screening rules were applied, it remains possible
that inaccurate responses were included in final analyses. This encompasses the handling of
with missing data. The amount of missing data was small, but the use of single imputation as
opposed to a more rigorous method (McKnight, 2007) may have affected the results.
Secondly, it is important to note that participants had been abstinent from their substance of
choice for an average of three months at the time of taking the survey, and were engaged in
substance dependence treatment. Therefore, the results may not generalise to people who are
actively using substances. Our sample size for the purpose of a CFA was at the lower
recommended limit, which may have impacted current results. Despite this concern our
sample was larger than that of the original study (Beck et al., 2004). A further limitation is
the lack of other insight measures with which to confirm concurrent validity. This was due to
the BCIS being one measure within a larger survey, thus to reduce burden an additional
insight measure was not included. As the BCIS has previously been validated (Beck et al.,
2004; Martin et al., 2010), the current study focused on confirming the factor structure of the
measure within a SUD population.
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The results of the current study indicate that the BCIS may be appropriate for use with
a SUD population. Future studies within a SUD population should interpret the BCIS with
care and consider conducting their own measures of validity, including assessing the function
of withdrawal on insight. Poor executive functioning in schizophrenia may be related to
lower insight scores on clinical measures (Aleman et al., 2006; Wiffen et al., 2012).
Currently, it is unclear what role acute withdrawal from substances has in the measurement of
insight. Research on insight in SUD populations has primarily involved people in treatment
for substance use, and so have been abstinent for some time, as in the current sample. Future
research should consider utilizing participants who are not actively engaged in treatment or in
a controlled environment. It could be argued that those in treatment voluntarily are there
because they have some level of insight into the nature of their problems. It is currently
unknown whether people compelled to attend treatment (e.g., under court order) have
differing insight to those who attend voluntarily. These kinds of referrals make up anywhere
from 9% to 56.4% of the population across treatment types (Australian Institute of Health and
Welfare, 2018b) so exploring the role of insight in this subset is important.
Cognitive insight may be critical for improving understanding of addiction and aiding
design of effective interventions. For example, within substance dependence treatment,
retention rates and treatment compliance are a common challenge (De Weert-Van Oene et al.,
2001; Dutra et al., 2008). For those with low insight, a therapy focused on metacognition may
be a beneficial adjunct to traditional treatment (Nosen & Woody, 2009). Cognitive insight is
overlooked in SUD populations, but may be important to improving treatment retention rates,
and reducing subsequent relapses.
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Chapter 4: Cognitive insight, medication adherence and methamphetamine
cessation in people enrolled in a pharmacotherapy trial for methamphetamine use

This chapter has been published in Journal of Substance Abuse Treatment. The chapter is
identical to the submitted manuscript except table numbers (Table 8 and Table 9) and figure
numbers (Figure 3) which have been altered to ensure uniformity in formatting across the
thesis.
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4.1 Introduction
Insight is a multifaceted construct and was initially clinically defined as the awareness
of one’s illness, and the need for treatment for this illness (Amador et al., 1993; Dam, 2006).
The definition of insight has subsequently been expanded to also encompass the capacity for
metacognition (i.e., thinking about one’s thinking) (Beck et al., 2004). These two factors of
insight are typically termed ‘clinical’, referring to problem awareness, and ‘cognitive’,
referring to capacity for metacognition. The majority of extant studies on both clinical and
cognitive insight have been conducted with people living with schizophrenia and bipolar
disorder. A link between low clinical insight and poor medication adherence is established
(Droulout et al., 2003; Lincoln et al., 2007; Rüsch & Corrigan, 2002), with suggestions that
the same relationship may be present for cognitive insight (Raffard et al., 2013). This
relationship is hypothesised to be due to the person’s lack of perceived need for medication,
and their perceptions of low efficacy of that medication, resulting in them seeing no reason to
take the prescribed medication (Rüsch & Corrigan, 2002). Clinical and cognitive insight are
also related to treatment outcomes, with studies showing good insight predicts improved
treatment outcomes such as symptom remission and better quality of life (Emsley et al.,
2008; Lincoln et al., 2007).
Investigation of insight in groups with Substance Use Disorder (SUD) is limited, but
clinical insight has been targeted as a potentially important factor in maintaining both
treatment adherence and ongoing drug abstinence following treatment (Giyaur et al., 2005;
Goethals et al., 2012; Jung et al., 2011; Willems et al., 1973b). Longitudinal studies in SUD
have found that clinical insight is related to higher likelihood of ongoing abstinence from
alcohol after 12 months (Kim, Park, et al., 2007) and 24 months (Willems et al., 1973b). Only
one study examining cognitive insight longitudinally has been conducted and found a
positive relationship between cognitive insight and longer treatment duration for people who
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use opiates (Giyaur et al., 2005). The near singular focus of clinical insight in SUD is a
limitation of the literature, as measures primarily used in substance disorder research are selfreport; researchers are relying on participants having good problem awareness from the
outset (Kim, Park, et al., 2007; Kim, Kim, et al., 2007). Examining cognitive insight may
complement the growing SUD insight literature.
A question that has emerged recently concerns the malleability of clinical and
cognitive insight. Within SUD research, three intervention studies have aimed to target
clinical insight in people with alcohol use disorder and found that insight improved (Im et al.,
2007; Jung et al., 2011; Slaski & Zylicz, 2006). Clinical insight also appears to change with
SUD treatment that does not specifically target insight (Verdejo-García & Pérez-García,
2008; Willems et al., 1973b). However, a limitation of this research is that it has primarily
been conducted in treatment settings, where participants are already abstinent and studies
have focused almost exclusively on alcohol and cocaine use disorders (Raftery et al., 2020).
Research exploring cognitive insight change is less available; there is a suggestion that
elements of cognitive insight related to certainty in one’s self are relatively static (Nair et al.,
2014), whereas reflection capacity may change over time (Palmer et al., 2015). This is
supported by research with people living with schizophrenia where their reflection capacity
changes while their self-certainty remains the same during treatment (Bora et al., 2007)
however there is no current literature looking at cognitive insight change in SUD. It is also
important to understand how both clinical and cognitive insight functions within groups with
different primary substances of concern since research shows that treatment engagement and
success differs by substance of choice (Brorson et al., 2013; Deane et al., 2012; VelazquezMillings, 2017).
The role of insight in people dependent on methamphetamine has not previously been
examined and may be of particular relevance given the experience of psychotic and
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depressive symptoms in some users (Akindipe et al., 2014; Darke et al., 2008; McKetin et al.,
2016; McKetin et al., 2006; Voce et al., 2019). Additionally, there is evidence of cognitive
deficits, specific to self-awareness and self-monitoring, in people dependent on stimulants
(Dean et al., 2015; Moeller et al., 2016; Proebstl et al., 2019; Simon et al., 2010). A study
examining metamemory (awareness of memory deficits) in people who use
methamphetamine (Casaletto et al., 2015) found people who used methamphetamine had
significantly worse ability to recognise their memory deficits, compared to controls. As
cognitive insight encompasses capacity for awareness of one’s own thoughts, it may therefore
be pertinent to examine in people with methamphetamine dependence. Methamphetamine
dependence is a rising global health problem (United Nations Office on Drugs and Crime,
2020) resulting in increased individual and societal harms (Australian Institute of Health and
Welfare, 2020; Degenhardt et al., 2017; Farrell et al., 2019; Liu et al., 2017; Marshall &
Werb, 2010; McKetin et al., 2014). Treatments for methamphetamine dependence are limited
in scope and efficacy (Farrell et al., 2019; Stuart et al., 2020). Pharmacotherapy for
methamphetamine dependence is still in its infancy (Farrell et al., 2019). There are limited
studies examining the factors influencing adherence to medication in SUD. Better
understanding of the role of cognitive insight in relation to medication adherence and
treatment outcomes for people with methamphetamine dependence may help in the
development of more effective psychological and pharmacological interventions.
4.1.1 Aims
The broad aim was to use the Beck Cognitive Insight Scale (BCIS; Beck et al., 2004)
to examine cognitive insight in people enrolled in a methamphetamine pharmacotherapy trial.
The BCIS is comprised of two subscales: Self-Certainty and Self-Reflection. High SelfReflection and low Self-Certainty are considered to indicate ‘good’ cognitive insight.
The first aim was to explore the baseline characteristics of the sample and their
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relationships to cognitive insight.
The second aim was to examine the relationship of cognitive insight to medication
adherence. It was hypothesised that trial participants with better cognitive insight at the start
of the trial would be more adherent to their medication during the trial.
The third aim was to determine the relationship between cognitive insight at the start
of the trial and change in methamphetamine use at the conclusion of the trial. It was
anticipated that those with higher Self-Reflection at baseline would show greater reductions
in methamphetamine use over the trial period.
The fourth aim was to examine change in cognitive insight over the trial period, with
the hypothesis that Self-Certainty would remain stable, and that Self-Reflection would
improve with reductions in methamphetamine use.
4.2 Method and Materials
4.2.1 Participants
Participants (n=152) were a subset of a sample recruited as part of a double-blind
randomised placebo-controlled trial of N-acetyl cysteine for methamphetamine dependence;
the N-ICE Trial. A full protocol for the N-ICE Trial is available elsewhere (McKetin, Dean,
et al., 2019). Participants were recruited from July 2018 through to December 2019.
Participants were dependent on methamphetamine, wanting to reduce or cut down their use
of methamphetamine, not currently engaged in any form of treatment for any substance
(including pharmacotherapy), and not diagnosed with a primary psychotic disorder.
4.2.2 Procedure
Participants attended an in-person baseline assessment, where informed written
consent was obtained. Following this, they were randomized and attended an assessment
(Time 0) at which they received the trial medication (2,400 mg N-Acetyl-Cysteine or
equivalent placebo), taken as two 600 mg capsules every morning and night for 12 weeks.
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Participants attended 12 further weekly assessments. Participants received $30 for each
assessment attended. For the current study, baseline and time zero were considered the ‘pretest’ (prior to medication), and time 12 (final assessment) data was post-test.
This study received ethics approval from relevant human research ethics committees:
Eastern Health (E21–2017), Barwon Health (17/202), the University of Wollongong and
Illawarra Shoalhaven Local Health District Health (2017/549), and Curtin University
(HRE2018–0205)
4.2.3 Measures
Demographics collected at baseline assessment included age, gender, education,
marital status, employment, income, and if participants had ever been incarcerated (yes/no).
Cognitive Insight was measured at baseline and 12-week assessment with the Beck
Cognitive Insight Scale (BCIS; Beck et al., 2004). The two subscales, Self-Certainty, (6
items; e.g., “I can trust my own judgement at all times”) and Self-Reflection (9 items; “I have
jumped to conclusions too fast”) were examined separately. Each item is scored on a fourpoint scale from ‘(0) Do not agree at all’ to ‘(3) Agree completely’. A subscale score is
obtained by summing the items, with higher scores indicating more Self-Certainty (range = 0
to 18) or Self-Reflection (range = 0 to 27). A composite score is calculated by subtracting the
Self-Certainty score from the Self-Reflection score (range = -18 to 27). There are currently
no established norms for this measure and research has shown differing results dependent on
primary disorder/illness (Van Camp et al., 2017). The BCIS has been validated for use in a
SUD population (Raftery et al., 2019). Based on the recommendations from Raftery et al.
(2019), items 12 and 14 were removed from analysis, thus the Self-Reflection subscale
contained seven items. In the current study, Self-Certainty internal reliability was low with
Cronbach’s α = .58. The original BCIS study found a comparable internal consistency of α =
.60 (Beck et al., 2004). Self-Reflection had satisfactory internal reliability with Cronbach’s α
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= .71.
Methamphetamine Use over the previous four weeks was collected at baseline, and
updated each assessment point using the Timeline Followback (TLFB; Sobell & Sobell,
1992). Methamphetamine use was calculated as a proportion of days in the 28-day period
prior to the baseline assessment and the 12-week assessment (proportions were used because
the number of days during the final 4-week period could vary depending on the date of
follow-up). Duration of methamphetamine use in years was the difference between current
age and age of first methamphetamine use. Three additional self-report methamphetamine
measures were administered at baseline: the Severity of Dependence Scale (SDS; Gossop et
al., 1995), Amphetamine Withdrawal Questionnaire (AWQ; Srisurapanont et al., 1999) and
Craving Experience Questionnaire-Strength (CEQ-S; May et al., 2014).
Mental health was measured at baseline using the Brief Psychiatric Rating Scale
(BPRS; Lukoff et al., 1986). Outcomes were the score on the BPRS items of hostility,
suspiciousness, unusual thoughts, hallucinations, depression, and suicidality. BPRS items are
scored on a seven-point anchored scale (Not present [1] through to Extremely Severe [7]).
BPRS ratings were reviewed weekly by the research team to ensure interrater consistency
across the three trial sites (Ventura et al., 1993).
Adherence to medication was captured using eCAPTM (Med-ic eCAP™, Information
Mediary Corp) medication bottle lids that tracked the date and time of bottle opening.
Adherence was defined as the percentage of non-missed doses of medication, with the dosing
schedule being two doses per day over the 12-week medication period. Medication adherence
data were available for 139 participants, based on 447 returned medication bottles (of 596
bottles dispensed), providing 1302 weeks of adherence data.
4.2.4 Analyses
All data were analysed in Stata version 16.0. All tests were two-sided with

83

significance set at p < 0.05.
To explore the baseline characteristics of the sample and their relationships to
cognitive insight, we examined the relationship between each BCIS subscale (Self-Reflection
and Self-Certainty) and the characteristics of the sample at baseline (demographics, drug use
history, and psychiatric symptoms) using Spearman correlations for all continuous variables,
Kruskal-Wallis tests for ordered skewed variables and Pearson’s chi-square tests for
categorical variables. Spearman correlations were used for normal and skewed continuous
variables for ease of interpretation. Median and IQR are reported for skewed variables (Table
8). Regression models were used to identify the most parsimonious set of predictors of SelfReflection and Self-Certainty respectively. These models included all variables that had a
significant relationship with the relevant BCIS subscale.
Variables that significantly correlated with baseline scores on Self-Reflection and
Self-Certainty respectively were used in the predictive linear regression modelling. To
determine the predictive relationship between cognitive insight (that is, higher SelfReflection and lower Self-Certainty) at the start of the trial and adherence to study
medication during the trial, we ran two linear regression models, each with medication
adherence as the outcome, one with the Self-Reflection subscale score as the predictor
variable, and the second with Self-Certainty as the predictor variable. Each of these models
was then adjusted for covariates, these included any baseline variable that significantly
correlated with baseline scores on Self-Reflection and Self-Certainty respectively.
To examine whether each BCIS subscale at baseline was predictive of change in
methamphetamine use at 12 weeks, we ran two regression models with change in
methamphetamine use as the outcome (proportion of days used at baseline minus proportion
of days used at 12 weeks). The first regression used baseline Self-Reflection as the predictor
variable and the second used baseline Self-Certainty as the predictor variable. Models were
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subsequently adjusted for treatment condition and covariates identified as significant
correlates with Self-Reflection and Self-Certainty respectively at baseline.
To examine whether BCIS scores changed over the trial period, paired samples t-tests
were conducted to determine differences between Self-Reflection and Self-Certainty scores at
baseline and at the 12-week follow-up. This analysis was restricted to participants who
completed the BCIS at week 12 (n = 79).
To examine whether change in methamphetamine use from baseline to 12 weeks
predicted Self-Reflection at 12 weeks, a linear regression was run with Self-Reflection at 12
weeks as the outcome and change in methamphetamine use as the predictor variable
(proportion of days used at baseline minus proportion of days used at 12 weeks), controlling
for baseline Self-Reflection. This model was then adjusted for treatment condition and
covariates, these being any baseline variable that correlated with change in methamphetamine
use. The same procedure was then repeated, substituting Self-Certainty at 12 weeks as the
outcome variable, and controlling for Self-Certainty at baseline.
4.3 Results
4.3.1 Participant characteristics
Participants had a mean age of 38 (SD = 8.9) years. The majority were male (59%),
born in Australia (93%), and single (61%). They had completed an average of 10 years of
school (SD = 1.5) and the majority had undertaken further education (Trade/Technical: 61%;
University: 11%). Despite this, more than half were unemployed (55%), and 60% earned
under $800 per fortnight. Twenty-eight percent of participants had been incarcerated.
4.3.2 Relationship between participant characteristics and cognitive insight
At baseline, the mean Self-Reflection score was 9.3 (SD = 4.0), and the mean Self-Certainty
score was 6.1 (SD = 3.3). Scores on neither BCIS subscale differed significantly between
participants who were allocated to placebo versus active medication (Self-Certainty: placebo,
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mean (SD) = 6.1 (3.3), active, mean (SD) = 6.0 (3.4), t = 0.19, p = 0.846; Self-Reflection:
placebo, mean (SD) = 9.7 (4.2), active, mean (SD) = 9.0 (3.8), t = 0.98, p = 0.328).
There were also no significant differences on either BCIS subscale at 12 weeks
between participants who were allocated to placebo versus active medication (Self-Certainty:
placebo, mean (SD) = 7.0 (4.3), active, mean (SD) = 5.8 (3.3), t = 1.36, p = 0.18; SelfReflection: placebo, mean (SD) = 7.0 (3.5), active, mean (SD) = 7.9 (3.7), t = -1.01, p =
0.32). Table 8 shows the relationship between baseline characteristics and BCIS subscale
scores at baseline. There were no significant correlations between either of the BCIS
subscales and days of methamphetamine use in the 28 days prior to the baseline assessment.
Higher Self-Reflection was related to younger age (rs = -.24, p = .003), more severe
withdrawal (rs = .37, p <.001) and cravings (rs = .15, p =.04), and symptoms of hostility,
depression, and suicidality. A linear regression model including all of these correlates of SelfReflection (F(5,141) = 9.10, p < .001) found that Self-Reflection remained significantly
associated with more severe hostility (b = .73, t = 3.14, p = .001) and withdrawal (b = .15, t =
2.77, p = .006) but not age (b = -.04, t = -1.04, p= .30), depression (b = .19, t = .79, p = .43)
or suicidality (b = .13, t = .38, p = .71).
Higher Self-Certainty was related to fewer years of schooling (rs = -.34, p < .001),
less tertiary education (rs = -.21, p = .01), past incarceration (rs = .20, p = .02) and longer
duration of methamphetamine use (rs = .26, p = .001). Inclusion of these variables in a linear
regression model (F(3,144) = 13.42, p < .001, R2 = .15) showed that years of schooling (b = .67, t = -3.85, p<.001), and years of methamphetamine use (b = .07, t = 2.27 p = .02)
remained significantly correlated with Self-Certainty but tertiary education (b = -.70, t = 1.63 p = .11) and past incarceration (b = .08, t = 2.20 p = .77) did not.
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Table 8.
Sample characteristics and correlations of BCIS subscales and composite to demographic and substance use variables at baseline, and with 12week BCIS subscale scores.
Baseline (n=152)

BCIS at 12-weeks (n= 79)

Self-Reflection

Self-Certainty

Self-Reflection

Self-Certainty

37.7 (8.2)

-0.24**

.14

-.23*

.34**

59

X2 = 22.34

X2 = 10.07

X2 = 8.30

X2 = 13.14

10.5 (1.5)

.05

-.34***

.20

-.16

Tertiary education (%)

71

.06

-.21*

.01

-.10

Single, never married (%)

61

X2 = 1.76

X2 = 2.90

X2 = 5.10

X2 = 3.81

Unemployed (%)

55

.10

.08

-.22

-.24

Income <$800/fortnight (%)

60

-.10

.06

.11

-.08

History of incarceration (%)

28

X2 = 24.96

X2 = 31.29*

X2 = 20.65

X2 = 22.00

Methamphetamine use (days of use/28), IQR

.88 (.61 to 1)

-.01

.13

.15

-.16

Age first used methamphetamine, IQR

20 (17 to 25)

-0.10

-0.14

-.07

0.20

Years of methamphetamine use, IQR

14 (8 to 22)

-0.14

0.26**

-.12

.04

Age, Mean (SD) years
Male (%)
Years of school, Mean (SD)
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AWQ, Mean (SD)

19.9 (7.4)

.37***

-0.06

.23*

-.06

SDS, Mean (SD)

12.4 (2.6)

.21

-.003

.12

-.05

CEQ, Mean (SD)

5.1 (2.4)

.15*

.01

.02

-.03

BPRS Hostility, IQR

3 (2 to 4)

X2 = 30.48***

X2 =2.18

-

-

BPRS Suspiciousness, IQR

2 (1 to 3)

X2 = 6.40

X2 = 6.65

-

-

BPRS Unusual Thoughts, IQR

1 (1 to 2)

X2 = 5.40

X2 = 2.32

-

-

BPRS Hallucinations, IQR

1 (1 to 1)

X2 = 6.24

X2 = 6.56

-

-

BPRS Depression, IQR

3 (2 to 4)

X2 = 15.74**

X2 = 8.03

-

-

BPRS Suicidality, IQR

1 (1 to 2)

X2 = 11.10*

X2 = 2.07

-

-

Note. *p< .05 **p≤.01 ***p≤.001. AWQ = Amphetamine Withdrawal Questionnaire, SDS= Severity of Dependence Scale, CEQ = Cravings
Experience Questionnaire, BPRS = Brief Psychiatric Rating Scale.
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4.3.3 Relationship between cognitive insight and medication adherence
Unadjusted linear regression models showed that neither Self-Reflection nor SelfCertainty at baseline were significant predictors of medication adherence (Table 9). These
associations remained non-significant after adjusting for correlates of baseline cognitive
insight. Adjusting for age, baseline AWQ and CEQ score, and baseline BPRS Hostility,
Depression, and Suicidality scores did not alter the relationship between Self-Reflection and
medication adherence (Table 9). Adjusting for years of school, tertiary education,
incarceration history, and years of methamphetamine use did not alter the relationship
between Self-Certainty and medication adherence (Table 9).
4.3.4 Relationship between cognitive insight and methamphetamine reduction
Neither Self-Reflection nor Self-Certainty at baseline were significant predictors of
change in methamphetamine use at 12 weeks in the unadjusted model (Table 9). Adjusting
for age, baseline AWQ and CEQ score, and baseline BPRS Hostility, Depression, and
Suicidality scores did not alter the relationship between Self-Reflection and change in
methamphetamine use (Table 9). Adjusting for years of school, tertiary education,
incarceration history, and years of methamphetamine use did not alter the relationship
between baseline Self-Certainty and change in methamphetamine use (Table 9).
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Table 9.
Unadjusted and adjusted coefficients for BCIS subscales predicting (a) medication adherence and (b) change in methamphetamine use, and
change in methamphetamine use predicting (c) Self-Reflection at 12 weeks and (d) Self-Certainty at 12 weeks.
Unadjusted
(a) Medication Adherence (n = 139)

Adjusted

b (SE)

p

b (SE)

p

Self-Reflection

-.73 (.43)

.09

-.31 (.48)1

.52

Self-Certainty

-.28 (.51)

.58

.19 (.58)2

.74

Self-Reflection

.001 (.01)

.95

-.0003 (.01)1

.98

Self-Certainty

.003 (.01)

.74

.01 (.01)2

.44

b (SE)

p

b (SE)

p

-1.68 (1.16)

.15

-1.99 (1.10)3

.07

-2.71 (1.16)

.02

-2.32 (1.15) 3

.046

(b) Change in Methamphetamine use (n = 121)

(c) 12 week Self-Reflection (n = 79)
Methamphetamine change at 12 weeks
(d) 12 week Self-Certainty (n = 79)
Methamphetamine change at 12 weeks

Note. 1Adjusted for treatment condition, age, baseline AWQ and CEQ score, and baseline BPRS scores for Hostility, Depression, and
Suicidality. 2Adjusted for treatment condition, years of school, tertiary education, incarceration history, and years of methamphetamine use.
3
Adjusted for treatment condition, and age.
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4.3.5 Relationship between change in methamphetamine use and BCIS subscales at week
12
There was a significant decrease in the mean Self-Reflection score from 8.9 (SD =
3.4) at baseline to 7.5 (SD = 3.7) at 12 weeks (t = 3.42, p = .001, d = .38). There was no
significant change in Self-Certainty score over time (baseline mean (SD) = 5.9 (3.3); follow
up mean (SD) = 6.3 (3.8), t = -.95, p = .35). There was no significant relationship between
change in methamphetamine use and Self-Reflection at 12 weeks, and adjusting for treatment
condition did not modify this (Table 9). Change in methamphetamine use was a significant
predictor of Self-Certainty at 12 weeks. This relationship remained significant after adjusting
the model to account for treatment condition and age (Table 9). Examining this effect closer
indicated that people who maintained or increased their use had a significant increase in SelfCertainty (n = 38; t= -2.12, p = .04, d = -0.34), whereas people who reduced
methamphetamine use maintained their Self-Certainty score (Figure 3).
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Figure 3.
Comparison of Self-Certainty mean score at baseline and 12 weeks grouped by
reduction in methamphetamine use at 12 weeks (two categories: (1) did not reduce/increased
use and (2) reduced methamphetamine use).

p = .04
n.s.

4.4 Discussion
This study is the first to examine cognitive insight amongst participants with
methamphetamine dependence. There was no relationship found between baseline cognitive
insight and trial medication adherence. The expectation of the relationship was based on
schizophrenia literature suggesting clinical insight is related to greater adherence to
medication (Droulout et al., 2003; Lincoln et al., 2007; Rüsch & Corrigan, 2002). The
relationship between cognitive insight and adherence (in any population) is not established.
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Additionally, there is discussion in mental health literature that for adherence, it is not
sufficient to consider only insight (Beck et al., 2011). Attitudes towards medication should
also be examined when considering medication adherence, and this may be valuable to
include in future pharmacotherapy trials.
The second surprising result from the current study was the lack of relationship
between Self-Reflection and change in methamphetamine use. Cognitive insight has been
shown to be associated with better outcomes in people with schizophrenia (Van Camp et al.,
2017) and the lack of a relationship in the current study may point to important differences of
the function of cognitive insight in a substance dependent sample compared to a mental
health sample. Within SUD insight research, clinical insight is the primary definition in use
and has been linked to ongoing abstinence (Raftery et al., 2020). Still, evidence is limited as
all longitudinal intervention studies with SUD populations with insight have been conducted
on a sample already in treatment. Thus, there is a need for further exploration of both clinical
and cognitive insight in samples of people actively using substances. It is interesting to note
that the mean Self-Reflection score at baseline in this study (9.3, SD = 4.0) is comparable to
that of a sample in residential treatment for substance use disorders (9.7, SD = 3.77; Raftery
et al., 2019).
The low reliability of the Self-Certainty scale was unexpected, though is comparable
to that found in Beck’s original validation of the BCIS (Beck et al., 2004). This subscale has
previously been found to have acceptable reliability in a substance dependent sample (α =
.72; Raftery et al., 2019). This sample however had been in treatment for an average of 11
weeks. Active substance use may influence responding to Self-Certainty items. Nevertheless,
the relationship of ongoing, or increased, methamphetamine use to increased Self-Certainty is
interesting, though tentative. It may be the case that participants perceived the trial
medication to have ‘failed’, increasing an implicit belief that the addiction is out of their
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control (Alexander et al., 2018; Brown et al., 1998; May & Pratt, 2020). The results here are
preliminary however are worth further exploration. In particular, further understanding the
concept of Self-Certainty as it pertains to individuals with SUD and how to measure this, and
the interaction with treatment success, perceived or actual.
Higher Self-Reflection was related to greater hostility and greater withdrawal at
baseline. The relationship of Self-Reflection and withdrawal symptoms replicates those found
using clinical insight measures in terms of better insight relating to more consequences of use
(Blume et al., 2000; Kim, Park, et al., 2007; Lyu et al., 2017; Yen, Dai, et al., 2009). This
may be due to more self-reflective people being more able to recognise the negative
consequences of their use. The finding that higher Self-Reflection was related to more severe
hostility goes against what has been found in studies of psychosis, where hostility is linked to
worse insight (Lera Calatayud et al., 2012; Lincoln et al., 2007; Wiffen et al., 2010).
Typically though, studies of clinical or cognitive insight and psychotic symptoms involve the
use of the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1989) which is
clinician-rated based on observation through the clinical interview. In our study, the BPRS
(Lukoff et al., 1986) was employed which additionally relies on participant information
regarding their behaviour over the past week. The addition of relying on participant
information may create a similar situation to the withdrawal/insight relationship; higher selfreflectiveness leads to more awareness of what constitutes hostile behaviour, and therefore
potentially higher reports of hostility, compared to people with lower self-reflectiveness.
There are also possibly differences in the causes of hostility in different populations (e.g.,
whether hostility arises from a lack of insight versus being related to substance use), and thus
the role of methamphetamine in hostility must also be acknowledged (Lapworth et al., 2009;
McKetin et al., 2016; McKetin et al., 2014; Zweben et al., 2004).
Finding that Self-Reflection decreased over the trial was surprising, as it was expected
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that cognitive insight would increase with engagement in the trial. As noted in the
Introduction, there is some suggestion in the literature that within SUD, clinical insight may
improve over time when a person is engaged in treatment for their substance use (Im et al.,
2007; Jung et al., 2011; Slaski & Zylicz, 2006; Verdejo-García & Pérez-García, 2008;
Willems et al., 1973b). Within the broader insight literature (i.e., focused on mental health
populations) there are questions regarding whether insight is a state or trait factor. Early
papers suggest that clinical insight may be a state, as it appears to be malleable and liable to
change with treatment (Wiffen et al., 2010). Evidence of change in cognitive insight is less
established. The current results suggest malleability of the different scales of the BCIS; in the
current study Self-Reflection across the whole sample decreased, while Self-Certainty
increased in those who maintained or increased their methamphetamine use. These
differential changes may be interpreted in the context of prior findings that Self-Reflection is
related to lower mood (Palmer et al., 2015) and thus may be more liable to greater change.
Self-Certainty is correlated with cognition (Nair et al., 2014); Literature examining
neurocognitive function in people with substance use disorder shows a relationship between
substance use and deficits in self-awareness and self-monitoring (Goldstein et al., 2009;
Goldstein & Volkow, 2002; Hester et al., 2009; Hester et al., 2007; Moeller et al., 2020;
Verdejo-García et al., 2013). People who are dependent on substances show a decreased
ability for identifying errors (Hester et al., 2009; Hester et al., 2007; Luijten et al., 2014).
Given knowledge of the cognitive recovery of ceasing methamphetamine use (Simon et al.,
2010), combining the neurological based research with the developing psychosocial
construction of insight will strengthen understanding in the SUD insight field.
4.4.1 Limitations
The time period of this study was relatively short. Future research in this field should
consider a longer follow-up period to further explore ongoing relationships, and examine how
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insight may influence ongoing abstinence or engagement in further treatment. With high rates
of relapse following treatment for methamphetamine use (Brecht & Herbeck, 2014), it is
important to conduct longer follow-up studies. The data contained in this report were
examined within the context of a randomised controlled trial and a dedicated study of insight
in substance use is warranted. Additionally, the internal reliability of the BCIS in this sample
was lower than in previous samples (Beck et al., 2004; Engh et al., 2007; Raftery et al.,
2019). It is unclear why the reliability was lower, particularly for the Self-Certainty scale.
Low measure reliability means that the results presented here should be interpreted with care,
and preferably replicated in future research. Though this measure has been validated with a
SUD sample in treatment (Raftery et al., 2019), it has not been employed with people who
are actively using substances. It may be that there are differences in cognitive insight between
people actively using substances and those who have ceased. A broader limitation of the
study is that the hypotheses were based on research that primarily employed a) clinical
insight and/or b) non-substance dependent samples. Though research where both cognitive
and clinical insight has been studied shows some similar clinical relationships (Nair et al.,
2014; O'Connor et al., 2013; Poyraz et al., 2016), this research is limited to psychosis and
there is currently a large gap in our knowledge regarding how well these results translate
across measures and clinical populations.
Finally, the sample size available to compare the change in BCIS scores over time
was relatively small (n=79), and based on only those followed up at 12 weeks, meaning the
results related to 12-week BCIS scores should be interpreted with caution.
4.4.2 Conclusion and future directions
The research surrounding the role of insight in SUD is still relatively young and
producing inconsistent results (Raftery et al., 2020). The current study adds to the evidence
by showing that there are stable participant characteristics (age, years of school) that have a
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relationship with cognitive insight. The findings also build on previous evidence of a
relationship between insight and mental health symptoms in a SUD population. The findings
do not support the hypothesis of a relationship between baseline insight and adherence to
medication, or reduction in methamphetamine use, though there is a potential link to ongoing
methamphetamine use and an increase in Self-Certainty that is worth further study. There is
still an unanswered question regarding other treatment adherence, particularly with relation to
psychological intervention. The majority of treatment available for substance use disorder is
psychological (Stuart et al., 2020), therefore it is important to explore insight in this modality
as well.
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Chapter 5: General Discussion

5.1. Summary of findings
This thesis had three primary aims: 1) collate existing research on insight in SUD and
create a synthesized understanding of the role and relationship of insight in SUD (Study 1);
2) validate a measure of cognitive insight for people with a SUD (Study 2) and; 3) explore
the role and relationship of cognitive insight in a longitudinal sample of people seeking
treatment for their methamphetamine use (Study 3).
Study 1 showed that the body of literature examining insight in SUD is relatively
small (n = 20 studies) and varies greatly with regards to conceptualization of insight and what
is deemed as an important outcome to measure. There is little consistency over how insight
has been measured, with 13 different measures used across the 20 studies. There is moderate
evidence of a relationship between better clinical insight and worse use and consequences.
As shown in Study 1, many studies have not appropriately validated (or shown
evidence of validation for) the measures of insight that have been used for the SUD
population. Study 2 found the Beck Cognitive Insight Scale (BCIS) to be valid for use in a
sample of people in treatment for SUD, with the exclusion of two items from the scale.
Importantly, this study also showed the ability of the BCIS to continue to discriminate
between those with and without psychological distress, and with and without (self-reported)
psychotic disorders. There was no difference in cognitive insight between those who
primarily used alcohol and those who primarily used methamphetamines. Showing that the
Beck Cognitive Insight Scale (Beck et al., 2004) is able to be used in SUD, with the
adjustment of removing items 12 and 14, allows for a starting point for understanding how to
conceptualize and measure cognitive insight in substance dependence.
Study 3 was the first examination of cognitive insight in people actively using a
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substance (methamphetamine) as they progressed through a medication trial. Study 3 found
no relationship between cognitive insight at the start of a medication trial and participants’
rate of adherence to the medication, or their change in methamphetamine use. This was
unexpected, as the literature would suggest that higher insight at baseline would predict
greater medication adherence, and better outcomes (i.e., lower or absent methamphetamine
use). Additionally, the study also showed a decrease in Self-Reflection over the trial period,
even with a significant reduction in methamphetamine use. This was contrary to what was
expected, as it was anticipated that as methamphetamine use decreased, Self-Reflection
would increase. An interesting, and unexpected, finding from the study was that SelfCertainty increased with ongoing or increased methamphetamine use.
5.2 Implications
The overall implications of the current thesis relate strongly to the appropriate
definition and measurement of insight in SUD, and contribute to the growing conversation
regarding the role of insight in SUD. As the concept of insight developed with a focus on
people living with a psychotic disorder, the shift to focusing on SUD has strongly relied on
the original conceptualizations and ways of measuring insight, however, the results in this
thesis indicate that there is a need to revisit this conceptualization for people living with a
SUD.
It is clear that there is some aspect of insight that is important to consider in SUD;
qualitative studies examining barriers to treatment for both consumers and clinicians
routinely highlight a perceived lack of need for treatment, or lack of problem awareness as
barriers to engagement and consistency in treatment (Alexander et al., 2018; Kenny et al.,
2011; Pennay & Lee, 2009; Sarkar et al., 2020). However, there may be some groundwork in
conceptual definition and measurement development required before the function of insight
can fully be realized in SUD.
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5.2.1 Conceptualization and definition of insight
The systematic review within this thesis highlighted the lack of a cognitive insight
conceptualization present in the current SUD literature. While clinical insight in SUD shows
reasonably consistent relationships between good clinical insight and worse substance use
related variables (Kim, Park, et al., 2007; Kim, Kim, et al., 2007; Lyu et al., 2017; Salloum et
al., 1998; Yen et al., 2008), the same relationship was not clear with cognitive insight, and
some studies suggest it may actually be a different relationship (Giyaur et al., 2005).
Understanding the cognitive insight of people living with SUD may help address some of the
difficulties of using clinical insight. As discussed through this thesis, measures used in SUD
research are typically self-report. This means researchers are relying on participants to be
able to accurately report their own substance use and its consequences. Researchers are
therefore relying on the presence of good clinical insight. This is not to say that there is no
place for clinical insight. The work related to the HAIS measure has shown some interesting
results. However, even the authors using this measure note the difficulty of identifying the
real relationship between clinical insight and substance use (Kim, Park, et al., 2007; Kim,
Kim, et al., 2007). As in the psychosis and broader mental health literature (Ekinci & Ekinci,
2013), using a combination of clinical and cognitive insight definitions may serve to broaden
the understanding, and therefore the functionality, of insight in SUD. There is already an
existing research base looking at metacognition in addiction, with a focus on craving and
coping (Lee et al., 2010; Spada et al., 2015) showing that the thoughts people have about
their addiction are related to treatment outcomes. Within addiction research, metacognition
refers to belief in one’s own thoughts (e.g., ‘using substances helps me cope’ or ‘I cannot
control my cravings’) (Spada et al., 2015). Lee et al. (2010) found that for people who use
methamphetamine (n = 214), the more they endorsed unrealistic or catastrophic beliefs about
their cravings, the less likely they were to report ongoing abstinence. Adding cognitive
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insight into this metacognitive conceptualization may allow for an understanding of a
person’s capacity for metacognition, and how well they are able to consider other people’s
views. Metacognition, as outlined by Spada et al., describes a rigidity in thinking that is
ultimately detrimental and perpetuates the substance dependence. As cognitive insight is
concerned with a person’s awareness of and flexibility in thought, these two concepts may be
complementary in further understanding the cognitive processes theorized to drive addiction
(Fattore & Diana, 2016; Goldstein et al., 2009; Manning, Verdejo-Garcia, et al., 2017; Ouzir
& Errami, 2016).
5.2.2 Measurement
The literature is inconsistent on how insight is measured. A myriad of measures are
used, and not all have received the same level of scrutiny with regards to validation for use
within SUD populations. Despite the understanding that insight is a complex and
multifaceted construct, there has been little time devoted to making sure it is being measured
accurately and appropriately in the SUD population. There are some exceptions to this.
Notably, the Hanil Alcohol Insight Scale (Kim et al., 1998) has evidence of validation and
development. There is additionally research from Italy using a specifically developed
measure of clinical insight for heroin use (Maremmani et al., 2012). This research was not
included in the systematic review contained in this thesis as they recruited people under 18
years of age, however it is worth examining. Their measure consisted of a structured
interview, developed through working clinically with people dependent on heroin. From the
interview, three items are scored on a binary yes/no, with insight overall scored as absent if
all items are scored ‘no’, and partial or full if at least one item is scored ‘yes’. The authors do
not offer any validation information, but do discuss the difficulty in obtaining it due to
changing staff during the development process. So, while there are beginnings of specific
measurement development in this field, it is currently in its fledgling stages, and limited to a

101

clinical insight frame.
The importance of ensuring the cognitive insight measure was suitable for a SUD
population was considered in this thesis, and the results indicate that further work is needed
in this area. This is further supported by the comparatively low Cronbach’s alphas found in
Chapter 4. There can be a number of influences on internal consistency such as inconsistent
responding, lack of attention or care, or misinterpretation of items (Fong et al., 2010) and it is
unclear currently what affected the internal consistency in Study 3. Though one of the
strengths of the BCIS (and likely cognitive insight measures in general) is that its items
generally do not relate to specific mental illness symptoms, as clinical insight measures do, it
was still developed with people living with psychosis in mind. There has been some
discussion in the research regarding the BCIS items relating to ‘unusual experiences’ (Engh
et al., 2007; Martin et al., 2010) and how well they relate to people without experience of
psychosis. Interestingly, in Chapter 3, it was not the items related to unusual experiences that
displayed difficulty within the model, but those related to relationships to others. As
discussed in Chapter 3, part of treatment for SUD often involves examining one’s
relationships with other people who also use drugs (Bathish et al., 2017; Dingle, Stark, et al.,
2015). Research shows that an important part of ongoing abstinence is having a network of
recovery orientated people who do not use substances (Stevens et al., 2015). As some items
related to Self-Reflection in the BCIS relate to considering other’s interpretations of events
(e.g., ‘If somebody points out that my beliefs are wrong, I am willing to consider it’) this may
have different implications in people who are potentially reevaluating their social
relationships as part of SUD treatment. Therefore, when considering the aspect of reflection
and being able to take on other people’s opinions, the CFA in Chapter 3 suggests that
considering the relationships of people living with SUD, and the changing nature of these
may be an important part of future measurement development.
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Nearly all current studies on insight in SUD have been conducted with people who are
already abstinent and engaged in treatment. This means that there is a lack of understanding
of insight in people who are actively engaged in their substance use, and if this differs to
those in recovery. The importance of considering this was highlighted in Study 1, with the
comparison of the HAIS in a community sample versus pooled treatment samples. This
comparison showed the community sample to primarily be scored as having poor clinical
insight, whereas the in-treatment samples were largely fair or good. Including participants
who are actively using substances as well as those who are abstinent will provide a richer
profile of insight (clinical or cognitive) within this population.
Within mental health research, both clinical and cognitive insight vary depending on
severity of symptoms (Colis et al., 2006; Dam, 2006; Ekinci & Ekinci, 2013; Engh et al.,
2007; Van Camp et al., 2017). Discussed further in the following section, there is a standing
question regarding the malleability of insight (clinical and cognitive) and ensuring that we are
measuring insight in the most appropriate manner will strengthen understanding of how
insight does (or does not) change with treatment and time.
5.2.3 Clinical Practice
The study presented in Chapter 4 was the first to assess any type of insight in people
who were actively dependent on a substance at the time of recruitment and to follow the
sample through a medication trial. It is also one of the few studies in the broader insight
literature that examines change in cognitive insight over time. As reported in Chapter 2,
clinical insight appears to improve over time in people living with a SUD as they progress
through treatment, and this might lead to more sustained treatment outcomes (Kim, Park, et
al., 2007; Willems et al., 1973b). The change of cognitive insight remains unclear.
Neurocognitive components of reduction or cessation of substance use are likely important to
consider (discussed further below).
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A broader implication of Chapter 4 is the suggestion that cognitive insight in and of
itself may not be crucial to medication adherence. As available pharmacotherapies for
substance use increase (Butelman & Kreek, 2017), adherence is going to be a key aspect to
target. There is currently very little research examining the relationship between cognitive
insight and medication adherence in the mental health literature (Van Camp et al., 2017),
with only clinical insight taking the focus. Comparing scores on the BCIS and competency to
consent to treatment for people living with schizophrenia showed that Self-Reflection was
significantly related to the ability to compare treatment options and consider consequences of
the options on everyday life (Raffard et al., 2013). However, no relationship was found with
actual medication adherence and BCIS scores in another study conducted with people living
with schizophrenia (Settem et al., 2019).
The two empirical studies presented in this thesis provide evidence of the relationship
between cognitive insight in SUD and comorbid mental health difficulties. Reflecting results
from previous research (Colis et al., 2006; Misdrahi et al., 2014; Van Camp et al., 2017),
there was a relationship between better cognitive insight and worse psychological
distress/depression in both Study 2 and 3. This raises the importance of thinking of the impact
of comorbidity within this population (Hunt et al., 2020; Kingston et al., 2017), and how that
may interplay with treatment availability, adherence, and outcome (Krawczyk et al., 2017;
Ritsher et al., 2002). Research examining more than 850,000 substance use treatment
episodes found that people who have a comorbid mental health condition are less likely to
complete treatment for their substance use, and have shorter treatment periods compared to
those without a mental health condition (Krawczyk et al., 2017). People with comorbid
mental illness and SUD have poorer outcomes, with shorter time to re-hospitalization (Hunt
et al., 2002), and are more likely to not be adherent to treatment (Herbeck et al., 2005). These
are factors that insight has also been shown to have an relationship with (Dam, 2006;
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Ghaemi, 1997; Ghaemi & Pope, 1994; Himle et al., 2006; Lincoln et al., 2007; Van Camp et
al., 2017). When looking at comorbid schizophrenia and AUD, Yen, Hsiao and colleagues
(2009) found that those with comorbid AUD had lower clinical insight into their symptoms of
schizophrenia compared to those without an AUD. The study employed two clinical insight
measures, one for schizophrenia and one for AUD, and found a positive relationship; better
insight into schizophrenia was related to better insight into AUD (Yen, Hsiao, et al., 2009).
Much of the insight literature (including the studies presented in this thesis) tends to play
down the comorbidities present in their research sample, and this is also reflected in many
treatment options being for either only mental health or only AOD (Lubman et al., 2014;
Torrens et al., 2012). As research is suggesting both clinical and cognitive insight to be
important for treatment outcomes for mental health disorders, it is important to consider how
they might influence outcomes for SUD, and vice versa. The empirical studies in this thesis
are a small indication that the understanding of insight in mental health may also carry over
to SUD in cases of comorbid presentations.
5.3 Limitations
Specific limitations for each chapter are contained within the respective chapter.
Therefore, this section will focus on the broader limitations of this thesis.
As has been stressed through this thesis, proper measurement of insight in SUD is
critical to understanding its role within substance dependence. Therefore, a significant
limitation of this thesis is the use of the BCIS in the third study. As has been noted
previously, it is worth developing a dedicated measure of insight for people living with
substance use disorders, such as that created by Kim et al (1998). Though care was taken to
ensure that the BCIS was valid for use within a substance dependent population (Study 2), it
is acknowledged that there remain some unanswered questions about its validity for use in
SUD. This includes the recommended exclusion of items 12 and 14 in the CFA model in
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Study 2, and the comparatively low internal validity of the subscales in Study 3. Sample size
in Study 3 precluded running a CFA for comparison, and there was no indication of any one
item being the culprit of the reduced alpha. The measurement of insight in schizophrenia has
a relatively long history, and consequently the measures that have been developed have a
sizeable amount of research behind them. As obvious as it may be to say, schizophrenia and
SUD are different disorders, and so it is likely not sufficient to take the learnings from
schizophrenia populations and apply them to SUD populations, without appropriate thought
and modification. As highlighted in the Implications section above, it may be worth
considering specific items and how they are interpreted by people living with SUD, or
building on knowledge gained from metacognition research.
There is no comparison to clinical insight in this thesis. A comparison of cognitive
and clinical insight is something that is overall lacking in the SUD and insight literature. It
was intended to compare the BCIS with items from a clinical insight measure (Birchwood et
al., 1994) within Study 3, however preliminary analysis indicated that the internal
consistency of the items was not acceptable, and this was not explored further. To fully
understand how insight functions within SUD, it will be beneficial to consider both clinical
and cognitive insight, as this would allow for a deeper exploration of the insight factors that
contribute to treatment adherence and outcomes in SUD (Riggs et al., 2012).
As noted in Study 1, there is a real lack of longitudinal studies including posttreatment follow up within insight in SUD literature. That Study 3 did not extend past the 12week trial period limits the ability to understand how insight influences ongoing abstinence
and/or subsequent treatment engagement for this population. This is particularly pertinent
given that in terms of methamphetamine withdrawal, three months is a relatively short time
(Proebstl et al., 2019), with studies showing that in the early stages of methamphetamine
withdrawal there is a decline in cognitive functioning (Simon et al., 2004) with deficits
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lasting at least one month post cessation (Simon et al., 2010), all of which may impact
cognitive insight (Dean et al., 2015).
Polysubstance use was not explored in this thesis. While studies 2 and 3 took the
position of identifying a primary substance of use, most participants were or had been
engaged in polysubstance use. This exclusion of polysubstance use is a common pattern
through the extant literature, as evidenced from Study 1. A recent national survey conducted
in Australia found that more people are reporting simultaneous polydrug use (Australian
Institute of Health and Welfare, 2020). People who engage in polysubstance use are more
likely to experience significant psychological distress (Connor et al., 2014). There are also
emerging neurocognitive implications of polysubstance use, with research indicating there is
a cumulative effect of polysubstance use of brain structure and function (Connor et al., 2014;
Crummy et al., 2020; Lewis et al., 2020). Therefore, focusing on only a ‘primary’ substance
may preclude the opportunity to fully explore the range of insight and how it interplays with
mental health, and treatment outcomes. With regard to Study 3, sample size prohibited
extracting those who only used methamphetamine. Additionally, all participants were
screened for methamphetamine dependence, and all participants were seeking to cease or
reduce their methamphetamine use.
An additional limitation of this thesis is that there was no examination of how insight
interplays with psychological therapy. The sample in Study 2 were recruited from a
residential rehabilitation facility with a focus on cognitive-behavioural programs to address
addiction, however the cross-sectional nature of this study limits the inferences that can be
made, and there were no targeted treatment engagement questions asked. While the sample
from Study 3 were able to access alternate treatment during the trial period, the number of
people who engaged with other treatment services was quite low (22%; McKetin et al.,
2021). Beyond the low numbers, there was no capacity within the study design to thoroughly
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examine the type of intervention received (i.e., therapy modality). Therefore, while the
current study did not find a relationship between cognitive insight and medication adherence,
the same cannot yet be said for psychological therapy. There is a dearth of literature
regarding how insight (clinical or cognitive) influences treatment outcomes as people make
the move from actively engaging in substance use to reducing or ceasing their use. This thesis
has only looked at how cognitive insight relates to one type of treatment, and that was
experimental (i.e., not currently supported as an effective treatment; McKetin et al., 2021).
5.4. Future Directions
Appropriate measurement is key. Future studies should endeavor to conceptualize and
define insight in a way that makes sense within a SUD population. This includes thinking
critically about the nature of clinical insight, and how it might inappropriately interact with
self-report measures of substance use frequency or consequences that are primarily employed
within research and clinical practice. Broadening the understanding of ‘insight’ to also
include cognitive insight may help pave the way for a deeper understanding of how insight
functions and how it can be understood in this population. Alongside the definition of insight
becoming clearer, developing specific and SUD-targeted insight measures will be important.
This includes laying the groundwork of validating and developing population norms related
to insight in SUD – both with in-treatment and non-treatment populations.
As mentioned through all three chapters, there is a need to engage people at all stages
of substance use, not just those already in treatment. Chapter 2 (Study 1) showed that there
was a large difference in distribution of people across clinical insight categories according to
the HAIS depending on if they were in treatment or not. The community sample employed in
one study (Yen et al., 2008) was largely rated as having ‘poor’ clinical insight, compared to
the in-treatment samples largely being ‘fair’ or ‘good’ (Im et al., 2007; Jung et al., 2011;
Kim, Park, et al., 2007; Kim, Kim, et al., 2007; Lyu et al., 2017). This lends itself to the idea
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that when people are willingly and actively engaged in treatment, it is a reasonable
assumption that their clinical insight will be higher as they have recognized their substance
use problem enough to take the steps necessary to enter treatment. A study exploring the
interplay of readiness to change and clinical insight found that people who were in PreContemplation had significantly lower clinical insight compared to those in Contemplation or
Action (Kim, Kim, et al., 2007). Studying only populations in treatment, or even seeking
treatment, precludes the ability to explore the full gamut of clinical and cognitive insight in
SUD. Some research suggests that people who are court mandated (or otherwise coerced) to
attend treatment have lower treatment motivation than those entering voluntarily (Marshall &
Hser, 2002; McSweeney et al., 2007). Thus, one step towards exploring insight further might
be engaging people who are mandated to attend treatment, rather than those who enter
voluntarily. In Study 3, the sample opted in to the trial, and one inclusion criteria was a
reported desire to reduce or cease use. While it is important to understand the role of insight
for those already actively engaged in treatment, there is also room to examine how to build
the insight to recognize the need for treatment as well.
The overlap of denial and insight in SUD also needs further exploration. These two
concepts were not contrasted in the studies in this thesis, however dedicated study examining
the relationship between these measures would be beneficial. From a neuropsychological
point of view, deficit in self-awareness is theorized to occur in part due to problems with
information processing (Verdejo-García et al., 2013) meaning that the information is simply
not accessible to the person. Denial, on the other hand, is theorized as a protective measure
guarding one’s emotional wellbeing from negative information (Dare & Derigne, 2010;
Verdejo-García et al., 2013). The result of these two internal processes is the same (i.e., a
person who does not acknowledge the impact of their substance use), however intervention to
address them is likely different. As denial is theorized to be motivated by self-preservation
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from painful emotions, working with the person on addressing feelings of shame and guilt
and working with the avoidance of painful emotions may be the best intervention (Luoma et
al., 2012; Zafar & Farhan, 2020). On the other hand, interventions focused on mindfulness
and increasing awareness of internal processes (e.g., Jung et al., 2011; Slaski & Zylicz, 2006)
may be the most beneficial for developing self-awareness and thus insight.
This thesis has not examined the neurocognitive profile of insight in people living
with SUD, though this literature base does exist (Goldstein et al., 2009; Hester et al., 2009;
Moeller et al., 2014). Currently, there appears to be little integration of the psychosocial
studies such as those presented here, and the neurocognitive based studies. Combining these
two fields will benefit the understanding of insight in substance use (Moeller & Paulus, 2018;
Schulte et al., 2014). There is a chasm to be bridged here, examining how these structural and
functional neurological changes are involved with the changing nature of insight, and how
that all plays into engagement and adherence to treatment, and abstinence maintenance post
treatment.
It is also important to further develop the understanding of insight across different
substances. As noted in chapter 2, the majority of research has focused on people living with
alcohol use disorders. However, as research is showing that treatment outcomes differ
depending on substance of choice (Deane et al., 2012; Fernández-Serrano et al., 2011), and
the knowledge that different substances have differing short and long term effects on the
brain (Fernández-Serrano et al., 2011), understanding how insight plays out for each
substance class may be worth further study. As noted in the limitations section, it is important
to also acknowledge the role and impact of polysubstance use. Taking the time to understand
whether insight does differ across substances, and with polysubstance use, will ultimately
strengthen this literature field.
The literature on the malleable nature of insight is also currently unclear. As

110

mentioned in Chapter 4, there is some discussion over whether insight is a state or trait factor,
and the idea that clinical insight may be state, whereas cognitive is trait (Nair et al., 2014). It
is worthwhile developing research to examine if and how insight changes through SUD
treatment, building on the work presented in Chapter 4. This will help to inform
interventions; if insight is able to be directly targeted for change and it is beneficial to do so,
then addressing it in treatment could be important. For example, metacognitive interventions
focusing on addressing the unhelpful thought management strategies people may employ
(rumination, worrying, avoidance) (Wells & Fisher, 2009). A meta-analysis examining the
effect of metacognitive interventions for people living with schizophrenia showed a medium
effect of improved cognitive insight, compared to controls (Lopez-Morinigo et al., 2020).
Within SUD, and as discussed in Chapter 2, there has been some exploration of intervention
for insight. Jung et al. (2011) delivered five motivation enhancement sessions within a
residential treatment facility, with a significant increase in clinical insight resulting. Im et al.
(2007) and Slaski and Zylicz (2006) both employed a metacognitive intervention with a
resulting increase in clinical insight. However, across both mental health and SUD literature
there is a lack of ongoing follow up studies examining the long term effects of these
interventions.
Ultimately, further research on insight in SUD will be beneficial. This includes
clarifying the best way to conceptualise and measure insight, examining insight across
individual SUDs, conducting more longitudinal studies, including follow up post treatment
and tracking insight throughout an individual’s treatment journey.
5.5 Conclusion
This thesis contains the first systematic review of insight in substance use disorder,
bringing together the previously siloed research and highlighting the gaps as they currently
stand in this field. The first longitudinal study of insight in people who were actively using
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any substance was conducted in this thesis. Though the results showed that cognitive insight
was not related to medication adherence or methamphetamine cessation, this may have been
due in part to the measure; Though the BCIS was validated within a sample in residential
substance dependence treatment, its further use in a community sample of people living with
a SUD suggests it is not the strongest measure for future use with people living with a SUD.
Insight remains an elusive construct. There is a lack of clarity regarding definition and
conceptualization within the current SUD research literature. There is significant
development to be done with SUD literature to understand the function of insight, and how it
may serve to inform treatment for this population. Future research would benefit from more
focused attention on the measurement of insight in SUD, building on the work in this thesis
and that of the HAIS.
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Appendix 2: Study 2 Survey Tool

Section A: Background Information
What We Help Ourselves Program are you attending? (Tick)
Hunter valley

£1

MTAR

Gunyah (men)

£2

Sunshine Coast£5

New Beginnings (women)

£3

RTOD

£4

£6

How many weeks have you been in the program for? _________
What is your age? _______
What is your gender? (Tick)
Male

£1

Female

£2

What country were you born in? (Tick)
Australia

£1

Other (Please Specify):

£2

Are you of Aboriginal or Torres Strait Islander descent?
Aboriginal and Torres Strait Islander

£1

Aboriginal but not Torres Strait Islander

£2

Neither

£3

Torres Strait Islander but not Aboriginal

£4

Not Stated / inadequately described

£5

(Tick)

What is the highest level of education you have attended? (Tick)
Primary school or less

TAFE/Trade

£4

High school (not completed) £2

Undergraduate degree/s

£5

High school (completed)

Postgraduate degree/s

£6

£1

£3
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A8. What is your main source of income? (Tick)
Government pension (e.g. Centrelink, disability support pension)

£1

Wage/ Salary

£2

Other

£3

A9. What is your marital status?
Single, never married

£0

Married

£1

De facto

£2

Separated

£3

Divorced

£4

Widowed

£5

A10. What is your level of satisfaction with your marital status?
Very dissatisfied

£1

Dissatisfied

£2

Neither satisfied nor dissatisfied

£3

Satisfied

£4

Very satisfied

£5

A11. Who did you live with before entering treatment?
Alone

£1

Family or significant other

£2

Friends

£3

Institution

£4

No fixed address

£5

A12. How would you rate your ability to read? (Circle)
0
Terrible or Very
Poor

1
Poor

2
Okay

3
Good

4
Excellent or
Very Good
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A13. How often do you need to have someone help you when you read instructions,
pamphlets, or other written material from your doctor or pharmacy? (Circle)
0
Never

1
Rarely

2
Sometimes

3
Often

4
Always
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Section B: Alcohol & Substance Abuse
How long have you had drug and/or alcohol problems? ___________Years
In the 12 months before you entered treatment, what substances had you used? (You may
tick multiple drugs)
Yes
No
Heroin

c1

c2

Marijuana/Cannabis

c1

c2

Amphetamines (e.g. speed, ice, crystal meth)

c1

Alcohol

c1

c2

Ecstasy

c1

c2

Cocaine

c1

c2

Abuse of prescription medication

c1

c2

c2

Others: Please Specify _____________________

What do you consider your primary drug of concern? (Please specify just one)
____________________________________________
Before entering treatment, how often would you take your primary drug of concern?
(Tick)
c1
Once a month

c2
More than once
a month

c3
At least once a
week

c4
Daily

c5
More than once
a day

Have you previously sought treatment for a substance dependence problem? (tick)
£1
£2
Yes
No

Not including tobacco, how long ago did you last use alcohol or other substance of
abuse? _________ weeks
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Do you currently smoke cigarettes or other tobacco products on a daily basis? (Tick)
Yes

£1

No

£2

How many cigarettes do you smoke a day? ___________ cigarettes
How soon after you wake up do you have your first cigarette? (Tick)
c Within 5 minutes

c 26-30 minutes

c 21-30 minutes

c After 60 minutes
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Section C: Medical History
C1. Have you ever previously received treatment for a mental health problem? (Tick)
Yes

£1

No

£2

If Yes, what diagnosis did you receive? _________________________
C2. Are you currently on medication for any mental health conditions? (Tick)
Yes

£1

No

£2

If Yes, please specify: _________________________
C3. Do you have any chronic diseases or conditions (e.g. heart problems, hepatitis, cancer,
diabetes, arthritis)? (Tick)
Yes

£1

No

£2

If Yes, please specify: _________________________
C4. How proactive are you in seeking medical support when needed (e.g. visiting a GP)?
0
Never

1
Rarely

2
Sometimes

3
Often

4
Very

C5. Are you good at following doctors instructions in regards to health care e.g. take
required medication and dosages, follow up on appointments?
0
Never

1
Rarely

2
Sometimes

3
Often

4
Very
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Section D: Understanding Health and Health Literacy Questionnaire
Please indicate how strongly you disagree or agree with the following statements by
circling the response that best describes you now.
D1. I feel I have good information about health.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D2. I have at least one healthcare provider who knows
me well.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D3. I can get access to several people who understand
and support me.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D4. I compare health information from different
sources.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D5. When I feel ill, the people around me really
understand what I am going through.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D6. I spend quite a lot of time actively managing my
health.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D7. When I see new information about health, I check
up on whether it is true or not.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D8. I have at least one healthcare provider I can discuss
my health problems with.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D9. I make plans for what I need to do to be healthy.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D10. I have enough information to help me deal with my
health problems.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D11. If I need help, I have plenty of people I can rely on.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D12. I always compare health information from
different sources and decide what is best for me.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D13. Despite other things in my life, I make time to be
healthy.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D14. I am sure I have all the information I need to
manage my health effectively.

Strongly
Disagree

Disagree

Agree

Strongly
Agree
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D15. I have at least one person who can come to
medical appointments with me.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D16. I know how to find out if the health information I
receive is right or not.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D17. I have the healthcare providers I need to help me
work out what I need to do.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D18. I set my own goals about health and fitness.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D19. I have strong support from family or friends.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D20. I ask healthcare providers about the quality of the
health information I find.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D21. There are things that I do regularly to make myself
more healthy.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D22. I can rely on at least one healthcare provider.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

D23. I have all the information I need to look after my
health.

Strongly
Disagree

Disagree

Agree

Strongly
Agree

Please indicate how easy or difficult the following tasks are for you to do by circling the
appropriate response.
D24. Find the right health care

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D25. Make sure that healthcare providers
understand your problems properly

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D26. Find information about health problems

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D27. Feel able to discuss your health concerns
with a healthcare provider

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D28. Confidently fill medical forms in the correct
way

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy
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D29. Find health information from several
different places

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D30. Have good discussions about your health
with doctors

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D31. Get to see the healthcare providers I need to

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D32. Accurately follow instructions from
healthcare providers

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D33. Get information about health so you are up
to date with the best information

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D34. Decide which healthcare provider you need
to see

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D35. Read and understand written health
information

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D36. Make sure you find the right place to get the
healthcare you need

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D37. Get health information in words you
understand

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D38. Discuss things with healthcare providers
until you understand all you need to

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D39. Find out what healthcare services you are
entitled to

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

5 Very
easy

D40. Read and understand all the information on
medication labels

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D41. Get health information by yourself

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D42. Work out what is the best care for you

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D43. Ask healthcare providers questions to get
the health information you need

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy

D44. Understand what healthcare providers are
asking you to do

Cannot
do

Very
difficult

Quite
difficult

Quite
easy

Very
easy
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Section E: Views about your health (SF-12)
Answer each question by choosing just one answer. If you are unsure how to answer a
question, please give the best answer you can. Tick the appropriate box.
E1. In general, would you say your health is:
£1

£2

£3

£4

£5

Excellent

Very good

Good

Fair

Poor

The following questions are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much? Tick the appropriate box.
E2. Moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or
playing golf or other similar activities within the treatment facility.
£1
Yes, limited a lot

£2
Yes, limited a little

£3
No, not limited at all

E3. Climbing several flights of stairs.
£1
Yes, limited a lot

£2
Yes, limited a little

£3
No, not limited at all

During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical health? Tick the appropriate box
E4. Accomplished less than you would like.
Yes

£1

No

£2

E5. Were limited in the kind of work or other activities.
Yes

£1

No

£2

During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of any emotional problems (such as feeling
depressed or anxious)? Tick the appropriate box
E6. Accomplished less than you would like.
Yes

£1

No

£2

E7. Did work or activities less carefully than usual.
Yes

£1

No

£2
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E8. During the past 4 weeks, how much did pain interfere with your normal work
(including work around and outside the treatment centre, and housekeeping)?
£1
Not at all

£2
A little bit

£3
Moderately

£4
Quite a bit

£5
Extremely

These questions are about how you have been feeling during the past 4 weeks. For each
question, please circle the box with the one answer that comes closest to the way you
have been feeling.
E9. Have you felt calm and
peaceful
E10. Did you have a lot of
energy
E11. Have you felt downhearted and blue

All of the
time
All of the
time
All of the
time

Most of
the time
Most of
the time
Most of
the time

A good bit of
the time
A good bit of
the time
A good bit of
the time

Some of
the time
Some of
the time
Some of
the time

A little of
the time
A little of
the time
A little of
the time

None of
the time
None of
the time
None of
the time

E12. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like spending time with peers or other
residents, visiting friends/family if on leave etc.)?
£1
All of the time

£2
Most of the
time

£3
A good bit of
the time

£4
Some of the
time

£5
A little of the
time

E13. How much bodily pain have you had during the past 4 weeks?
£1
None

£2
Very mild

£3
Mild

£4
Severe

£5
Very severe
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Section F: Quality of Life Scale
F1. How would you rate your quality of life?
£1
Very poor

£2
Poor

£3
Neither poor nor
good

£4
Good

£5
Very good

F2. How satisfied are you with your health?
£1

£2

£3

£4

£5

Very dissatisfied

Dissatisfied

Neither satisfied or
dissatisfied

Satisfied

Very satisfied

F3. Do you have enough energy for everyday life?
£1
Not at all

£2
A little

£3
Moderately

£4
Mostly

£5
Completely

F4.How satisfied are you with your ability to perform your daily living activities?
£1
Very dissatisfied

£2
Dissatisfied

£3
Neither satisfied or
dissatisfied

£4
Satisfied

£5
Very satisfied

F5. How satisfied are you with yourself?
£1

£2

£3

£4

£5

Very dissatisfied

Dissatisfied

Neither satisfied or
dissatisfied

Satisfied

Very satisfied

F6. How satisfied are you with your personal relationships?
£1

£2

£3

£4

£5

Very dissatisfied

Dissatisfied

Neither satisfied or
dissatisfied

Satisfied

Very satisfied

F7. Have you enough money to meet your needs?
£1

£2

£3

£4

£5

Not at all

A little

Moderately

Mostly

Completely

F8. How satisfied are you with the conditions of your living place?
£1

£2

£3

£4

£5

Very dissatisfied

Dissatisfied

Neither satisfied or
dissatisfied

Satisfied

Very satisfied
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Section H: Mental Health (K-6)
The following questions ask about how you have been feeling during the past 30 days. For
each question, please circle the response that best describes how often you had this feeling.
H1. During the last 30 days, about how often did you feel…
a. Nervous?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

b. Hopeless?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

c. Restless or fidgety?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

d. So depressed that nothing
could cheer you up?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

e. That everything was an
effort?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

f. Worthless?

All of the
time

Most of the
time

Some of
the time

A little of
the time

None of
the time

Section I: UCLA
Please indicate how often you generally feel for each of the questions below by circling the
corresponding number.
Hardly Ever

Sometimes

Often

I1. How often do you feel that you lack companionship?

1

2

3

I2. How often do you feel left out?

1

2

3

I3. How often do you feel isolated from others?

1

2

3
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Section J: BCIS
Below is a list of sentences about how people think and feel. Please read each sentence in
the list carefully. Indicate how much you agree with each statement by the corresponding
number.
Do not
agree at
all

Agree
slightly

Agree a
lot

Agree
completely

J1. At times, I have misunderstood other people’s
attitudes towards me.

1

2

3

4

J2. My interpretations of my experiences are
definitely right.

1

2

3

4

J3. Other people can understand the cause of my
unusual experiences better than I can.

1

2

3

4

J4. I have jumped to conclusions too fast.

1

2

3

4

J5. Some of my experiences that have seemed very
real may have been due to my imagination.

1

2

3

4

J6. Some of the ideas I was certain were true turned
out to be false.

1

2

3

4

J7. If something feels right, it means that it is right.

1

2

3

4

J8. Even though I feel strongly that I am right, I could
be wrong.

1

2

3

4

J9. I know better than anyone else what my
problems are.

1

2

3

4

J10. When people disagree with me, they are
generally wrong.

1

2

3

4

J11. I cannot trust other people’s opinion about my
experiences.

1

2

3

4

J12. If somebody points out that my beliefs are
wrong, I am willing to consider it.

1

2

3

4

J13. I can trust my own judgment at all times.

1

2

3

4

J14. There is often more than one possible
explanation for why people act the way they do.

1

2

3

4

J15. My unusual experiences may be due to my
being extremely upset or stressed.

1

2

3

4
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Section K: SELSA-S

Strongly
disagree

Disagree

Somewhat
disagree

Neither
agree nor
disagree

Somewhat
agree

Agree

Strongly
agree

For each of the statements below, please indicate the degree to which you generally agree or
disagree with the corresponding number.

K1. I feel alone when I am with my
family

1

2

3

4

5

6

7

K2. I feel part of a group of friends

1

2

3

4

5

6

7

K3. I have a romantic partner with
whom I share my most intimate
thoughts and feelings

1

2

3

4

5

6

7

K4. There is no one in my family I can
depend on for support and
encouragement but I wish there was

1

2

3

4

5

6

7

K5. My friends understand my motives
and reasoning

1

2

3

4

5

6

7

K6. I have a romantic or marital
partner who gives me the support and
encouragement I need

1

2

3

4

5

6

7

K7. I don’t have any friends who share
my views, but I wish I did

1

2

3

4

5

6

7

K8. I feel close to my family

1

2

3

4

5

6

7

K9. I am able to depend on my friends
for help

1

2

3

4

5

6

7

K10. I wish I had a more satisfying
romantic relationship

1

2

3

4

5

6

7

K11. I feel part of my family

1

2

3

4

5

6

7

K12. My family really cares about me

1

2

3

4

5

6

7

K13. I do not have any friends who
understand me, but I wish I did

1

2

3

4

5

6

7

K14. I have a romantic partner to
whose happiness I contribute

1

2

3

4

5

6

7

K15. I have an unmet need for a close
romantic relationship

1

2

3

4

5

6

7
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Section L: Mental Health Screening Form
Please answer the following questions about your mental health. Circle either yes or no for
both the last 30 days and your lifetime for each question:
L1. Have you ever talked to a psychiatrist, psychologist, therapist, social worker, or
counsellor about an emotional problem?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L2. Have you ever felt you needed help with your emotional problems, or have you had
people tell you that you should get help for your emotional problems?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L3. Have you ever been advised to take medication for anxiety, depression, hearing voices,
or for any other emotional problem?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L4. Have you ever been seen in a psychiatric emergency room or been hospitalized for
psychiatric reasons?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L5. Have you ever heard voices no one else could hear or seen objects or things which
others could not see?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L6. a) Have you ever been depressed for weeks at a time, lost interest or pleasure in most
activities, had trouble concentrating and making decisions, or thought about killing
yourself?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L6. b) Did you ever attempt to kill yourself?
During the last 30 days
Yes
£1
During your lifetime
Yes
£1

No
No

£2
£2

L7. Have you ever had nightmares or flashbacks as a result of being involved in some
traumatic/terrible event? For example, warfare, gang fights, fire, domestic violence, rape,
incest, car accident, being shot or stabbed?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
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L8. Have you ever experienced any strong fears? For example, of heights, insects, animals,
dirt, attending social events, being in a crowd, being alone, being in places where it may
be hard to escape or get help?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L9. Have you ever given in to an aggressive urge or impulse, on more than one occasion
that resulted in serious harm to others or led to the destruction of property?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L10. Have you ever felt that people had something against you, without them necessarily
saying so, or that someone or some group may be trying to influence your thoughts or
behaviour?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L11. Have you ever experienced any emotional problems associated with your sexual
interests, your sexual activities, or your choice of sexual partner?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L12. Was there ever a period in your life when you spent a lot of time thinking and
worrying about gaining weight, becoming fat, or controlling your eating? For example, by
repeatedly dieting or fasting, engaging in much exercise to compensate for binge eating,
taking enemas, or forcing yourself to throw up?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L13. Have you ever had a period of time when you were so full of energy and your ideas
came very rapidly, when you talked nearly non-stop, when you moved quickly from one
activity to another, when you needed little sleep, and believed you could do almost
anything?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L14. Have you ever had spells or attacks when you suddenly felt anxious, frightened,
uneasy to the extent that you began sweating, your heart began to beat rapidly, you were
shaking or trembling, your stomach was upset, you felt dizzy or unsteady, as if you would
faint?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
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L15. Have you ever had a persistent, lasting thought or impulse to do something over and
over that caused you considerable distress and interfered with normal routines, work, or
your social relations? Examples would include repeatedly counting things, checking and
rechecking on things you had done, washing and rewashing your hands, praying, or
maintaining a very rigid schedule of daily activities from which you could not deviate.
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L16. Have you ever lost considerable sums of money through gambling or had problems at
work, in school, with your family and friends as a result of your gambling?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
L17. Have you ever been told by teachers, guidance counsellors, or others that you have a
special learning problem?
During the last 30 days
Yes
£1
No
£2
During your lifetime
Yes
£1
No
£2
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Section M: Satisfaction
Please rate how strongly you agree with the following statements.
1. It was a straightforward process accessing WHOs

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

2. The staff have not always understood the kind of
help I want.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

3. I have been well informed about decisions made
about my treatment.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

4. The staff and I have had different ideas about what
my treatment objectives should be.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

5. There has always been a member of staff available
when I have wanted to talk.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

6. The staff have helped to motivate me to sort out my
problems.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

7. I have not liked all of the group sessions I have
attended.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

8. I have not had enough time to sort out my problems

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

9. I think the staff have been good at their jobs.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

10. I have received the help that I was looking for.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

11. I have not liked some of the WHOs rules or
regulations.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

12. I’m happy with the support I receive for my mental
health problems.

Strongly
disagree

Disagree

Unsure

Agree

Strongly
agree

In what ways could We Help Ourselves (WHOs) improve support for people with mental
health issues?
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
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CSQ-8
Directions – We would like you to answer some questions about WHOs. We are interested
in your honest opinion, whether positive or negative. Please answer all of the questions.
1. How would you rate the quality of the
service you have received?

3
Good

2
Fair

1
Poor

2
No, not really

3
Yes,
generally

4
Yes,
definitely

3
Most of my
needs have
been met

2
Only a few of
my needs
have been
met

1
None of my
needs have
been met

2
No, I don’t
think so

3
Yes, I think
so

4
Yes,
definitely

1
Quite
unsatisfied

2
Indifferent or
mildly
dissatisfied

3
Mostly
satisfied

4
Very
satisfied

6. Have the services you received helped
you deal more effectively with your
problems?

4
Very
satisfied

3
Yes, they
helped
somewhat

2
No, they
really didn’t
help

7. In an overall, general sense, how
satisfied are you with the service you
have received?

4
Very
satisfied

3
Mostly
satisfied

8. If you were to seek help again, would
you come back to our program?

1
No,
definitely
not

2
Indifferent or
mildly
dissatisfied

1
No, they
seemed to
make things
worse

2
No, I don’t
think so

3
Yes, I think
so

2. Did you get the kind of service you
wanted?

3. To what extent had our program met
your needs?
4. If a friend were in need of similar help,
would you recommend our program to
him or her?
5. How satisfied are you with the amount
of help you have received?

4
Excellent
1
No,
definitely
not
4
Almost all of
my needs
have been
met
1
No,
definitely
not

1
Quite
dissatisfied
4
Yes,
definitely

If completing this survey raises any emotional issues with you we strongly encourage that you
discuss this with a We Help Ourselves (WHOs) staff member.
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Appendix 3: Ethics Approval for Study 3

Dayle Raftery
From:
Sent:
To:
Cc:
Subject:

irma-support@uow.edu.au
Wednesday, 31 January 2018 2:35 PM
pkelly@uow.edu.au; kpierce@uow.edu.au; Leigh.Lees@health.nsw.gov.au
Dayle Raftery; rso-ethics@uow.edu.au
HREC Approval of Application 2017/549

Dear Associate Professor Kelly,
I am pleased to advise that the application detailed below has been approved.
Ethics Number:

2017/549

Approval Date:

31/01/2018

Expiry Date:

30/01/2019

AuRed Number:

HREC/17/WGONG/159

Project Title:

The N-ICE trial: A randomised controlled trial of the safety and efficacy of N-Acetyl
Cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence

Researcher/s:

Raftery Dayle; Kelly Peter

Documents
Approved:

HREA form v1 03/11/2017
NICE Recruitment Advertisement V1 - 11/11/2017
NICE Assessment Form v1 26102017
NICE Baseline Form v1 26102017
NICE Case Report Form v1 26102017
NICE Protocol V1 02102017
NICE Participant information and consent form v1 30082017
Clinical Trials Certificate of Currency (Curtin University) 2017-2018 (NOTED)
McKetin - NHMRC MIA APP1128147 - Fully Executed Agreement v1 17072017
(NOTED)
NICE Assessment Form final WOLLONGONG v1 26102017
NICE Eligibility Form v1 26102017
NICE Participant Contact Form v1 26102017
NICE Screening Questionnaire v1 26102017
N-ICE Trial Investigator Brochure v1 26102017
On Ice Participant Handout

Sites:
Site

Principal Investigator for
Site

Monash University and Eastern Health
Melbourne

Professor Daniel Lubman

Deakin University and Barwon Health

Dr Olivia Dean
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University of Wollongong and Wollongong
Hospital

Associate Professor Peter
Kelly

The HREC has reviewed the research proposal for compliance with the National Statement on Ethical
Conduct in Human Research and approval of this project is conditional upon your continuing compliance
with this document. Compliance is monitored through progress reports; the HREC may also undertake
physical monitoring of research.
Approval is granted for a twelve month period; extension of this approval will be considered on receipt of a
progress report prior to the expiry date. Extension of approval requires:
The submission of an annual progress report and a final report on completion of your project.
Approval by the HREC of any proposed changes to the protocol or investigators.
Immediate report of serious or unexpected adverse effects on participants.
Immediate report of unforeseen events that might affect the continued acceptability of the project.
If you have any queries regarding the HREC review process or your ongoing approval please contact the
Ethics Unit on 4221 3386 or email rso-ethics@uow.edu.au.
Please note that Governance approval is required for research within the NSW Ministry of Health. If you
have not already done so, you will need to complete a Site Specific Application for each site and lodge it
with the appropriate Research Governance unit for each site.
Yours sincerely,

Susan Thomas
Dr Susan Thomas,
Chair, UOW & ISLHD Health and Medical Human Research Ethics Committee
The University of Wollongong and Illawarra and Shoalhaven Local Health District Health and Medical
HREC is constituted and functions in accordance with the NHMRC National Statement on Ethical Conduct
in Human Research. The processes used by this HREC to review multi-centre research proposals have been
certified by the National Health and Medical Research Council.

2

162

Appendix 4: N-ICE Trial Baseline Assessment (Study 3)

Participant ID Number: |____|____|____| - |__0__|____|____|

Allocate only if eligible as per instructions below:

SITE CODE: Melbourne [1] Geelong [2] Wollongong [3]
RANDOMISATION STRATA: Male [1] or Female [2]; inject [1] not inject [2]
Sequence number [chronological number within each of the above strata]

For example:
Melbourne Male & inject, first person recruited in this strata [111-001]
Melbourne Male & inject, second person recruited in this strata [111-002]
Melbourne Female & inject, first person recruited in this strata [121-001]
Geelong Male & not inject, third person recruited in this strata [212-003]
Wollongong Male & not inject, fifth person recruited in this strata [312-005]

Date of interview:

BASELINE FORM

[SITE CODE] – [RANDOMISATION STRATA] – [SEQUENCE NUMBER]

____/____/____

Screening ID: |____|____|

Interviewer initials: |____|____|
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INTRODUCTION
The main aim of this study is to learn whether a new medication (N-Acetyl-Cysteine or NAC) can
help people reduce their methamphetamine use.
This questionnaire is designed to get a general idea of your current health and well-being. It asks
about your drug use, your drug treatment history, psychological health and emotional well-being.
Many sections of the questionnaire have been used in other research and large surveys. The
questions may not relate to your personal experience, and they don’t necessarily relate to your
methamphetamine use, but we need to you to answer them the best you can.
As I mentioned before, any information you give me will be kept confidential. We will only
disclose this information with your permission or as required by law. This essentially means only if
we are subpoenaed by a court of law to provide the information, or if we are seriously concerned
about your safety or the safety of someone else (for example if you tell us you are suicidal, or if you
indicate that you intend to harm someone, we may call someone on your behalf).
You can choose not to answer any questions that you don’t feel comfortable with and you are free
to terminate the interview at any time without prejudice. You will be reimbursed regardless of
whether you complete the interview.
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SECTION A: DEMOGRAPHICS
A 1.

How old are you now? ________ yrs

A 2.

Sex
Male ................................... 1
Female ................................ 0

A 3.

In which country were you born?
Australia ............................. 1
Other .................................. 2 Specify_______________

A 4.

What is the main language you speak at home?
English ............................... 1
Other .................................. 2 Specify _________________

A 5.

Do you identify as Aboriginal or Torres Strait Islander?

Neither ..................................... 0
Aboriginal ................................ 1
Torres Strait Islander ............... 2
Both ......................................... 3
Prefer not to say ....................... 4
A 6.

How many years of school did you complete? _________ yrs

A 7.

Have you completed any qualification courses since leaving school?
No courses.......................... 0
Yes, trade/technical ............ 1 (do not include certificates like bar courses, only formal qualifications)
Yes, university/college....... 2

A 8.

What is your current employment status? (mark only one)
Unemployed ............................................................. 0
Casual/part-time employment .................................. 1
Full-time employment.............................................. 2
Student ..................................................................... 3
Home duties ............................................................. 4
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A 9.

What was your main source of income during the past month? (include only legal income)
No income

0 Skip to A11

Full-time employment

1

Casual/Part-time employment

2

Government pension, allowance or benefit ............. 3 Specify type: _____________
Other income............................................................ 4 Specify: __________________
A 10. How much did you earn in the past fortnight after tax? (include only legal income)
$_______
Less than $200
$200-399

1
.................. 2

$400-799

3

$800-1199

4

$1200 or more

5

A 11. What is your current marital status?
Single ....................................................................... 1
Married/De-facto ..................................................... 2
Separated .................................................................. 3
Divorced................................................................... 4
Widowed .................................................................. 5
A 12. Who were you living with in the past month? (Circle all that apply):
Alone ........................................................................ 1
Partner/Spouse/De-facto .......................................... 2
Children

3

Parent(s) ................................................................... 4
Non-related adult/flatmates...................................... 5
Other ........................................................................ 6 Specify:_____________________
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A 13. What was your usual form of accommodation in the past month?
Public housing.......................................................... 1
Privately rented house or flat ................................... 2
Privately owned house or flat .................................. 3
Parents’ home ......................................................... 4
Boarding house/hostel/shelter or refuge .................. 5
Drug treatment residence ......................................... 6
No fixed address/homeless ...................................... 7
Other ........................................................................ 8 Specify: ___________________
A 14. Have you had any children?
No............................................................................. 0 Skip to A15
Yes ........................................................................... 1
(a) How many of these children are currently under 16 years of age? ______
(b) How many of these children (< 16 years of age) are currently living with you? ________
A 15. (a) Have you ever been in prison (i.e., served a prison sentence)?
Yes .............. 1
No................ 0
A 16. Have you ever been told by a doctor that you had any of the following mental health
problems?
Mania or bipolar disorder

Yes ......... 1

No...........0

Schizophrenia

Yes ......... 1

No...........0

Drug-induced psychosis: Drug Involved ________________

Yes ......... 1

No...........0

Other psychosis (eg associated with depression, post-partum) Yes ......... 1

No...........0

Depression (i.e., unipolar depression)

Yes ......... 1

No...........0

Anxiety disorder (eg panic, agoraphobia, social phobia, GAD) Yes ......... 1

No...........0

ADHD

Yes ......... 1

No...........0

Post-traumatic Stress Disorder (PTSD)

Yes ......... 1

No...........0

Personality disorder (e.g,. Antisocial personality, borderline)

Yes ......... 1

No...........0

Other: Specify________________________________

Yes ......... 1

No...........0

Comments (if relevant):
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SECTION B: HISTORY
Now I'm going to ask you some questions about your methamphetamine and other drug use. When I
ask about methamphetamine, I’m including all the different forms of methamphetamine, such as ice,
speed or base. I'll emphasise again that the information you give me is completely confidential.
B 1.

How old were you when you first got drunk or used any other drug? _______ yrs

B 2.

How old were you when you first used methamphetamine? ____________ yrs

B 3.

What way did you first use methamphetamine?
Inject ................................................. 1
Smoke/Inhale .................................... 2
Snort .................................................. 3
Swallow ............................................ 4

B 4.

Have you ever injected any drug?
No.............................. 0 Go to B5
Yes ............................ 1
a.

How old were you when you first injected any drug? __________ yrs

b.

Have you ever injected methamphetamine?

No...................................................... 0 Go to B5
Yes .................................................... 1
c.
B 5.

How old were you when you first injected methamphetamine? ____________ yrs

Have you ever started any drug treatment for your methamphetamine use (e.g., detox, rehab,
drug counselling)?
No ............................................................................ 0
Yes ........................................................................... 1

B 6.

Have you ever received any other professional help for your methamphetamine use?
No................................... 0
Yes ................................. 1 Specify: ________________________
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B 7.

Are you currently receiving any treatment or other help to cut back or reduce your
methamphetamine use?
No................................... 0
Yes ................................. 1 Specify: ____________________

B 8.

What do you want to get out of this trial?
Not expecting any change in my methamphetamine use ................. 0
Take a break from using methamphetamine .................................... 1
A reduction in my methamphetamine use ....................................... 2
Complete abstinence from methamphetamine ................................. 3
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SECTION C: CIDI METHAMPHETAMINE DEPENDENCE
This next section focuses on your methamphetamine use in the past 12 months, including speed,
base, and crystal meth or ice. Interviewer: For treatment participants this relates to the 12 months
before they entered detox/treatment.
C1 a) Think about the period in the last 12 months when you were using methamphetamine the
most frequently. About how often did you use it? (circle one)
a) Almost every day? ..... ........................... 5
b) 3 or 4 days a week? ................................ 4
c) 1 or 2 days a week? ................................ 3
d) 1 to 3 days a month? .............................. 2
e) Less than once a month? ........................ 1
b) How old were you when you first used methamphetamine that frequently? ________ yrs
C2 a) In the past 12 months, did you find that you had to use much more methamphetamine than
before to get the effect you wanted?
No .............................................. 0

If no, ask (b)

Yes ............................................ 1*

If yes, skip to C3
SD1

b) In the past 12 months, did you find that the same amount of methamphetamine had less
effect on you than it once did?
No .............................................. 0
Yes ............................................ 1*
SD1
C3 a) In the past 12 months, have you wanted to stop or cut down on your use of
methamphetamine?
No .............................................. 0

If no, skip to C4

Yes ............................................ 1*

If yes, ask (b)

b) In the past 12 months, were you able to cut down for at least one month?
No .............................................. 0*
Yes ............................................ 1
SD4
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C4

In the past 12 months, have you spent a lot of your time using, getting, or getting over the
effects of methamphetamine?
No .............................................. 0
Yes ............................................ 1*

C5

SD5
In the past 12 months, have you often used methamphetamine in larger amounts or for a
longer period than you intended?
No .............................................. 0
Yes ............................................ 1*

SD3
C6 a) Did stopping or cutting down on methamphetamine during the past 12 months cause you
any of the problems like those listed on this card? (Interviewer: HAND CARD L3 TO
RESPONDENT).
No .............................................. 0

If no, skip to C7

Yes ............................................ 1*

If yes, ask (b)
SD2

Fatigue or exhaustion
Sweating
Diarrhoea
Tremors (hands tremble)

Anxious
Depressed
Irritable
Restless
Trouble sleeping

Intense craving

Seeing or hearing
things that weren’t
really there

Stomach ache
Head ache
Weakness
Nausea or vomiting
Muscle aches or
cramps
Change in appetite

Fits or seizures
Runny eyes or nose
Yawning
Fever
Heart beating fast

b) In the past 12 months, did you use methamphetamine or another drug like it to keep from
having problems like those on the card?
No .............................................. 0
Yes ............................................ 1*
SD2
C7 a) In the past 12 months, did methamphetamine cause you any medical problems as a result of
using it, like an overdose, persistent cough, seizures, infections, hepatitis, abscesses, or heart
trouble?
No .............................................. 0

If no, skip to C8

Yes ............................................ 1*

If yes, ask (b)

b) In the past 12 months, did you continue to use methamphetamine after you knew that it was
causing you any of these health problems?
No .............................................. 0
Yes ............................................ 1*
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SD7
C8 a) In the past 12 months, did methamphetamine cause you any emotional or psychological
problems – such as being uninterested in your usual activities, being depressed, suspicious
or distrustful of people, or having strange thoughts?
No .............................................. 0

If no, skip to C9

Yes ............................................ 1*

If yes, ask (b)

b) In the past 12 months, did you continue to use methamphetamine after you knew that it was
causing you any of these emotional or psychological problems?
No .............................................. 0
Yes ............................................ 1*
SD7
C9
In the past 12 months, have you given up or greatly reduced important activities in order to
get or use methamphetamine – activities like sports, work, or associating with friends or relatives –
for a whole month, or several times over two months?
No
Yes

0
1*
SD6

C10 Interviewer: Is there an asterisk ‘*” for three or more of the questions C2-C9 (only count
one asterisk per question)?
No
Yes

0# Skip to Section D
1

(a) You said that your methamphetamine use had caused problems for you, like (LIST
SYMPTOMS CODED ‘*’ IN C2-9).
ONS: How old were you the first time you had three or more of these problems from
methamphetamine use in the same year?
AGE ONSET: ___/___
REC: When was the last time you had three or more of these problems?
AGE REC: ___/___
Interviewer: Offer responses in order below
In the past month ....................... 0 (meets eligibility for dependence)
> 1 month ago (< 6 months) ...... 1#
More than six month ago .......... 2#
#Ineligible
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SECTION D: CURRENT USE
D 1. Interviewer: Complete TLFB for methamphetamine use using the calendar & instructions
below for the past 28 days
To help us evaluate your drug use, we need to get an idea of what your use was like in the past
month. To do this we use a calendar like this one (show sample calendar).
• During this time period we want to get an idea of on how many days you used methamphetamine.
• This is not hard to do, especially when we use a calendar to help you recall your drug use.
• The idea is that for each day on the calendar we will record whether you “used" or “did not use”
drugs.
• On days when you did not use drugs, we will write a “0” in the box.
• On days when you did use drugs, we will put a “1” in the box.

Your Best Estimate
• In filling out the calendar, we want you to be as accurate as possible. However, we recognize that
it is not always easy to recall events with 100% accuracy, whether it is drug use or anything else.
• What is important is for us to write something in for every day.
• If you are not sure whether you used a certain drug on a Thursday or a Friday of a certain week,
GIVE IT YOUR BEST GUESS!
(a) From date: _____/______/______(d/m/yr)
_____/______/______(d/m/yr)

(b) To date:

(c) Days in this period: ______
(d) Days of methamphetamine use in this period: _______
Interviewer instructions:
(1) Guide the participant to the correct start date and work through the calendar with them up
until yesterday. Do not ask about drug use on the day of the interview. Mark these on the
calendar with a cross.
(2) Mark on the calendar any periods of incarceration, hospitalisation or other inpatient
treatment and any other significant events disclosed by participant.
(3) Check boxes with a 1 or 0 as per instructions above for each day of methamphetamine use
or abstinence. You can use the calendar to help record other drug use if necessary, but
please record with another coding system (e.g. C for cannabis, H for heroin etc.)
(4) Record start and end dates for the period covered, the number of days in the period, and
how many days the person used methamphetamine (this can be recorded on the calendar
and entered above at the end of the interview).
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D 2.

What was the main way you took methamphetamine during the past month? (circle only one)
No use ............................................... 0
Inject ................................................. 1
Smoke/Inhale .................................... 2
Snort .................................................. 3
Swallow ............................................ 4

D 3.

What was the main type of methamphetamine that used used in the past month?
Crystal meth/ice ................................ 1
Powder or ‘speed’ ............................. 2
Other (e.g. base, liquid, pills)............ 3

Specify: _______________

Crystal meth or ice

(also called crack, tina, crystal, skates)

Large translucent/white crystals of methamphetamine

Powder - usually called ‘speed’ but not always
Powdery form of methamphetamine that is usually white or
beige, but can vary in colour

‘Base’ / Damp or oily meth
Can vary in colour – doesn’t have to be brown – key quality is
damp texture
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TIMELINE FOLLOWBACK CALENDAR
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SECTION E: OTHER USE
B1 This next table just gets a bit of a summary of your drug use.
(Interviewer: for each drug class listed below ask):

a) Have you ever used ‘drug name’?
b) Have you used ‘drug name’ in the past month?
c) How many days have you used ‘drug name’ in the past four weeks?

(NB: Indicate yes with a 1, no with a 0)
DRUG CLASS

A) EVER USED

B) USED IN
PAST MONTH

B) DAYS
USED IN
PAST 4
WEEKS
(0-28)

1. Heroin
2. Other opiates (e.g. morphine,
codeine, street methadone or
prescribed methadone)
4. Cocaine
5. Ecstasy
6. Other hallucinogens (e.g. LSD,
magic mushrooms)
7. Inhalants (e.g. amyl/rush, laughing
gas/bulbs, glue)
8. Cannabis
9. Alcohol
10. Tobacco
11. Benzodiazepines (e.g. Valium,
Serepax, Temazepam)
12. Antidepressants (e.g. Prozac,
Zoloft, Sinequan)
13. Antipsychotics (eg, Zyprexa,
Seroquel, Risperdal)
14. Any other drug use
Specify drug: __________________
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SECTION F: MOTIVATION
The following section is designed to identify how you personally feel about your
methamphetamine use at the moment. I will read a number of statements. Please listen
carefully to these statements and decide whether you agree or disagree with the
statements. The options are as follows: strongly disagree, disagree, unsure, agree,
strongly agree.
Strongly Disagree Unsure
Disagree
-2
-1
0

Agree
1

Strongly
Agree
2

F 1.

I don’t think I use too much
methamphetamine

P

F 2.

I am trying to use less
methamphetamine than I
used to

A

F 3.

I enjoy my methamphetamine
use, but sometimes I use too
much

C

F 4.

Sometimes I think I should cut
down on my methamphetamine
use

C

F 5.

It’s a waste of time thinking
about my methamphetamine
use

P

F 6.

I have just recently changed
my methamphetamine use

A

F 7.

Anyone can talk about wanting
to do something about
methamphetamine use, but I
am actually doing something
about it

A
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Strongly Disagree Unsure
Disagree

Agree

Strongly
Agree

F 8.

I am at the stage where I
should think about using
less methamphetamine

C

F 9.

My methamphetamine use
is a problem sometimes

C

F 10. There is no need for me to
think about changing my
methamphetamine use

P

F 11. I am actually changing my
methamphetamine use right now

A

F 12. Using less methamphetamine
would be pointless for me.

P
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SECTION G: SAPAS
The following questions are about how you think and behave in different situations. Think
about how you feel most of the time in most situations. These questions are not meant to be
about your meth use particularly. We are asking them because we think they may relate to
how you do in treatment. Just answer them best you can.
G 1.

In general, are you a perfectionist?

Yes .............. 1
No ............... 0
G 2.

Are you normally an impulsive sort of person?

Yes .............. 1
No ............... 0
G 3.

Are you normally a worrier?

Yes .............. 1
No ............... 0
G 4.

Do you normally lose your temper easily?

Yes .............. 1
No ............... 0
G 5.

Would you normally describe yourself as a loner?

Yes .............. 1
No ............... 0
G 6.

In general, do you have difficulty making and keeping friends?

Yes .............. 1
No ............... 0
G 7.

In general, do you depend on others a lot?

Yes .............. 1
No ............... 0
G 8.

In general, do you trust other people?

Yes .............. 1
No ............... 0
Note. Order of questions has been changed from original SAPAS
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SECTION H: BECK QUESTIONNAIRE
The following questions are about how you think about things and how interpret events
around you. Again, they are not about your drug use and they are part of a standard
questionnaire used in psychology. The data are being used by one of our students to see
whether this affects how you respond to the treatment. Remember, this is completely
voluntary and you don’t have to answer any of the questions if you don’t want to.
I 1.

At times, I have misunderstood other people’s attitudes towards me
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 2.

My interpretations of my experiences are definitely right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 3.

Other people can understand the cause of my unusual experiences better than I can
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 4.

I have jumped to conclusions too fast
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 5.

Some of my experiences that have seemed very real may have been due to my
imagination
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 6.

Some of the ideas I was certain were true turned out to be false
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
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I 7.

If something feels right, it means that it is right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 8.

Even though I feel strongly that I am right, I could be wrong
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 9.

I know better than anyone else what my problems are
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 10.

When people disagree with me, they are generally wrong
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 11.

I cannot trust other people’s opinion about my experiences
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 12.

If somebody points out that my beliefs are wrong, I am willing to consider it
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 13.

I can trust my own judgment at all times
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
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I 14.

There is often more than one possible explanation for why people act the way
they do
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 15.

My unusual experiences may be due to my being extremely upset or stressed
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 16.

I feel psychologically well
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 17.

I do not need treatment or medication for my substance use
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 18.

If someone said I had a substance use problem, they would be right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 19.

None of the unusual things I have experienced were due to substance use
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

186

SECTION I: FAMILY HISTORY
(Leave missing and make note if family not known, e,g, participant is adopted)
I 1. Family history of schizophrenia+
+First (parents, siblings, children) or second degree relative (aunts, uncles, cousins) has a
psychiatric disorder (schizophrenia in the appropriate section) severe enough to warrant
psychiatric referral.
Do you know of anyone in your family (including aunts, uncles, cousins) who has had
schizophrenia or psychosis?
0 = No family history of schizophrenia
1 = Family history of schizophrenia
I 2. Family history of psychiatric disorder*
*This item includes any psychiatric disorder other than schizophrenia. The respondent needs
to give a clear description of a psychiatric disorder, either by name, symptoms or medication
being taken, and/or receiving professional psychiatric care. Do not rate a “breakdown”,
schizophrenia, adopted relatives or neurological disorders (i.e. epilepsy or intellectual
disability).
Do you know of anyone in your family (including aunts, uncles, cousins) who has had any
other psychiatric disorder?
Did they see a doctor for that problem?
Have they been in hospital for that problem?
Do you know what treatment they received (medication, ECT)?
Do you know what the doctors said was wrong with them?
Can you describe the behaviours or symptoms?
0 = No family history
1 = Family history of affective disorder
2 = Family history of other psychiatric disorder (not including psychotic or affective
disorders)
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SECTION J: MINI

This appendix has been removed due to copyright:
Sheehan, D. V. (2016). MINI International Neuropsychiatric Interview for
Schizophrenia and Psychotic Disorders Studies [Measurement instrument].
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SECTION K: PREGNANCY TEST
For women only: We also need to confirm that you are not pregnant. That is because we can’t
be confident that the medication we are giving you is safe for an unborn baby. To do this, we
need you to do a pregnancy test. It is quite simple. I will show you to the bathroom. All you
need to do is pee on this stick, and wait a little while to see the results. Two lines means that
you’re pregnant. I want you to tell me what the result was. You can keep the test stick or
discard it when you are done. You can show me the test result if you want, but I’m happy to
trust you.

K 1.

Pregnancy test taken?
Yes .............. 1
Yes .............. 0
Male/N/A .... 2

K 2.

Pregnancy test result?
Negative ...... 0
Positive ....... 1
Male/N/A .... 2
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SECTION L: OTHER COMMENTS OR QUESTIONS?
We have now finished the questionnaire. Now I need to take you to see the trial doctor.
Before we do that, do you have any questions or comments about what we have discussed
today? Or about the study more generally?

THANK YOU VERY MUCH FOR YOUR TIME
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Appendix 5: N-ICE Trial Time 0 Assessment (Study 3)

Date of interview:

____/____/____

Interviewer code: |____|____|

ASSESSMENT FORM 0

Participant ID Number: |____| - |____| - |____| - |____|____|____|

N-ICE

Funded by the
National Health and
Medical Research
Council
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Conducted by

INTRODUCTION

This questionnaire asks about your drug use, well-being and contact with treatment, health
and criminal justice services. They are standard questions that we used to assess how you are
going in treatment and we’ll do these questions every time we catch up. As I mentioned
before, any information you give me will be kept confidential, and none of the treatment staff
will have access to your questionnaire.
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SECTION A: DAYS OF USE
Interviewer note: Methamphetamine use should be completed using information recorded in the
TLFB on the CRF. The TLFB should be used to assist with other substance use since the last
interview. Refer to baseline form for relevant TLFB data (i.e., if this fell within the past 4 weeks).
B2 This next table is about other drug use in the past 4 weeks.
(Interviewer: for each drug class listed below ask):
(a) How many days have you used ‘drug name’ in the past 4 weeks? Use Timeline Followback
calendar to estimate number of days use (include day of last assessment and exclude today).
(b) How many days in the past week did you use ‘drug name’? (record out of 7 days, excluding
today)

DRUG CLASS

A) DAYS OF
USE IN PAST
4 WEEKS

B) DAYS OF USE
IN PAST WEEK
(OUT OF 7 DAYS)

(OUT OT 28
DAYS)

1. Methamphetamine (ice, crystal,tina, speed,base etc)
2. Heroin
3. Other opiates (e.g. morphine, codeine, street
methadone or prescribed methadone)
4. Cocaine
5. Ecstasy
6. Other hallucinogens (e.g. LSD, magic mushrooms)
7. Inhalants (e.g. amyl/rush, laughing gas/bulbs, glue)
8. Cannabis
9. Alcohol
10. Tobacco
11. Benzodiazepines (e.g. Valium, Serepax,
Temazepam)
12. Antidepressants (e.g. Prozac, Zoloft, Sinequan)
13. Antipsychotics (e.g., Zyprexa, Seroquel,
Risperdal)
14. Any other drug use
Specify drug: __________________
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SECTION B: OTHER MA MEASURES
SDS
The following questions are about how you felt about your methamphetamine use in the past
week, including all the various forms, like speed or powder, ice and base.
B1

Did you think your methamphetamine use was out of control in the past week?
0
1
2
3

B2

During the past week did the prospect of missing a hit/dose of methamphetamine
make you anxious or worried?
0
1
2
3

B3

not at all
a little
quite a lot
a great deal

Did you wish you could stop using methamphetamine in the past week?
0
1
2
3

B5

never or almost never
sometimes
often
always or nearly always

Did you worry about your use of methamphetamine in the past week?
0
1
2
3

B4

never or almost never
sometimes
often
always or nearly always

never or almost never
sometimes
often
always or nearly always

How difficult did you find it to stop, or to go without methamphetamine in the past
week?
0
1
2
3

not difficult
quite difficult
very difficult
impossible
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CEQ-S
B6

Over the past week how much did you want meth?
0

1

2

3

4

5

6

7

8

9

10

Did not want it at all

B7

Wanted it constantly

How much did you need it?
0

1

2

3

4

5

6

7

8

9

10

Did not need it at all

B8

Needed it constantly

How strong was the urge to have it?
0

1

2

3

4

5

6

7

8

9

10

Not strong at all

B9

Extremely strong

Over the past week how hard were you trying not to think about meth?
0

1

2

3

4

5

6

7

8

9

10

Wasn’t trying hard

B10

Trying extremely hard

How intrusive were the thoughts?
0

1

2

3

4

5

6

7

8

9

10

Not at all intrusive

B11

Extremely intrusive

How hard was it to think about anything else?
0

1

2

3

4

5

6

7

8

9

10

Not at all difficult

B12

Extremely difficult

How often over the past week, did you picture meth?
0

1

2

3

4

5

6

7

8

9

10

Never

B13

Constantly

How often did you imagine its smell or taste?
0

1

2

3

4

5

6

7

8

9

10

Never

B14

Constantly

How often did you imagine what it would feel like to smoke or inject it?
0
Never

1

2

3

4

5

6

7

8

9

10
Constantly
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AWQ
Over the past week…

0

1

2

3

4

Not at
all

Very
little

A little

Quite a
lot

Very
much

Have you felt sad?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B17 Have you lost interest in
things or no longer take pleasure
in them?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B18

Have you felt anxious?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B19 Have you felt as if your
movements were slow?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B20

Have you felt agitated?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B21

Have you felt tired?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B22 Has your appetite
increased or are you eating too
much?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B23 Have you had any vivid or
unpleasant dreams?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B24 Have you been craving for
sleep or sleeping too much?

Not at
all

Very
little

A little

Quite a
lot

Very
much

B15 Have you been craving
methamphetamine?
B16
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SECTION C: BPRS
Interviewer: Please brief the participant on the nature of the upcoming questions. For
example: The following questions are about how you have been getting along over the past
week and how you’ve been feeling. They are part of a standard health assessment that we ask
everyone. They are not necessarily about your drug use. I want you to tell me about
everything you’ve experienced regardless of whether it is related to your meth use.
Sometimes I will have to ask quite personal questions. Please remember you don’t have to
answer any of the questions if you don’t want to.
C 1.

Hostility

In the past week:
How have you been getting along with people (family, co-workers etc.)?
Were you/have you been irritable or grumpy? (How did you show it? Did you keep it to
yourself?)
Were you so irritable that you would shout at people or start fights or arguments?
Did you find yourself yelling at people you didn’t know?
Did you hit anyone?
Rating:
Notes:

Animosity, contempt, belligerence, threats, arguments, tantrums, property destruction, fights, and any other
expression of hostile attitudes or actions. Do not infer hostility from neurotic defences, anxiety or somatic
complaints. Do not include incidents of appropriate anger or obvious self-defence.
1 = Not present
2 = Very Mild

Irritable or grumpy, but not overtly expressed.

3 = Mild

Argumentative or sarcastic.

4 = Moderate

Overtly angry on several occasions OR yelled at others excessively.

5 = Moderately Severe

Has threatened, slammed about, or thrown things.

6 = Severe

Has assaulted others but with no harm likely, e.g., slapped or pushed, OR destroyed
property, e.g., knocked over furniture, broken windows.

7 = Extremely Severe

Has attacked others with definite possibility of harming them or with actual harm,
e.g., assault with hammer or weapon.
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C 2.

Suspiciousness

In the past week:
Did you feel uncomfortable in public? Did it seem as though others were watching you?
Were they talking about you, laughing or criticizing you? (ask what they were saying)
Were you concerned about anyone’s intentions toward you?
Did you think anyone was going out of their way to give you a hard time, or try to hurt you?
Did you feel in any danger?
Ask respondent to describe experiences at this time and also ask:
How often were you concerned that [use participant’s description]? / How often did you
have these feelings? Did you tell anyone about these experiences?
Rating:
Notes:

Expressed or apparent belief that other persons have acted maliciously or with discriminatory intent. Include
persecution by supernatural or other non-human agencies (e.g. the devil).
Interviewer Note: ratings of ‘3’ or above should also be rated under C3.Unusual Thought Content.
1 = Not present
2 = Very Mild

3 = Mild

4 = Moderate
5 = Moderately Severe
6 = Severe
7 = Extremely Severe

Seems on guard. Unresponsive to “personal” questions. Reports being overly selfconscious in public.
Describes incidents where other persons have harmed or wanted to harm him/her
that sound plausible. Feels as if others are watching, laughing at or criticizing
him/her in public, but this occurs only occasionally or rarely. Little or no
preoccupation.
Says other persons are talking about him/her maliciously or says others intend to
harm him/her. Beyond likelihood of plausibility but not delusional. Incidents of
suspected persecution occur occasionally with some preoccupation.
Same as 4, but incidents occur frequently, such as more than once in a week.
Moderately preoccupied with ideas of persecution OR reports persecutory delusions
expressed with much doubt (e.g., partial delusion).
Delusional. Speaks of Mafia plots, the FBI, or others poisoning food, persecution
by supernatural forces.
Same as 6, but the beliefs are bizarre or more preoccupying. Tends to disclose or
act on persecutory delusion.
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C 3.

Unusual thoughts

In the past week:
Did you have any strange thoughts that you couldn’t explain? For example:
Did you feel as if anyone could read your mind? Did you receive any special messages from
your surroundings?
Did you feel like thoughts were put into your head that were not your own?
Did you feel you were under the control of another person or force?
Ask respondent to describe experiences at that time and also ask:
At this time did these thoughts interfere with your ability to perform usual activities or work,
or influence your actions?
How did you explain these things at the time? How sure were you that they were true?
Rating:
Notes:

Unusual, odd, strange or bizarre thought content. Rate the degree of unusualness, not the degree of
disorganisation of speech. Delusions are patently absurd, clearly false or bizarre ideas that are expressed with
full conviction. Consider the patient to have full conviction if he/she has acted as though the delusional belief
were true. Ideas of reference/persecution can be differentiated from delusions in that ideas are expressed with
much doubt and contain more elements of reality. Include thought insertion, withdrawal and broadcast. Include
grandiose, somatic and persecutory delusions even if rated elsewhere. Note. If Somatic Concern, Guilt,
Suspiciousness or Grandiosity are rated 6 or 7 due to delusions, the Unusual Thought Content must be rated a 4
or above.
1 = Not present
Ideas of reference (people stare/laugh at him/her). Ideas of persecution (people
2 = Very Mild
mistreat him/her). Unusual beliefs in psychic powers, spirits, UFO’s, or unrealistic
beliefs in one’s own abilities. Not strongly held. Some doubt.
Same as 2, but degree of reality distortion is more severe as indicated by highly
unusual ideas or greater conviction. Content may be typical of delusions (even
3 = Mild
bizarre), but without full conviction. The delusion does not seem to have fully
formed, but is considered as one possible explanation for an unusual experience.
Delusion present but no preoccupation or functional impairment. May be an
4 = Moderate
encapsulated delusion or a firmly endorsed absurd belief about past delusional
circumstances.
Full delusion(s) present with some preoccupation OR some areas of functioning
5 = Moderately Severe
disrupted by delusional thinking.
6 = Severe

Full delusion(s) present with much preoccupation OR many areas of functioning
disrupted by delusional thinking.

7 = Extremely Severe

Full delusion(s) present with almost total preoccupation OR most areas of
functioning disrupted by delusional thinking.
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C 4.

Hallucinations

In the past week:
Did you hear any sounds or people talking to you, or about you, when there was nobody
around?
If voices, ask: What did the voices say? Did it have a voice quality?
Did you see any visions or smell any smells others didn’t seem to notice?
Ask respondent to describe experiences at that time and also ask:
At this time did these experiences interfere with your ability to perform usual activities or
work?
How did you explain them?
How often did they occur?
Rating:
Notes:

When rating degree to which functioning is disrupted by hallucinations, include preoccupation with the content
and experience of the hallucinations, as well as the functioning disrupted by acting out on the hallucinatory
content (e.g., engaging in deviant behaviour due to command hallucinations). Include thoughts aloud, or pseudohallucinations (e.g., hears voice inside head) if a voice quality is present.
1 = Not present
2 = Very Mild

3 = Mild

4 = Moderate
5 = Moderately Severe

While resting or going to sleep, sees visions, smells odours or hears voices, sounds
or whispers in absence of external stimulation, but no impairment in functioning
OR hallucinatory quality of the report doubtful.
While in a clear state of consciousness, hears a voice calling the subject’s name,
experiences nonverbal auditory hallucinations (e.g., sounds or whispers), formless
visual hallucinations or has sensory experiences in the presence of a modalityrelevant stimulus (e.g., visual illusions) infrequently (e.g., 1-2 times per week) and
with no functional impairment.
Occasional verbal, visual, olfactory, tactile or gustatory hallucinations but no
impairment in functioning OR nonverbal auditory hallucinations/visual illusions
occurring more than infrequently or with impairment.
Experiences daily hallucinations OR some areas of functioning are disrupted by
hallucinations.

6 = Severe

Experiences verbal or visual hallucinations several times a day OR many areas of
functioning are disrupted by hallucinations.

7 = Extremely Severe

Persistent throughout the day or most areas of functioning are disrupted by
hallucinations.
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C 5.

Depression

In the past week:
How has your mood been in the past week?
Have you felt depressed, down or like you didn’t care lately?
Do you find that you have lost interest or enjoyment in things you used to enjoy, like spending
time with family, friends, doing hobbies, watching TV or eating?
If client reports feelings of depression:
How long do these feelings usually last?
Can you switch your attention to more pleasant topics when you want to?
Has it interfered with your ability to perform your usual activities or work?

Sadness, unhappiness, anhedonia, hopelessness, loss of self-esteem, or preoccupation with depressing topics
(can’t attend to other things due to depression). Don’t rate vegetative symptoms
1 = Not present
2 = Very Mild

Occasionally feels sad, unhappy, or depressed.

3 = Mild

Frequently feels sad or unhappy but can readily turn attention to other things.
Worried frequently but can readily turn attention to other things.

4 = Moderate

Frequent periods of feeling very sad, unhappy, moderately depressed, but able to
function with extra effort.

5 = Moderately Severe

Frequent, but not daily, periods of deep depression OR some areas of functioning
are disrupted by depression.

6 = Severe

Deeply depressed daily but not persisting throughout the day OR many areas of
functioning are disrupted by depression.

7 = Extremely Severe

Deeply depressed daily OR most areas of functioning are disrupted by depression.
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C 6.

Suicidality

In the past week:
Have you felt that life wasn’t worth living?
Have you thought about harming or killing yourself?
Have you felt tired of living or as though you would be better off dead?
If client reports suicidal ideation:
How often have you thought about [using client’s words – ending your life]?
Do you have a specific plan? What is the plan?
Have you attempted in the past?

Expressed desire, intent or actions to harm or kill self.

1 = Not present
2 = Very Mild

Occasional feelings of being tired of living. No overt suicidal thoughts.

3 = Mild

Occasional suicidal thought without intent or specific plan OR they feel they would
be better off dead.

4 = Moderate
5 = Moderately Severe
6 = Severe
7 = Extremely Severe

Frequent suicidal thoughts without intent or plan.
Many fantasies of suicide by various methods. May seriously consider making an
attempt with specific time or plan OR impulsive suicide attempt using no-lethal
method or in full view of possible rescue.
Clearly wants to kill self. Searches for appropriate means and time, OR potentially
serious suicide attempt with client’s knowledge of possible rescue.
Specific suicide plan or intent (e.g. as soon as__ I will do it by __) OR suicide
attempt characterised by a plan client thought was lethal or attempted in a secluded
environment.

Referral
4/5: Offer referral to Trial Physician for review. Offer other appropriate services, e.g., call Suicide Call Back
& provide details for Adult Mental Health teams.
6/7: Refer immediately to Trial Physician and/or other appropriate service for assessment and treatment
according to N-ICE suicide protocol & local SOPs.
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SECTION D: EQ 5D
Under each heading, please indicate which option best describes your health TODAY
Interviewer: Read out heading then read options aloud.
E 1.

Mobility
I have no problems in walking about .......................................... 1
I have slight problems in walking about ..................................... 2
I have moderate problems in walking about ............................... 3
I have severe problems in walking about ................................... 4
I am unable to walk about ........................................................... 5

E 2.

Self-care
I have no problems washing or dressing myself ......................... 1
I have slight problems washing or dressing myself .................... 2
I have moderate problems washing or dressing myself .............. 3
I have severe problems washing or dressing myself .................. 4
I am unable to wash or dress myself ........................................... 5

E 3.

Usual activities
I have no problems doing my usual activities ............................ 1
I have slight problems doing my usual activities........................ 2
I have moderate problems doing my usual activities.................. 3
I have severe problems doing my usual activities ...................... 4
I am unable to do my usual activities ......................................... 5

E 4.

Pain/discomfort
I have no pain or discomfort ....................................................... 1
I have slight pain or discomfort .................................................. 2
I have moderate pain or discomfort ............................................ 3
I have severe pain or discomfort ................................................. 4
I have extreme pain or discomfort .............................................. 5

E 5.

Anxiety/depression
I am not anxious or depressed .................................................... 1
I am slightly anxious or depressed.............................................. 2
I am moderately anxious or depressed........................................ 3
I am severely anxious or depressed ............................................ 4
I am extremely anxious or depressed.......................................... 5
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E 6. We would like to know how good or bad your health is TODAY
This Scale is numbered 0 to 100
100 means the best health you can imagine
0 means the worst health you can imagine
Mark an X on the scale to indicate how your health is TODAY
YOUR HEALTH TODAY = ____________
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SECTION E: HEALTH SERVICE UTILISATION
The following questions are about your contact with health services and also the criminal
justice sector in the past 4 weeks. We are interested in whether you’ve had contact with these
services regardless of whether it was related to your drug use.
Interviewer: At assessment 0, ask these questions for the past 4 weeks.
F 1.

In the past 4 weeks have you received any treatment or help for your methamphetamine
or other drug use?
No ............................. 0 Go to E2
Yes ............................ 1
a. What help have you received for your drug use in the past 4 weeks? (read options and
circle all that apply)

F 2.

Counselling (outpatient) .......................................... 1

No. Sessions: _________

Detox/withdrawal .................................................... 2

No. days:

_________

Residential rehab ..................................................... 3

No. days:

_________

Other drug treatment ............................................... 4

Specify:_____________

How many times in the past 4 weeks have you been admitted to hospital? (include
psychiatric hospital attendances) ______
a. For that/those admissions how many nights in total did you stay in hospital?
______

F 3.

How many times in the past 4 weeks have you received help from an
emergency department? ______
a. How many of those times were you admitted to hospital? _______

F 4.

How many times in the past 4 weeks have you received help from an ambulance?
________
a. How many of those times were you taken to hospital? _________

F 5.

In the past 4 weeks, how many times have you been to…
a. …the doctor/GP? ____
b. …the dentist? _____
c. …a counsellor or psychologist? ___
d. …a psychiatrist? ____
e. …have you received help from any other health service in the past 4 weeks?
(if yes, list below)
f. Service: _____________________________

No. Times: _______
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F 6.

Have you been arrested in the past 4 weeks?
No ............................. 0
Yes ............................ 1
a. How many times were you arrested? ____________
b. What were you arrested for?

ABS code (complete later)

(i)

________________________
____________

(ii)

________________________
____________

(iii)

________________________

____________

(iv)

________________________

____________

(v)

________________________
____________

Interviewer: list all offences for which participant was arrested during the timeframe

F 7. Have you been to court in the past 4 weeks?
No ............................. 0
Yes ............................ 1 Specify number of times ____________
F 8.

Have you been held in a police lock up, or put in prison, in the past 4 weeks?
No ............................. 0
Yes ............................ 1

If yes, specify number of days detained.___________
From _____/____/______(d/m/yr) To _____/____/______(d/m/yr)
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SECTION F: WPAI-GH
The following questions ask about the effect of your health problems on your ability to work
and perform regular activities. By health problems, we mean any physical or emotional
problem or symptom. Please fill in the blanks or circle a number, as indicated.
F 1.

Are you currently employed (working for pay)?
No ............................. 0

If no skip to F6.

Yes ............................ 1

F 2.

During the past seven days (not including today), how many hours did you miss from
work because of your health problems? Include hours you missed due to sick days, times
when you went in late, left early, etc., because of your health problems. Do not include
time off to participate in this study. ________hours

F 3.

During the past seven days (not including today), how many hours did you miss from
work for any other reason, such as holidays or time off to participate in this study?
________hours

F 4.

During the past seven days (not including today), how many hours did you actually
work? ________hours

F 5.

During the past seven days (not including today), how much did your health problems
affect your productivity while you were working?
Think about days when you were limited in the amount or kind of work you could do, days
when you accomplished less than you would like, or days when you could not do your work
as carefully as usual. If health problems affected your work only a little, choose a low
number. Choose a high number if health problems affected your work a great deal.
Consider only how much health problems affected productivity while you were
working.
Health problems
had no effect on
my work

0

1

2

3

4

5

6

7

8

9

Health problems
completely
10
prevented me
from working

CIRCLE A NUMBER
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F 6. During the past seven days (not including today), how much did your health problems
affect your ability to do your regular daily activities, other than work at a job?
By regular activities, we mean the usual activities you do, such as work around the
house, shopping, childcare, exercising, and studying, etc. Think about times when you
were limited in the amount or kind of activities you could do and times when you
accomplished less than you would like. If health problems affected your activities only
a little, choose a low number. Choose a high number if health problems affected your
activities a great deal.
Consider only how much health problems affected your ability to do your regular daily
activities, other than work at a job.
Health
problems had
no effect on
my daily
activities

0

1

2

3

4

5

6

7

8

9

Health problems
completely
10 prevented me from
doing my daily
activities

CIRCLE A NUMBER
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SECTION G: OTHER COMMENTS
Are there any other health, lifestyle, emotional or social problems related to your
methamphetamine use or treatment that we haven’t already covered that you’d like to talk
about?

THANK YOU VERY MUCH FOR YOUR TIME
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Appendix 6: N-ICE Trial Time 12 Assessment (Study 3)

Date of interview:

____/____/____

Interviewer code: |____|____|

ASSESSMENT FORM 1-12

Participant ID Number: |____| - |____| - |____| - |____|____|____|

N-ICE

Funded by the
National Health and
Medical Research
Council
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Conducted by
NDRI, Curtin University
IMPACT, Deakin University

INTRODUCTION

The questions I’ll be asking you are similar to the ones you answered last week. We’re interested to
see if anything has changed for you since the last time we spoke. This questionnaire asks about
your drug use, treatment history, criminal activity, psychological health and emotional well-being.
Remember you’re here voluntarily and don’t have to answer anything you don’t want to. As I
mentioned before, any information you give me will be kept confidential, and none of the treatment
staff will have access to your questionnaire.
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SECTION A: AE Form
A1. How have you been since I last saw you?
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
A2. Have you had any problems with your health since we last interviewed you? (if yes, probe:
did these problem develop or worsen since you’ve been taking the trial medication? )
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
*Note the definition for an adverse event (Section 8.3 of the protocol) does not include conditions present before
starting the trial medication unless they worsen after starting the trial medication. Record events regardless of
whether or not the condition/event it is considered to be related to the trial medication.

A3.

Have you missed taking any of your trial medicine?
No.............................. 0 Go to 1.4
Yes ............................ 1
If yes, how many days?_________ (partial dose = 0.5 days)
Why did you miss taking the medication?
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………

Interviewer note: At this point, do eCAP reading and review medication compliance. Counsel
participant on adherence strategies.
A4.

Have you had any problems relating to the trial capsules?

…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
A5. Do you have any other problems or worries in relation to the trial?
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
NB: Record all adverse events on the Adverse Event Log on CRF
Trial physician f/up required?

YES

/ NO
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SECTION B: DAYS OF USE
Interviewer note: Methamphetamine use should be completed using information recorded in the
TLFB on the CRF. The TLFB should be used to assist with other substance use since the last
interview.
This next table is about other drug use since we last interviewed you.
(Interviewer: for each drug class listed below ask):
a) How many days in the past week have you used ‘drug name’? (record out of 7 days)
b) How many days have you used ‘drug name’ since we last interviewed you? Use Timeline
Followback calendar to estimate number of days use (include day of last assessment and
exclude today).

DRUG CLASS

A) DAYS OF
USE IN PAST
WEEK

B) DAYS OF USE
SINCE LAST
INTERVIEW

B1. Methamphetamine (ice, crystal,tina, speed,base
etc)
B2. Heroin
B3. Other opiates (e.g. morphine, codeine, street
methadone or prescribed methadone)
B4. Cocaine
B5. Ecstasy
B6. Other hallucinogens (e.g. LSD, magic mushrooms)
B7. Inhalants (e.g. amyl/rush, laughing gas/bulbs,
glue)
B8. Cannabis
B9. Alcohol
B10. Tobacco
B11. Benzodiazepines (e.g. Valium, Serepax,
Temazepam)
B12. Antidepressants (e.g. Prozac, Zoloft, Sinequan)
B13. Antipsychotics (e.g., Zyprexa, Seroquel,
Risperdal)
B14. Any other drug use
Specify drug: __________________
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SECTION C: OTHER MEASURES
SDS
Ask even if no methamphetamine use since last interview
The following questions are about how you felt about your methamphetamine use in the past
week, including all the various forms, like speed or powder, ice and base.
C1

Did you think your methamphetamine use was out of control in the past week?
0
1
2
3

C2

During the past week did the prospect of missing a hit/dose of methamphetamine
make you anxious or worried?
0
1
2
3

C3

not at all
a little
quite a lot
a great deal

Did you wish you could stop using methamphetamine in the past week?
0
1
2
3

C5

never or almost never
sometimes
often
always or nearly always

Did you worry about your use of methamphetamine in the past week?
0
1
2
3

C4

never or almost never
sometimes
often
always or nearly always

never or almost never
sometimes
often
always or nearly always

How difficult did you find it to stop, or to go without methamphetamine in the past
week?
0
1
2
3

not difficult
quite difficult
very difficult
impossible

226

CEQ-S
C6

Over the past week how much did you want meth?
0

1

2

3

4

5

6

7

8

9

10

Did not want it at all

C7

Wanted it constantly

How much did you need it?
0

1

2

3

4

5

6

7

8

9

10

Did not need it at all

C8

Needed it constantly

How strong was the urge to have it?
0

1

2

3

4

5

6

7

8

9

10

Not strong at all

C9

Extremely strong

Over the past week how hard were you trying not to think about meth?
0

1

2

3

4

5

6

7

8

9

10

Wasn’t trying hard

C10

Trying extremely hard

How intrusive were the thoughts?
0

1

2

3

4

5

6

7

8

9

10

Not at all intrusive

C11

Extremely intrusive

How hard was it to think about anything else?
0

1

2

3

4

5

6

7

8

9

10

Not at all difficult

C12

Extremely difficult

How often over the past week, did you picture meth?
0

1

2

3

4

5

6

7

8

9

10

Never

C13

Constantly

How often did you imagine its smell or taste?
0

1

2

3

4

5

6

7

8

9

10

Never

C14

Constantly

How often did you imagine what it would feel like to smoke or inject it?
0
Never

1

2

3

4

5

6

7

8

9

10
Constantly
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AWQ
Over the past week…

0

1

2

3

4

Not at
all

Very
little

A little

Quite a
lot

Very
much

Have you felt sad?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C17 Have you lost interest in
things or no longer take pleasure
in them?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C18

Have you felt anxious?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C19 Have you felt as if your
movements were slow?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C20

Have you felt agitated?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C21

Have you felt tired?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C22 Has your appetite
increased or are you eating too
much?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C23 Have you had any vivid or
unpleasant dreams?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C24 Have you been craving for
sleep or sleeping too much?

Not at
all

Very
little

A little

Quite a
lot

Very
much

C15 Have you been craving
methamphetamine?
C16
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SECTION D: BPRS
Interviewer: Please brief the participant on the nature of the upcoming questions. For
example: The following questions are about how you have been getting along over the past
week and how you’ve been feeling. They are part of a standard health assessment that we ask
everyone. They are not necessarily about your drug use. I want you to tell me about
everything you’ve experienced regardless of whether it is related to your meth use.
Sometimes I will have to ask quite personal questions. Please remember you don’t have to
answer any of the questions if you don’t want to.
D 1.

Hostility

In the past week:
How have you been getting along with people (family, co-workers etc.)?
Were you/have you been irritable or grumpy? (How did you show it? Did you keep it to
yourself?)
Were you so irritable that you would shout at people or start fights or arguments?
Did you find yourself yelling at people you didn’t know?
Did you hit anyone?
Rating:
Notes:

Animosity, contempt, belligerence, threats, arguments, tantrums, property destruction, fights, and any other
expression of hostile attitudes or actions. Do not infer hostility from neurotic defences, anxiety or somatic
complaints. Do not include incidents of appropriate anger or obvious self-defence.
1 = Not present
2 = Very Mild

Irritable or grumpy, but not overtly expressed.

3 = Mild

Argumentative or sarcastic.

4 = Moderate

Overtly angry on several occasions OR yelled at others excessively.

5 = Moderately Severe

Has threatened, slammed about, or thrown things.

6 = Severe

Has assaulted others but with no harm likely, e.g., slapped or pushed, OR destroyed
property, e.g., knocked over furniture, broken windows.

7 = Extremely Severe

Has attacked others with definite possibility of harming them or with actual harm,
e.g., assault with hammer or weapon.
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D 2.

Suspiciousness

In the past week:
Did you feel uncomfortable in public? Did it seem as though others were watching you?
Were they talking about you, laughing or criticizing you? (ask what they were saying)
Were you concerned about anyone’s intentions toward you?
Did you think anyone was going out of their way to give you a hard time, or try to hurt you?
Did you feel in any danger?
Ask respondent to describe experiences at this time and also ask:
How often were you concerned that [use participant’s description]? / How often did you
have these feelings? Did you tell anyone about these experiences?
Rating:
Notes:

Expressed or apparent belief that other persons have acted maliciously or with discriminatory intent. Include
persecution by supernatural or other non-human agencies (e.g. the devil).
Interviewer Note: ratings of ‘3’ or above should also be rated under C3.Unusual Thought Content.
1 = Not present
2 = Very Mild

3 = Mild

4 = Moderate
5 = Moderately Severe
6 = Severe
7 = Extremely Severe

Seems on guard. Unresponsive to “personal” questions. Reports being overly selfconscious in public.
Describes incidents where other persons have harmed or wanted to harm him/her
that sound plausible. Feels as if others are watching, laughing at or criticizing
him/her in public, but this occurs only occasionally or rarely. Little or no
preoccupation.
Says other persons are talking about him/her maliciously or says others intend to
harm him/her. Beyond likelihood of plausibility but not delusional. Incidents of
suspected persecution occur occasionally with some preoccupation.
Same as 4, but incidents occur frequently, such as more than once in a week.
Moderately preoccupied with ideas of persecution OR reports persecutory delusions
expressed with much doubt (e.g., partial delusion).
Delusional. Speaks of Mafia plots, the FBI, or others poisoning food, persecution
by supernatural forces.
Same as 6, but the beliefs are bizarre or more preoccupying. Tends to disclose or
act on persecutory delusion.
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D 3.

Unusual thoughts

In the past week:
Did you have any strange thoughts that you couldn’t explain? For example:
Did you feel as if anyone could read your mind? Did you receive any special messages from
your surroundings?
Did you feel like thoughts were put into your head that were not your own?
Did you feel you were under the control of another person or force?
Ask respondent to describe experiences at that time and also ask:
At this time did these thoughts interfere with your ability to perform usual activities or work,
or influence your actions?
How did you explain these things at the time? How sure were you that they were true?
Rating:
Notes:

Unusual, odd, strange or bizarre thought content. Rate the degree of unusualness, not the degree of
disorganisation of speech. Delusions are patently absurd, clearly false or bizarre ideas that are expressed with
full conviction. Consider the patient to have full conviction if he/she has acted as though the delusional belief
were true. Ideas of reference/persecution can be differentiated from delusions in that ideas are expressed with
much doubt and contain more elements of reality. Include thought insertion, withdrawal and broadcast. Include
grandiose, somatic and persecutory delusions even if rated elsewhere. Note. If Somatic Concern, Guilt,
Suspiciousness or Grandiosity are rated 6 or 7 due to delusions, the Unusual Thought Content must be rated a 4
or above.
1 = Not present
Ideas of reference (people stare/laugh at him/her). Ideas of persecution (people
2 = Very Mild
mistreat him/her). Unusual beliefs in psychic powers, spirits, UFO’s, or unrealistic
beliefs in one’s own abilities. Not strongly held. Some doubt.
Same as 2, but degree of reality distortion is more severe as indicated by highly
unusual ideas or greater conviction. Content may be typical of delusions (even
3 = Mild
bizarre), but without full conviction. The delusion does not seem to have fully
formed, but is considered as one possible explanation for an unusual experience.
Delusion present but no preoccupation or functional impairment. May be an
4 = Moderate
encapsulated delusion or a firmly endorsed absurd belief about past delusional
circumstances.
Full delusion(s) present with some preoccupation OR some areas of functioning
5 = Moderately Severe
disrupted by delusional thinking.
6 = Severe

Full delusion(s) present with much preoccupation OR many areas of functioning
disrupted by delusional thinking.

7 = Extremely Severe

Full delusion(s) present with almost total preoccupation OR most areas of
functioning disrupted by delusional thinking.
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D 4.

Hallucinations

In the past week:
Did you hear any sounds or people talking to you, or about you, when there was nobody
around?
If voices, ask: What did the voices say? Did it have a voice quality?
Did you see any visions or smell any smells others didn’t seem to notice?
Ask respondent to describe experiences at that time and also ask:
At this time did these experiences interfere with your ability to perform usual activities or
work?
How did you explain them?
How often did they occur?
Rating:
Notes:

When rating degree to which functioning is disrupted by hallucinations, include preoccupation with the content
and experience of the hallucinations, as well as the functioning disrupted by acting out on the hallucinatory
content (e.g., engaging in deviant behaviour due to command hallucinations). Include thoughts aloud, or pseudohallucinations (e.g., hears voice inside head) if a voice quality is present.
1 = Not present
2 = Very Mild

3 = Mild

4 = Moderate
5 = Moderately Severe

While resting or going to sleep, sees visions, smells odours or hears voices, sounds
or whispers in absence of external stimulation, but no impairment in functioning
OR hallucinatory quality of the report doubtful.
While in a clear state of consciousness, hears a voice calling the subject’s name,
experiences nonverbal auditory hallucinations (e.g., sounds or whispers), formless
visual hallucinations or has sensory experiences in the presence of a modalityrelevant stimulus (e.g., visual illusions) infrequently (e.g., 1-2 times per week) and
with no functional impairment.
Occasional verbal, visual, olfactory, tactile or gustatory hallucinations but no
impairment in functioning OR nonverbal auditory hallucinations/visual illusions
occurring more than infrequently or with impairment.
Experiences daily hallucinations OR some areas of functioning are disrupted by
hallucinations.

6 = Severe

Experiences verbal or visual hallucinations several times a day OR many areas of
functioning are disrupted by hallucinations.

7 = Extremely Severe

Persistent throughout the day or most areas of functioning are disrupted by
hallucinations.
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D 5.

Depression

In the past week:
How has your mood been in the past week?
Have you felt depressed, down or like you didn’t care lately?
Do you find that you have lost interest or enjoyment in things you used to enjoy, like spending
time with family, friends, doing hobbies, watching TV or eating?
If client reports feelings of depression:
How long do these feelings usually last?
Can you switch your attention to more pleasant topics when you want to?
Has it interfered with your ability to perform your usual activities or work?

Sadness, unhappiness, anhedonia, hopelessness, loss of self-esteem, or preoccupation with depressing topics
(can’t attend to other things due to depression). Don’t rate vegetative symptoms
1 = Not present
2 = Very Mild

Occasionally feels sad, unhappy, or depressed.

3 = Mild

Frequently feels sad or unhappy but can readily turn attention to other things.
Worried frequently but can readily turn attention to other things.

4 = Moderate

Frequent periods of feeling very sad, unhappy, moderately depressed, but able to
function with extra effort.

5 = Moderately Severe

Frequent, but not daily, periods of deep depression OR some areas of functioning
are disrupted by depression.

6 = Severe

Deeply depressed daily but not persisting throughout the day OR many areas of
functioning are disrupted by depression.

7 = Extremely Severe

Deeply depressed daily OR most areas of functioning are disrupted by depression.
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D 6.

Suicidality

In the past week:
Have you felt that life wasn’t worth living?
Have you thought about harming or killing yourself?
Have you felt tired of living or as though you would be better off dead?
If client reports suicidal ideation:
How often have you thought about [using client’s words – ending your life]?
Do you have a specific plan? What is the plan?
Have you attempted in the past?

Expressed desire, intent or actions to harm or kill self.

1 = Not present
2 = Very Mild

Occasional feelings of being tired of living. No overt suicidal thoughts.

3 = Mild

Occasional suicidal thought without intent or specific plan OR they feel they would
be better off dead.

4 = Moderate
5 = Moderately Severe
6 = Severe
7 = Extremely Severe

Frequent suicidal thoughts without intent or plan.
Many fantasies of suicide by various methods. May seriously consider making an
attempt with specific time or plan OR impulsive suicide attempt using no-lethal
method or in full view of possible rescue.
Clearly wants to kill self. Searches for appropriate means and time, OR potentially
serious suicide attempt with client’s knowledge of possible rescue.
Specific suicide plan or intent (e.g. as soon as__ I will do it by __) OR suicide
attempt characterised by a plan client thought was lethal or attempted in a secluded
environment.

Referral
4/5: Offer referral to Trial Physician for review. Offer other appropriate services, e.g., call Suicide Call Back
& provide details for Adult Mental Health teams.
6/7: Refer immediately to Trial Physician and/or other appropriate service for assessment and treatment
according to N-ICE suicide protocol & local SOPs.
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SECTION E: EQ 5D
Under each heading, please indicate which option best describes your health TODAY
Interviewer: Read out heading then read options aloud.
E 1.

Mobility
I have no problems in walking about .......................................... 1
I have slight problems in walking about ..................................... 2
I have moderate problems in walking about ............................... 3
I have severe problems in walking about ................................... 4
I am unable to walk about ........................................................... 5

E 2.

Self-care
I have no problems washing or dressing myself ......................... 1
I have slight problems washing or dressing myself .................... 2
I have moderate problems washing or dressing myself .............. 3
I have severe problems washing or dressing myself .................. 4
I am unable to wash or dress myself ........................................... 5

E 3.

Usual activities
I have no problems doing my usual activities ............................ 1
I have slight problems doing my usual activities........................ 2
I have moderate problems doing my usual activities.................. 3
I have severe problems doing my usual activities ...................... 4
I am unable to do my usual activities ......................................... 5

E 4.

Pain/discomfort
I have no pain or discomfort ....................................................... 1
I have slight pain or discomfort .................................................. 2
I have moderate pain or discomfort ............................................ 3
I have severe pain or discomfort ................................................. 4
I have extreme pain or discomfort .............................................. 5

E 5.

Anxiety/depression
I am not anxious or depressed .................................................... 1
I am slightly anxious or depressed.............................................. 2
I am moderately anxious or depressed........................................ 3
I am severely anxious or depressed ............................................ 4
I am extremely anxious or depressed.......................................... 5

235

E 6. We would like to know how good or bad your health is TODAY
This Scale is numbered 0 to 100
100 means the best health you can imagine
0 means the worst health you can imagine
Mark an X on the scale to indicate how your health is TODAY
YOUR HEALTH TODAY = ____________
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SECTION F: HEALTH SERVICE UTILISATION
The following questions are about your contact with health services and also the criminal
justice sector since we last interviewed you on XXXX. We are interested in whether you’ve
had contact with these services regardless of whether it was related to your drug use.
Interviewer: Refer to TLFB to assess with identifying time since last interview and events
since, if necessary. Include all events since last completed assessment.
F 1.

Since we last interviewed you, have you received any treatment or help for your
methamphetamine or other drug use?
No ............................. 0 Go to F2
Yes ............................ 1
a. What help have you received for your drug use since we last interviewed you? (read
options and circle all that apply)

Counselling (outpatient) .......................................... 1
__________

No. Sessions:

Detox/withdrawal .................................................... 2
____________

No. days:

Residential rehab ..................................................... 3
____________

No. days:

Other drug treatment ............................................... 4
F 2.

-

Specify:_____________

How many times since we last interviewed you (on XXXX) have you been admitted to
hospital? (include psychiatric hospital attendances) ______
a. For that/those admissions how many nights in total did you stay in hospital?
______

F 3.

How many times since we last interviewed you (on XXXX) have you received help from
an emergency department? ______
a. How many of those times were you admitted to hospital? _______

F 4.

How many times have you received help from an ambulance since we last interviewed
you (on XXXX)? ________
a. How many of those times were you taken to hospital? _________

F 5.

Since we last interviewed you, how many times have you been to…
a. …the doctor/GP? ____
b. …the dentist? _____
c. …a counsellor or psychologist? ___
d. …a psychiatrist? ____
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e. …have you received help from any other health service since we last saw you?
(if yes, list below)
f. Service: _________________________________
__________
F 6.

No. Times:

Have you been arrested since we last interviewed you?
No ............................. 0
Yes ............................ 1
a. How many times were you arrested? ____________
b. What were you arrested for?

ABS code (complete later)

(i)

________________________
____________

(ii)

________________________
____________

(iii)

________________________

____________

(iv)

________________________

____________

(v)

________________________
____________

Interviewer: list all offences for which participant was arrested during the timeframe

F 7. Have you been to court since we last interviewed you?
No ............................. 0
Yes ............................ 1 Specify number of times ____________
F 8.

Have you been held in a police lock up, or put in prison, since we last interviewed you?
No ............................. 0
Yes ............................ 1

If yes, specify number of days detained.___________
From _____/____/______(d/m/yr) To _____/____/______(d/m/yr)
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SECTION G: WPAI-GH
The following questions ask about the effect of your health problems on your ability to work
and perform regular activities. By health problems, we mean any physical or emotional
problem or symptom. Please fill in the blanks or circle a number, as indicated.
G 1.

Are you currently employed (working for pay)?
No ............................. 0

If no skip to G6.

Yes ............................ 1

G 2.

During the past seven days (not including today), how many hours did you miss from
work because of your health problems? Include hours you missed due to sick days,
times when you went in late, left early, etc., because of your health problems. Do not
include time off to participate in this study. ________hours

G 3.

During the past seven days (not including today), how many hours did you miss from
work for any other reason, such as holidays or time off to participate in this study?
________hours

G 4.

During the past seven days (not including today), how many hours did you actually
work? ________hours

G 5.

During the past seven days (not including today), how much did your health problems
affect your productivity while you were working?
Think about days when you were limited in the amount or kind of work you could do,
days when you accomplished less than you would like, or days when you could not do
your work as carefully as usual. If health problems affected your work only a little,
choose a low number. Choose a high number if health problems affected your work a
great deal.
Consider only how much health problems affected productivity while you were
working.
Health problems
had no effect on
my work

0

1

2

3

4

5

6

7

8

9

Health problems
completely
10
prevented me
from working

CIRCLE A NUMBER
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G 6.
During the past seven days (not including today), how much did your health
problems affect your ability to do your regular daily activities, other than work at a
job?
By regular activities, we mean the usual activities you do, such as work around the
house, shopping, childcare, exercising, and studying, etc. Think about times when you
were limited in the amount or kind of activities you could do and times when you
accomplished less than you would like. If health problems affected your activities only
a little, choose a low number. Choose a high number if health problems affected your
activities a great deal.
Consider only how much health problems affected your ability to do your regular daily
activities, other than work at a job.
Health
problems had
no effect on
my daily
activities

0

1

2

3

4

5

6

7

8

9

Health problems
completely
10 prevented me from
doing my daily
activities

CIRCLE A NUMBER
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SECTION H: TSQM II (Only Assessments 4, 8 and 12 – leave blank
for other wks)
These questions are about the trial medication you are taking.
H 1.

How satisfied or dissatisfied are you with the ability of the medication to prevent or
treat your condition?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7

H 2. How satisfied or dissatisfied are you with the way the medication relieves your
symptoms?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7

H 3.

As a result of taking this medication, do you currently experience any side effects at
all?
No ............................. 0 Skip to H7
Yes ............................ 1

H 4.

How dissatisfied are you by side effects interfering with your physical health and
ability to function (i.e., strength, energy levels, etc.)?
Not applicable ............................................................................. 0
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Somewhat dissatisfied ................................................................ 3
Slightly dissatisfied ..................................................................... 4
Not at all dissatisfied .................................................................. 5
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H 5.

How dissatisfied are you by side effects that interfere with your mental function (i.e.,
ability to think clearly, stay awake, etc.)?
Not applicable ............................................................................. 0
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Somewhat dissatisfied ................................................................ 3
Slightly dissatisfied ..................................................................... 4
Not at all dissatisfied .................................................................. 5

H 6.

How dissatisfied are you by side effects that interfere with your mood or emotions
(e.g., anxiety/fear, sadness, irritation/anger)?
Not applicable ............................................................................. 0
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Somewhat dissatisfied ................................................................ 3
Slightly dissatisfied ..................................................................... 4
Not at all dissatisfied .................................................................. 5

H 7.

How satisfied or dissatisfied are you with how easy the medication is to use?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7

H 8.

How satisfied or dissatisfied are you with how easy it is to plan when you will use the
medication each time?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7
.........................................................................................................................
.........................................................................................................................
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H 9.

How satisfied or dissatisfied are you by how often you are expected to use/take the
medication?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7

H 10. How satisfied are you that the good things about this medication outweigh the bad
things?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7
H 11. Taking all things into account, how satisfied or dissatisfied are you with this
medication?
Extremely dissatisfied ................................................................. 1
Very dissatisfied ......................................................................... 2
Dissatisfied ................................................................................. 3
Somewhat satisfied ..................................................................... 4
Satisfied ...................................................................................... 5
Very satisfied .............................................................................. 6
Extremely satisfied ..................................................................... 7

H 12. Do you think you are receiving the active trial medication (NAC) or the placebo (no
drug)?
Don’t know/unsure ..................................................................... 0
Active NAC ................................................................................ 1
Placebo ........................................................................................ 2
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SECTION I: BECK QUESTIONNAIRE (week 12 only)
The following questions are about how you think about things and how interpret events
around you. Again, they are not about your drug use and they are part of a standard
questionnaire used in psychology. The data are being used by one of our students to see
whether this affects how you respond to the treatment. Remember, this is completely
voluntary and you don’t have to answer any of the questions if you don’t want to.
I 1. At times, I have misunderstood other people’s attitudes towards me
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
I 2.

My interpretations of my experiences are definitely right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 3.

Other people can understand the cause of my unusual experiences better than I can
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 4.

I have jumped to conclusions too fast
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 5.

Some of my experiences that have seemed very real may have been due to my
imagination
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 6.

Some of the ideas I was certain were true turned out to be false
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
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I 7.

If something feels right, it means that it is right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 8.

Even though I feel strongly that I am right, I could be wrong
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 9.

I know better than anyone else what my problems are
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 10.

When people disagree with me, they are generally wrong
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 11.

I cannot trust other people’s opinion about my experiences
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 12.

If somebody points out that my beliefs are wrong, I am willing to consider it
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 13.

I can trust my own judgment at all times
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
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I 14.

There is often more than one possible explanation for why people act the way they do
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 15.

My unusual experiences may be due to my being extremely upset or stressed
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 16.

I feel psychologically well
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 17.

I do not need treatment or medication for my substance use
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 18.

If someone said I had a substance use problem, they would be right
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3

I 19.

None of the unusual things I have experienced were due to substance use
Do not agree at all ............................. 0
Agree slightly.................................... 1
Agree a lot......................................... 2
Agree completely .............................. 3
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SECTION J: OTHER COMMENTS
Are there any other health, lifestyle, emotional or social problems related to your
methamphetamine use or treatment that we haven’t already covered that you’d like to talk
about?

THANK YOU VERY MUCH FOR YOUR TIME
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